Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation

ANDRZEJ SLOMINSKI, DESMOND J. TOBIN, SHIGEKI SHIBAHARA, AND JACOBO WORTSMAN

Department of Pathology, University of Tennessee, Memphis, Tennessee; Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, United Kingdom; Department of Molecular Biology and Applied Physiology, Tohoku University School of Medicine, Sendai, Miyagi, Japan; and Department of Medicine, Southern Illinois University, Springfield, Illinois

I. Melanin Pigment
   A. Melanins: chemical and physical properties
   B. Melanin pigment in skin physiology and pathology

II. Biochemistry and Cellular and Molecular Biology of Melanogenesis
   A. Melanocytes as Melanin-Producing cells: cell biology and ultrastructure
   B. Biochemistry of melanogenesis
   C. Extrapigmentary functions of melanogenesis-related proteins

III. Mechanisms of Regulation of Melanogenesis
   A. Transcriptional regulation
   B. Intracellular signal transduction pathways
   C. Dual function of L-tyrosine and L-DOPA: reaction substrates and bioregulators
   D. Summary

IV. Hormonal Stimulators of Melanogenesis and Their Receptors
   A. G protein-coupled receptors and ligands
   B. SCF and its receptor
   C. Nuclear receptors and their ligands
   D. Other positive regulators of melanogenesis: bone morphogenetic proteins
   E. Summary

V. Hormonal Inhibitors of Melanogenesis and Receptors
   A. G protein-coupled receptors and their ligands
   B. Melanocortins antagonists
   C. Cytokines, growth factors, and receptors
   D. Other negative regulators of melanogenesis
   E. Summary

VI. Miscellaneous Regulation of Melanogenesis By Nuclear Receptors and Their Ligands
   A. Glucocorticoids and their receptors
   B. Retinoids and their receptors
   C. Summary

VII. Functional Regulation of Follicular (Hair) and Epidermal Melanin Units
   A. The epidermal melanin unit
   B. Regulation of hair cycle-coupled follicular melanogenesis

VIII. Unified Concept for the Transcriptional Regulation of Melanogenesis: a Key Role for Microphthalmia-Associated Transcription Factor

IX. Melanogenesis as Molecular Sensor and Transducer of Environmental Signals and Regulator of Local Homeostasis

X. Comments and Future Directions

Sloinski, Andrzej, Desmond J. Tobin, Shigeki Shibahara, and Jacobo Wortsman. Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation. Physiol Rev 84: 1155-1228, 2004; 10.1152/physrev.00044.2003.—Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents interacting via pathways activated by receptor-dependent and -independent mechanisms, in hormonal, auto-, para-, or intracrine fashion. Because of the multidirectional nature and heterogeneous character of the melanogenesis modifying agents, its controlling factors are not organized into simple linear sequences, but they interphase instead...
in a multidimensional network, with extensive functional overlapping with connections arranged both in series and in parallel. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortins and ACTH, whereas among the negative regulators agouti protein stands out, determining intensity of melanogenesis and also the type of melanin synthesized. Within the context of the skin as a stress organ, melanogenic activity serves as a unique molecular sensor and transducer of noxious signals and as regulator of local homeostasis. In keeping with these multiple roles, melanogenesis is controlled by a highly structured system, active since early embryogenesis and capable of superselective functional regulation that may reach down to the cellular level represented by single melanocytes. Indeed, the significance of melanogenesis extends beyond the mere assignment of a color trait.

I. MELANIN PIGMENT

A. Melanins: Chemical and Physical Properties

Melanins, the end-products of complex multistep transformations of l-tyrosine, are polymorphous and multifunctional biopolymers, represented by eumelanin, pheomelanin, neuromelanin, and mixed melanin pigment (323, 597, 598). Melanin biosynthesis can be initiated from either the hydroxylation of l-phenylalanine to l-tyrosine (nonobligatory step, operative in vivo) or directly from l-tyrosine, which is then hydroxylated to l-dihydroxyphenylalanine (l-DOPA) (obligatory step both in vitro and in vivo). l-DOPA serves as a precursor to both melamins and catecholamines, acting along separate pathways (Fig. 1). The next step, oxidation of l-DOPA to dopaquinone, is common to both eu- and pheomelanogenic pathways (597, 598). Eumelanogenesis involves the further transformation of dopaquinone to leukodopachrome, followed by a series of oxidoreduction reactions with production of the intermediates dihydroxyindole (DHI) and DHI carboxylic acid (DHICA), that undergo polymerization to form

**FIG. 1.** Synthesis of melanins. GSH, glutathione; Cys, cysteine. 1: Phenylalanine hydroxylation (by PH); 2: tyrosine hydroxylation (by either tyrosinase or TH); 3: DOPA oxidation (by tyrosinase or metal cations); 4: dopachrome tautomerization (by DCT/Tyrp2 or metal cations); 5a: DHICA oxidation (by Tyrp1 or peroxidase); 5b: DHI oxidation (by tyrosinase or peroxidase); 6: hydrolysis of glutathionyllopa (by y-glutamyltranspeptidase); b: oxidation of cysteinyldopa (by peroxidase); c: intramolecular cyclization of cysteinyldopaquinone (may be facilitated by peroxidase); l: DOPA decarboxylation (by AAD); II: hydroxylation of dopamine (by DBH); III: methylation of norepinephrine (by PNMT).
eumelanin (323, 573, 597). Pheomelanogenesis also starts with dopaquinone; this is conjugated to cysteine or glutathione to yield cysteinyldopa and glutathionyldopa, for further transformation into pheomelanin (323, 597, 598). Mixed melanin contains both eu- and pheomelanin.

L-DOPA generation of catecholamines requires its enzymatic decarboxylation, hydroxylation, and methylation to produce dopamine, norepinephrine, and epinephrine, respectively (790). In vitro, all of these catecholamines can potentially convert into neuromelanin through several oxidation/reduction reactions (Fig. 1) (787); in vivo, only dopamine and cysteinyldopamine can serve as primary precursors to the pigment (101, 151, 930).

Melanin pigments have in common their arrangement of several units linked by carbon-carbon bonds (C-C), but differ from each other in chemical composition, as well as structural and physical properties (323, 597, 598). Thus eumelans are polymorphous nitrogenous biopolymers (predominantly copolymers of DHI and DHICA), black to brown in color, insoluble in most solvents (597, 598), and tightly associated with proteins through covalent bonds. Eumelans behave like polyanions with the capability to reversibly bind cations, anions, and polyamines in reactions facilitated by their high carboxyl group content (323, 597, 598). A feature unique to eumelanin is a stable paramagnetic state that results from its semiquinone units (Fig. 2) (61, 126). Thus the electron paramagnetic resonance (EPR) spectrum of eumelanin corresponds to a slightly asymmetric singlet that generates a free radical signal at approximately $g = 2.004$. The semiquinone units are also responsible for eumelanin actions as redox pigment with both reducing and oxidizing capabilities towards oxygen radicals and other chemical redox systems (126, 597, 598). Both eumelanin physical structure and electrical properties are consistent with its behavior as an amorphous semiconductor (210, 392, 544). Another interesting property of eu- and pheomelanin chemiluminescence is related to oxidative degradation of the melanin pigment (164, 658, 712).

In contrast to eumelanin, pheomelanin has a backbone of benzothiazine units and exhibits a yellow to reddish-brown color and is alkali soluble (323, 597, 598). Pheomelanin is tightly bound to proteins, indicating that in vivo it occurs as a chromoprotein (323, 597, 598), with high variability in nitrogen and sulfur content (C/N and C/S ratios) (597, 598). Pheomelanin can also act as a binding agent for drugs and chemicals (73, 458) and, like eumelanin, contains semiquinones with their associated paramagnetic properties, but it also holds additional semiquinonimine centers (688, 689). The resulting EPR spectra of pheomelans correspond therefore to a hyperfine structure with an unpaired electron localized near the nucleus of $^{14}$N. These properties allow identification of melanin type and quantification with EPR (Fig. 2) (443, 586, 688, 689, 713, 739, 744, 745). Pheomelans are photolabile, and its photolysis products include superoxide,
hydroxyl radicals, and hydrogen peroxide (597, 598). The trichromes B, C, E, and F are pheomelanin-related products containing a basic structure unit consisting of 1,4-benzothiazine that can exist in two tautomeric forms (597, 598).

Neuromelansins are macropolymers composed of aminochromes and noradrenalinochromes (101, 151, 522, 787, 930). Similar to other melamins, neuromelansins are brown/black pigment with stable paramagnetic properties, insoluble in organic solvents, bleached by hydrogen peroxide, and labeled by silver stain (930). Neuromelansins have mixed properties of both eu- and pheomelansins; they chelate metals and interact with several inorganic and organic compounds (9, 151, 428, 930). Other types of melamins may be generated by enzymatic oxidation of serotonin or tryptophan via tyrosinase; the resulting products have structures different from classical melanin (45). Melanin-like substances can also result from the tyrosinase-mediated transformation of opioid peptides that produce black to brown pigments with paramagnetic properties almost identical to DOPA-melanin (633).

B. Melanin Pigment in Skin Physiology and Pathology

1. Human skin

Epidermal melanin has important evolutionary and physiological implications, particularly for unclothed humans. Thus high melanin content (racial pigmentation) protects the skin against ultraviolet (UV)-induced skin damage through its optical and chemical filtering properties (8). Indeed, skin pigment levels and anthropological origin are closely associated, with higher pigment amounts in regions of lower latitude and higher UV radiation levels. However, this connection may only be a recent human adaptation since early hominids may have possessed dark, dense, terminal body hair. A closely related primate, the chimpanzee, similar to most other non-human primates, exhibits white or lightly pigmented epidermis (591). Interestingly, chimpanzees have active melanocytes only in the epidermis of those areas directly exposed to UV radiation, e.g., face and friction surfaces (488).

The tendency toward relative hairlessness in modern humans has been explained by the need to maintain thermal balance under the progressive increase in demands for heat dissipation that results from the enhanced blood flow to the brain. Alternately or complementarily, hairlessness would also reduce parasitic infestations (549). Without concomitant increase in epidermal melanization, the end result of reduced hair coverage in humans residing in high UV radiation areas would be direct exposure to the adverse effects of that radiation. These include sunburn damage to the sweat glands with resultant suppression of sweating and abnormal thermoregulation (550), carcinogenesis, and nutrient inactivation by photolysis (e.g., folate) (74). Human populations living in areas with lower UV levels would adapt with lesser pigmentation, which also facilitates the cutaneous UV radiation-mediated conversion of 7-dehydrocholesterol to pre-vitamin D₃ (876) In fact, if UV exposure of pigmented humans is limited in duration and/or intensity (e.g., northern latitudes), vitamin D₃ deficiency and its associated pathologies may result, as seen in Southern Asians (Indians) living in northern European cities (267). Nevertheless, the value of the melanin pigmentation as a truly effective sunscreen for seasonal tanning is debatable since its sun protection factor (SPF) is only 1–2 (902). Additional properties of melanin may include a bactericidal potential via the production of orthoquinones (618), and contribution to the tensile strength of hair via cross-linking with proteins.

Hair color may have undergone a far more complex evolution than skin pigmentation. Although most humans are dark-haired and dark-eyed, melanization in skin, hair, and eyes do not closely correlate. Indeed, a large fraction of humans have dark eyes and hair but their skin would rate as “white,” whereas in some western European populations, black hair commonly coexists with blue eyes. The occurrence of black scalp hair, a potent trap for radiant heat, may appear as a paradoxical development for primates and humans living in tropical climates; however, black scalp hair may provide some protection from sunstroke by helping with the salt balance through the highly efficient and fast ion exchange property by melanin (746, 902). In fact, the pigmented hair on the human scalp may have resulted from the littoral residence of Homo sapiens residing on sea coasts or riverbanks, with diet dominant in fish (many of which concentrate heavy metals). In this context, the capability to rapidly excrete toxic metals provided by the very high turnover of melanized cortical keratinocytes in the pigmented hair shaft would confer a selection advantage (46). Thus the long, melanized scalp hair with its capability to trap and/or bind chemicals, toxins, and heavy metals would prevent their access to living tissues. Pigmented hair may also provide antioxidant defense for the skin and hair follicles due to the high capacity of melanin for binding transition metals. This buffering capacity as applied to calcium would imply a role for melanin in cell function, since calcium is a critical second messenger in pigmentation signaling, acting in the transfer of melanosome to keratinocytes, and in epithelial cell differentiation (746).

A) SEXUAL DIFFERENCES IN SKIN MELANIZATION. The epidermis of adult human females is less melanized than in adult males, suggesting a gender-specific effect (626). One possible explanation for this discrepancy could be the higher need for vitamin D in women that is imposed by the
increased intestinal calcium absorption of pregnancy and lactation (894).

B) MELANIN ROLE IN HUMAN PATHOLOGY. The main action of melanin in human skin appears to be attenuation of UV penetration to blood in dermal vessels. This may be inferred from the observation that peak UV absorption for oxyhemoglobin occurs at 545 nm, a value that in light-skinned individuals produces the strongest erythema reaction, and consequent pigmentary response. Also, when exposed to UV radiation, melanin can undergo photosensitization generating superoxide radicals and lethal injury in individual cells. Paradoxically, this action would however confer protection against the more deleterious outcome of cell neoplasia, consistent with the decreased proliferation rate of highly melanized normal skin cells (194), and with the close linkage between melanin production and photorepair of UV-induced DNA damage (212). Taken together, these data imply that melanin is important for skin homeostasis and that tanning itself represents a distress signal. The same pathophysiological explanation would apply to the localized pigmentation that follows the exposure of melanin to toxic compounds, and that may result in marked increases in melanin granules and melanin deposition (427).

Abnormalities in the transfer of melanosomes out of the melanocytes and into receiving keratinocytes represent the human counterpart of the dilute mutation in mice where the motor protein myosin V is defective. Disorders associated with aberrant melanosomes include the macromelanosome and autophagic giant melanosome complexes of nevocellular nevi, lentigo simplex, malignant melanoma, and the neuroectodermal melanolysosomal diseases that include the Elejalde, Chediak, Higashi, and Griscelli syndromes (515, 779, 780). These syndromes are megaloblastic in nature (for many species, melanin affords significant additional protective value, e.g., seasonal change of coat color in the arctic fox), social and sexual communication (involving visual stimuli, odorant dispersal, etc.) and sensory perception (e.g., whiskers). Many furred mammals, including the mouse, lack melanogenically active melanocytes in their adult truncal epidermis; instead, melanin is produced in the hair follicle bulb. There is, however, considerable variation in pigment patterns within and between furred mammals; for example, perifollicular melanocytes extend to the dermis in the hairy truncal skin of the adult Syrian golden hamster (602).

Mammalian hair color exhibits a wide range of shades. The highly variable color of murine pelage reflects variation in the copolymerization of eu- and phaeomelansins, which results in the production of black, brown, yellow, gray, or white hair fibers. Natural eumelansins are produced by comixtures of DHI and DHICA, which provide variable contributions to pigmentation. For example, dilution mutant mice (e.g., slaty) exhibit a 30% reduction in total melanin compared with the black hair type, but the specific reduction in DHICA content can be >80% (548). DHICA melanins determine brown colors in the animal kingdom (538), although the ratio of DHI to DHICA in the brown mutation is similar to that seen in the black hair type. The light mutation at the brown locus produces variable contributions to pigmentation. For example, dilution mutant mice (e.g., slaty) exhibit a 30% reduction in total melanin compared with the black hair type, but the specific reduction in DHICA content can be >80% (548). DHICA melanins determine brown colors in the animal kingdom (538), although the ratio of DHI to DHICA in the brown mutation is similar to that seen in the black hair type. The light mutation at the brown locus results in the presentation of melanin only at the hair fiber tips due to premature death of follicular melanocytes (339). The silver mutation in mice is also associated with progressive graying caused by loss of melanocytes. Silver melanin is similar to brown and light melanosins and those light-silver animals producing a diffuse “soluble” melanin within degenerating melanocytes.

Studies performed on the yellow (Ay/a) mouse and on the tortoise-shell guinea pig, with its potential to develop black, red, yellow, or white hair, have shown that...
A. Melanocytes as Melanin-Producing Cells: Cell Biology and Ultrastructure

Under physiological conditions, melanin synthesis in melanocytes is restricted to melanosomes, and its enzymatic and structural elements are organized and assembled separately in a process resembling lysosome formation (333, 335, 487, 515, 597), although membrane traffic pathways differ between melanosomes and lysosomes (187). In general, melanosome structure correlates with the type of melanin produced, e.g., eumelanosomes are elliptical and contain fibrillar matrix while pheomelanosomes shape is variable with predominantly rounded contour and contains vesiculoglobular matrix (515). Melanosome development involves four steps. Stage I corresponds to the early matrix organization. In stage II, the matrix is already organized but without melanin formation (eumelanosomes); in pheomelanosomes melanin is already formed at this stage. In stage III there is deposition of melanin. In stage IV, melanosomes are fully melanized (completely filled with melanin) (Fig. 3). Under pathological conditions (e.g., melanoma), this orderly process is deregulated; for example, tyrosinase may already be activated at stage I of melanosome formation, whereas melanin can be deposited within organelles as a “granular type” without fibrillar or vesiculoglobular matrix (65, 334). These granular melanosomes produce eumelanin (Fig. 3C). There is no evidence for differences in melanosome biogenesis between follicular and epidermal melanocytes. Thus, in black hair follicles, melanocytes contain the largest number and most electron-dense melanosomes (eumelanosomes), each with a fibrillar matrix; in brown hair, bulb melanocytes are somewhat smaller, and in blonde hair melanosomes are poorly melanized, often with only the melanosomal matrix visible. Red hair pheomelanosomes contain a vesicular matrix, but melanin is deposited irregularly, in blotches (Fig. 3). Of interest, both eumelanogenic and pheomelanogenic melanosomes can coexist in the same human cell (316), but not within the same pathway, e.g., there is a switch committing melanosomes to either eu- to pheomelanin synthesis (547). These structural principles apply to follicular melanocytes and also probably to human epidermal melanocytes and rodent cutaneous melanocytes (181, 515).

Melanosome-genesis involves interactions between rough endoplasmic reticulum (RER) structures and vesicles and channels of the trans-Golgi Network (TGN); thus early premelanosomes (stage I) are formed by outpouching of a smooth membrane from the RER (487, 515, 782), and at stage II of the eumelanogenic pathway a fibrillar matrix is formed. It was recently proposed that late endosomes may be the initial sites of stage I melanosome formation (333, 335, 456, 608); further maturation would be driven by delivery of structural and enzymatic proteins, and by their activation followed by substrate delivery. Others believe that formation of melanosomes is driven by independent, but overlapping, mechanisms (384). Maturation of eumelanosomes is the subject of two main views. One suggests that the enzymatic proteins required for melanogenesis are delivered via coated vesicles to melanosomes that originate from the endoplasmic reticulum and Golgi (335). An alternate interpretation is
that tyrosinase and other melanogenesis-related proteins are sorted to early endosomes by the adaptor protein-3 system (from the TGN) and from there to late endosomes, which then fuse with stage I melanosomes (384). Stage I melanosomes may contain some melanogenesis-related proteins (MRPs), but these remain catalytically inactive until subsequent protein cleavage events release them into the interior of melanosomes. These events are associated with a change in melanosome shape, from spherical to ellipsoidal, and with the formation of an intramelanosomal fibrillar network (eumelanosomes). Melanogenesis commences when tyrosinase and other relevant enzymes are cleaved, and initiation of activity may depend on an acidic environment provided by proton pumps (454, 601). It is believed that at acidic pH fully mature tyrosinase hydroxylates L-tyrosine to L-DOPA to begin melanin synthesis forming stage III melanosomes (454, 487, 515, 537, 538).

**FIG. 3.** Electron microscopy of melanosome development during eumelanogenesis in normal melanocytes (a–j), of pheomelanogenesis (g–j), and of granular melanosomes in melanoma cells that synthesize eumelanin (k). I, II, III, and IV in a–j and 1, 3, and 4 in k represent stages of melanosomal development. Scale bars are as follows (in μm): a, 0.20; b, 0.23; c, 0.24; d, 0.22; e, 0.20; f, 0.35; g, 0.23; h, 0.26; i, 0.26; j, 0.30; k, 0.5.
Another theory postulates earlier involvement of tyrosine hydroxylase to produce L-DOPA that acts as a necessary cofactor for tyrosinase enzyme action (457). The initial hydroxylation reactions, as well as L-DOPA stability, require an acidic environment that is provided by premelanosomes, where pH is regulated by a proton pump system (145, 487, 601). However, once L-DOPA is present, efficient formation of melanin pigment requires an increased pH (preferably neutral or basic) (19, 191), since acidification inhibits melanin synthesis (191, 487). The mechanism(s) for delivery of MRPs is under intensive investigation, and the timing of their actual incorporation into melanosomes is still unclear. Proper folding and assembly of MRPs in the ER requires their interaction with calnexin, glycosylation in the TGN, and the interaction of tyrosinase with TyrP1 or P protein (262, 385). MRP transport requires the formation of special vesicles, with assembly of coat proteins on the cytoplasmic side of the TGN to select MRPs for melanosomal delivery (333, 692). The adapter protein-3 (AP-3) that binds a dileucine motif in the cytoplasmic tail of tyrosinase-related proteins (TRPs) is important for the transport of TRPs from the TGN to melanosomes (335, 692). Small GTP binding proteins such as Rab 5 and 7, and phosphatidylinositol 3-kinase are involved in the intracellular trafficking of MRPs (333). An updated model of melanosome formation and trafficking of MRPs (Fig. 4) (132) includes tyrosinase, TyrP1, TyrP2, MART-1, P and gp100, and also the pathological misrouting of tyrosinase and TyrP1 (385). Proteomic analysis of early melanosomes has provided new information on the recruitment of organelle specific proteins and on membrane remodeling crucial for melanosome formation, movement, and transfer (Fig. 5) (33).

The recently cloned pink-eyed dilution mouse gene (p) and its human P homolog encode a melanosomal protein with 12 transmembrane domains with partial homology to a tyrosine specific transporter protein in Escherichia coli (204, 620). Mutations in this gene lead to decreased pigmentation in mice (620) and to type II ocularcutaneous albinism in humans (OCA2) (204). It has been proposed that P protein could act as transporter for tyrosine (204, 620), as ion exchange protein in the melanosomal membrane (601), or as regulatory protein for the processing and assembly of MRPs (539). Alternatively, P protein could act as specific “L-tyrosine receptor/transducer” (736, 739) after binding L-tyrosine or related molecules; thus it would regulate the assembly of the melanogenic apparatus in vivo (293, 720, 732–734). This would be consistent with the homology of the P protein to the tyrosine specific transporter (204, 620), and with the proposed regulatory role for P protein in the assembly of the melanogenic apparatus (539).

Melanosomes also contain the lysosome-associated membrane proteins (LAMP) that protect the lysosomal membrane (333, 335, 654) and, as already mentioned, the presence of LAMP-1, -2, and -3 proteins in melanosomes supports a common ancestral origin for melanosomes and lysosomes. It has been suggested that LAMP-1 protects melanosomal integrity by acting as a scavenger of free radicals produced during melanogenesis, while the membrane-bound calcium binding protein calnexin (p90) of 90 kDa would participate in the assembly of melanosomal proteins and regulation of tyrosinase (335, 654). Melanosomes contain a proton pump that allows regulation of intramelanosomal pH; melanosomes also internalize cell surface melanocyte-stimulating hormone (MSH) receptors via the endocytic pathway (487). These properties together with the incorporation of lysosomal enzymes such as acid phosphatase and the lysosomal protective protein LAMP strengthen the view that lysosomes and melanosomes share a common pathway of organellogenesis (333, 335, 487, 607, 654). The MSH-induced delivery of MSH receptor to melanosomes points to a possible intra-
cellular mechanism for specific and precise regulatory function of MSH (415, 487, 561).

The mechanism of phaeomelanosome formation is less precisely defined than for eumelanosomes. Briefly, vesiculoglobular bodies are incorporated into stage I melanosomes. At stage II melanosomes, phaeomelanin is deposited on a vesiculoglobular matrix (333, 335, 515, 597, 708), indicating the presence of tyrosinase activity at an earlier phase than in the eumelanogenic pathway. The process of phaeomelanogenesis depends on the presence of tyrosinase activity, which is comparatively low, and on the availability of cysteine to conjugate dopaquinone formed by tyrosinase action (515, 597, 598).

Because melanosomes are metabolically active organelles, their activity is bound to affect the function of the host melanocyte or keratinocyte (746). Thus melanosomes modify the cellular energy-yielding metabolism by switching oxidative catabolism to anaerobic glycolysis (684), altering the intracellular NAD/NADH and NADP/NADPH ratios (682) and/or stimulating the pentose phosphate pathway (683). The presence of pigment granules that can regulate intracytosolic calcium concentration, or reversibly bind cations or bioregulatory compounds such as catecholamines, serotonin, and prostaglandins, may also affect the function of the host cell (736, 746). Based on this, it has been further proposed that melanosomes could serve as an accurate indicator for cellular responses to the environment (262). Results of proteomics analyses appear to support the notion that melanosomes are complex organelles (Fig. 5) (33) that regulate the function of melanocytes and perhaps other surrounding cell types (262, 385, 736–738, 746).

B. Biochemistry of Melanogenesis

1. Introduction to melanogenesis

Cutaneous pigmentation is under complex genetic control regulated by more than 150 alleles spread over 90 loci (262, 263, 328, 385, 515, 673, 708). Protein products of these loci acting as enzymes, structural proteins, transcriptional regulators, transporters, receptors, and growth factors have a wide array of functions and cellular targets (263, 515). Among them are the important structural, enzymatic, and regulatory melanosomal proteins coded by albino(c)/TYR, brown(b)/TYRP1, slaty(slt)/TYRP2/DCT, silver(slt)/SILV, pink-eyed dilute(p)/P/OCA2, underwhite(uw)/LOC51151, MART1, and OA1 loci (263, 515).

An early obligatory and rate-limiting step in melanogenesis is the hydroxylation of L-tyrosine to L-DOPA catalyzed by either the tyrosine hydroxylase activity of tyrosinase (EC 1.14.18.1) (264, 413, 464, 575, 597) or possibly by tyrosine hydroxylase itself (457). Once L-DOPA is formed, further steps of melanogenesis (series of oxidoreduction reactions and intramolecular transformations) can occur spontaneously, at varying rates depending on hydrogen ion concentration, presence, and concentration of metal cations, reducing agents, thiols, and oxygen (597). Most importantly, the velocity and specificity of the pathway are regulated by the melanogenesis-related enzymes (MREs) of which the most important is tyrosinase (264, 575, 597).

The availability of L-tyrosine for enzymatic oxidation is a central component of melanogenesis, regulated at the
level of transport both through the plasma membrane, and from the cytosol into the melanosome (592, 593). Another source of L-tyrosine, L-phenylalanine (taken up actively by melanocytes via neutral amino acid Na\(^+\)-Ca\(^{2+}\)-ATPase antiporter system) (673, 790) and hydroxylated by phenylalanine hydroxylase (PAH) (EC 1.14.16.1) can generate relatively high intracellular concentrations of L-tyrosine, sufficient to initiate melanogenesis (673, 676). Thus initiation of melanogenesis is dependent on either transport of L-tyrosine from the extracellular space or intracellular hydroxylation of L-phenylalanine by PAH regulated by availability of reduced tetrahydropteridine cofactor (661, 670, 673).

The type of melanin produced is determined by the enzymatic library available and its prevalent metabolism (Fig. 1). For example, in the central nervous system, enzymatic decarboxylation of DOPA by aromatic amino acid decarboxylase (AAD) yields catecholamines that may be oxidated to neuromelansins. It is nevertheless unclear whether oxidation of catecholamines in substantia nigra with transformation into neuromelansins is catalyzed enzymatically or whether it is dependent on physicochemical factors (e.g., pH, presence of metal cations, and thiols concentration) (930). The involvement of macrophage inhibitory factor in the formation of neuromelanin has been already demonstrated (262, 467, 638, 664), but not the involvement of peroxidase (930). In melanocytes, the presence of tyrosinase allows rapid oxidation of tyrosine or L-DOPA to dopaquinone, initiating eu- or pheomelanogenesis pathways. Similarly, high concentrations of metal ions such as Mn\(^{2+}\) or Cu\(^{2+}\) also rapidly oxidized DOPA to melanin. Metal cations such as copper, zinc, and iron are also involved in the rearrangement of dopachrome to DHICA, thus affecting the composition of the melanin polymer (597, 598).

The formation of eu- or pheomelanin is directly determined by the presence/absence of cysteine (actively transported through the melanosomal membrane) (262, 594, 597, 598), and of GSH in fully reduced thiolate state and redox potential (high GSH for eumelanin and low for pheomelanin). Therefore, the presence and actual activity in the melanocyte of antioxidant enzymes such as catalase, superoxide dismutases, glutathione peroxidase, glutathione reductase, and thioredoxin reductase/thioredoxin would modify quantitatively or qualitatively the melanogenetic pathway (664). When concentration of sulfhydryl compounds is low, dopaquinone is converted to dopachrome, initiating the eumelanogenic pathway. High concentrations of cysteine and glutathione lead to their conjugation with dopaquinone and corresponding formation of cysteinylidopa (5-S-cysteinyldopa is the major isomer while 2-S-cysteinyldopa, 6-S-cysteinyldopa, and 2,5-dicysteinyldopa are minor isomers) and glutathionylidopa (597, 598). The transformation of oxidized glutathione (GSSG) to reduced glutathione (GSH) by glutathione reductase, which requires NADPH, is crucial for the formation of glutathionylidopa (GSDOPA). Hence, the NADPH/NADP recycling system and consequently the pentose phosphate shunt are indirectly involved in the regulation of melanogenesis (682, 683). GSDOPA is further transformed by glutamyltranspeptidase to cysteinylidopa (323), which serves as the starting point of pheomelanogenesis. The velocity of the postcysteinylidopa steps of pheomelanogenesis is increased by peroxidase and tyrosinase through oxidative transformation of benzothiazinylalanines (597, 598).

### 2. Tyrosinase, the main enzyme regulating melanin synthesis

The key regulatory enzyme of melanogenesis, tyrosinase (EC 1.14.18.1), is encoded by the TYR or c-locus that maps to chromosome 11q14–21 in humans (32) and chromosome 7 in mice, respectively, and is composed of five exons and four introns (387, 515, 820). The posttranscriptional processing of pro-tyrosinase mRNA generates several alternatively spliced products (351, 407, 590, 702) of which some are translated to protein products with only one expressing tyrosinase activity (500, 642). It has been proposed that products of translation of alternatively spliced tyrosinase mRNA could serve as regulatory protein (736, 739), acting for example as “receptors” for L-tyrosine and L-DOPA (739). It must be noted that enzymatically nonfunctional tyrosinase proteins can be expressed in nonmelanocytic cells of neural crest origin (254, 826).

The structure of tyrosinase protein is highly conserved among different species and shows high homology with other tyrosinase-related proteins including tyrosinase-related protein 1 (TRP1/TYRP1) and tyrosinase-related protein 2 (TRP2/TYRP2/DCT) (Fig. 6). The NH\(_2\)-terminal domain of tyrosinase comprises the NH\(_2\)-terminal signal peptide (important for intracellular trafficking and processing), the EGF-like/cysteine-rich domain, two histidine-rich regions binding copper with a cysteine-rich region between them (the important catalytic domain), as well as the COOH-terminal hydrophobic transmembrane segment and cytoplasmic tail (387, 389, 515, 702). The transmembrane and cytoplasmic domains are necessary for targeting the enzyme to the melanosome (333, 335, 692), while the NH\(_2\) terminus cysteine-rich region may serve as a protein binding/regulatory domain unrelated to enzymatic function. Newly synthesized tyrosinase has a molecular mass of 55–58 kDa and an isoelectric point of 4.2. Proper folding of tyrosinase protein in the endoplasmic reticulum (ER) appears to be crucial for its further transport to Golgi apparatus. Proteolytic cleavage of the transmembrane portion of the newly synthesized enzyme generates two soluble molecular forms: a 53-kDa unmodified protein, or a 65-kDa glycosylated tyrosinase, which
may be active in the melanosome or secreted into the extracellular environment. After glycosylation in the trans-Golgi complex, tyrosinase increases in size to 65–75 kDa or even 80 kDa (140, 141, 264, 335, 655). The higher molecular mass forms of tyrosinase (140, 655, 720, 722, 741) may represent dimmers, tight complexes with other melanogenic proteins (542), or high-molecular-weight tyrosinase proteins. It is still unclear how or when copper ions (necessary for enzymatic activity) are integrated into apotyrosinase. However, recent data suggest that the Menkes copper transporter (MNK) is required for copper loading of tyrosinase enzyme and consequently its activation (581). The catalytic site of tyrosinase is represented by two copper atoms ligated to six histidine residues. Defects in TYR gene lead to the tyrosinase negative oculocutaneous albinism type 1 (OCA1) (524, 809, 838). In addition to mutations in hot spots (copper binding domains), virtually the entire coding sequence of the gene is susceptible to mutations. These include missense, nonsense, frameshift, and splicing abnormalities (524) (http://www.cbc.umn.edu/tad). If translated, mutant tyrosinase proteins are routed for degradation by proteasomes (due to the retention of misfolded proteins in the ER), rather than allowed to pass to the Golgi apparatus for glycosylation and further transport to premelanosomes (244, 246, 249, 385, 841, 842). Similarly in OCA3, mutated TYRP1 is retained within ER and appropriate processing of normal tyrosinase is aborted leading to its proteasomal degradation and consequently significantly reduced pigmentation (385, 841, 842). In OCA2 (mutation of P) or OCA4 (mutation of MATP) tyrosinase sorting from TGN to melanosomes is also disrupted (115, 132, 385, 840). There is also a large body of experimental evidence generated in various melanocytes systems, showing that proper processing within the ER is a necessary step for tyrosinase maturation, its targeting to melanosomes, and consequently melanin pigment production (243, 244, 246, 248–250). Thus the defects underlying OCA1 through OCA4 strongly imply that in vivo melanogenic activity depends mainly on posttranslational pathways, of which the most important is effective processing of tyrosinase (Fig. 4). In fact, the levels of tyrosinase mRNA are similar in cultured melanocytes from European white and African black individuals (318), and tyrosinase gene expression level appears to be similar across human racial groups (191, 324). Other points of potential dysregulation of the melanogenic activity of tyrosinase are represented by lack of melanosomes with resulting accumulation of the enzyme in TGN or block in translocation from TGN to melanosomes (65, 714, 733), presence of intracellular tyrosinase inhibitors (344) or protein kinase-dependent phosphorylation of regulatory residues (373, 552, 900).

Tyrosinase catalyzes three distinct reactions in the melanogenic pathway: hydroxylation of monophenol (L-tyrosine), dehydrogenation of catechol (L-DOPA), and dehydrogenation of DHI; L-DOPA serves as cofactor in the first and third reactions (264, 374, 413, 575). Both ortho hydroxylation of tyrosine and dehydrogenation of DOPA
may proceed in a single step in which the substrate binding site for l-tyrosine and L-DOPA is the same, and the reaction involving electrons exchange with copper atoms generates orthoquinone and water as final products (reviewed in Refs. 400, 401, 515, 619). It has been proposed that production of DOPA during tyrosine oxidation by tyrosinase is the result of spontaneous reductive cyclization of dopaquinone to cycloDOPA that undergoes redox exchange with dopaquinone to yield dopachrome and DOPA. The latter is necessary for copper reduction and formation of deoxytyrosinase. Thus the stability, folding, and activation of tyrosinase are critically controlled by redox conditions. Activation of inactive enzyme (met-tyrosinase) involves the reduction of its two Cu2+ sites to two Cu1+ centers (fully active form; deoxytyrosinase) requiring a two-electron reduction step. L-DOPA is the most efficient electron donor necessary to start tyrosine hydroxylation, although ascorbic acid, dopamine, and superoxide anion radicals can potentially activate the enzyme (903). The effect of ascorbic acid on the monophenolase activity of tyrosinase has been explained by its reducing action on enzymatically generated quinines, thus inducing accumulation of L-DOPA, the main electron donor to the Cu2+-Cu2+ enzyme active site (629). A similar mechanism may be responsible for the reduction in lag period for tyrosine hydroxylation by catecholamines, by reduced tri- and diphosphopyridine nucleotides, and by high concentrations of tetrahydropteridine (587). However, these explanations may be valid only at relatively high pH (6.8 or higher), since at low pH (5.0), tyrosine hydroxylation proceeds independently of L-DOPA (in the presence of ascorbic acid as the only reductant). At acid pH tyrosine loses its ability to bind at its allosteric site and cresolase activity is not inhibited by excess of tyrosine (145) and since DOPA oxidase activity is inhibited by acidic pH the excess of l-DOPA could escape catalytic site and diffuse to other cellular compartments. Tyrosinase activity can also be inhibited by interactions with cysteine, by chelation of copper ions, by competitive occupancy of the catalytic site (for example, by l-phenylalanine), by feedback inhibition by intermediates of melanogenesis, and by direct inactivation by melanin pigment. Tyrosinase activity in vitro is thus regulated by the local chemical environment and, by the process of melanogenesis itself including its final product melanin.

3. TRP1 and TRP2 as modifiers of pathway velocity

Two additional TRPs stimulate eumelanin synthetic rate: TRP1, product of TYRP1 (human) or b (mouse) locus, and TRP2 product of TYRP2/DCT (human) and slaty locus (mice). The gene for TYRP1 is 37 kb long and contains eight exons separated by seven introns (515, 656). The TYRP1 proteins is encoded by exons 2–8, with exon 1 containing a noncoding sequence (329, 700). However, functional analysis of the human TYRP1 promoter showed that the downstream region, containing 5-untranslated region (exon 1) and intron 1 had enhancer activity for the gene (703, 704). Alternative splicing of TYRP1 pre-mRNA generates at least two isoforms, one coding for the correct protein and another containing a deletion of 103 bp at the 5’-end of exon 8 to generate soluble TYRP1 protein without transmembrane domain because of frame shift (700). The potential for production of multiple alternatively spliced isoforms had been predicted based on analysis of the TYRP1 gene sequence (329). The gene for TYRP2 is 60 kb long and contains at least eight exons and seven introns; all eight exons encode the final protein (84). Similar to TYR and TYRP1, TYRP2 transcription and processing also generates several alternatively spliced forms (356, 445, 585). These include the correct TYRP2 mRNA, and the isoforms TYRP2–6b (contains an in frame insertion of two novel exons from intron 6), TYRP2-INT2 (retains an intron 2 with stop codon), TYRP2-LT (has an extended 3’-untranslated end), and TYRP2–8b (contains a novel exon 8b replacing exon 8) (356, 445, 585). TYRP2-LT codes for a protein identical to TYRP2. TYRP2–6b codes a protein with sequence almost identical to TYRP2 with the in-frame insertion of 33 amino acids; most likely this represents a fully functional enzyme. The remaining TYRP2-INT2 and TYRP2–8b isoforms correspond to truncated enzymatically inactive soluble proteins without transmembrane domains (445, 585). TYRP1 and TYRP2/DCT proteins share ~40% amino acid homology with tyrosinase, with which they also have structural similarity (84, 329, 387, 515, 700). The proteins contain an NH2-terminal signal sequence, EGF-like domains, and other cysteine-rich region, two histidine-rich metal binding domains, and a COOH-terminal transmembrane segment with short cytoplasmic tail. However, different exons code for different homologous segments in tyrosinase and tyrosinase-related proteins (Fig. 6). In TYRP2, the metal binding domain binds zinc, while in TYRP1 it weakly binds iron. The COOH terminus and transmembrane domains are crucial for targeting the enzyme to the melanosome. Newly synthesized TYRP1 and TYRP2 have ~55 kDa molecular mass and after posttranslational folding are targeted to the Golgi apparatus for further processing (262, 333, 335, 385). Mature and glycosylated proteins of 70–75 kDa are sorted from the Golgi apparatus to melanosomes. Because of the presence of sequences homologous to EGF in TYRP2, they can form multimeric complexes of 200–700 kDa, which may be important in the regulation of melanogenesis (330, 452, 542), or in the synthesis and assembly of the melanogenic apparatus (452, 736, 739).

In the mouse, TYRP1 acts as a DHICA oxidase to generate indole-5,6-quinone-carboxylic acid (329, 336, 368). However, some authors have proposed that TYRP1...
does not catalyze the reaction in humans exhibiting instead tyrosine hydroxylase activity at low concentration of substrate (62). TYRP1 activity appears to be important for eumelanogenesis, as suggested by its lack or defective expression in cells displaying an active phaeomelanic pathway (142, 722). An additional function of TYRP1 may be the securing of appropriate processing of tyrosinase (see above) and stabilization of its enzymatic activity and, possibly, maintenance of melanosomal structure integrity (262, 410, 656, 657). TYRP-2 acts as dopachrome tautomerase (EC 5.3.2.3) catalyzing transformation of dopachrome to DHICA (330, 843, 920). TYRP-2, similar to TYRP1, is considered to be a eumelanogenic enzyme and also stabilizes tyrosinase activity. Most recently, a role for TYRP2 in melanocyte survival has been demonstrated (reviewed in Ref. 262). Thus both TYRP1 and TYRP2 can act as enzymes modifying eumelanogenesis velocity, as regulators/stabilizers of the eumelanogenic apparatus in vivo and, perhaps, as regulators of other functions of the melanocyte.

4. Tetrahydropteridines, phenylalanine, and tyrosine hydroxylase as regulators of melanogenesis

A recent theory proposes that tetrahydropteridines, phenylalanine, and tyrosine hydroxylase participate in the regulation of the initial steps of melanogenesis in the human skin (673). Thus in human epidermis synthesis of melanin is dependent on the in situ l-tyrosine production by phenylalanine hydroxylase (PH) (EC 1.14.16.1), which in turn requires the presence of cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (6BH4). Both PH and the full system for the de novo synthesis and recycling of 6BH4 are expressed in human melanocytes (661, 670, 676). Transport of l-tyrosine by keratinocytes (they surround melanocytes in the epidermis) is very low, making its relative availability to melanin through this pathway also low (673). Conversely, in vitro experiments (673) had demonstrated active transport of l-phenylalanine and in situ turnover to l-tyrosine, thus contributing two-thirds of the substrate needed for melanogenesis, whereas only one-third originates from l-tyrosine transport. These findings are consistent with l-tyrosine control of synthesis/assembly and activity of melanogenic apparatus in amelanotic Bomirski hamster melanoma cells and the lack of such effect in Cloudman S-91 melanoma cells (735). The latter express PH activity making them independent of external tyrosine supply (77). This concept is also consistent with the findings in human epidermis of proportionality between 6BH4 levels, PH activity, and skin phototypes. PH activity and 6BH4 are lowest in skin type I and highest in type VI skin (661, 670). Production of the cofactor in concentrations that would yield l-DOPA needed for activation of Met-tyrosinase could alternately be met by local tyrosine hydroxylase, since this is expressed in both human keratinocytes and melanocytes (457). Indirect support for this concept comes from the documentation in human skin of tryptophan hydroxylase expression (749, 752, 757); this enzyme, similar to PH and TPH, requires 6BH4 as its cofactor.

Lastly, a central role for 6BH4 in the initial regulation of melanogenesis is emerging from studies in vitiligo patients who have a blockade in the recycling of that cofactor originating from the deactivation of the rate-limiting recycling enzyme 4a-carbinolamine dehydratase (DH) (EC 4.2.1.96) by hydrogen peroxide (H2O2) (667, 671, 673, 674). As a consequence, the accumulated 7BH4 inhibits PH reducing the supply of l-tyrosine, while 6BH4 can act as allosteric inhibitor of tyrosinase (904). Conversely, photo-oxidation of 6BH4 by UV-B to 7,8-dihydroxanthopterine or perhaps, its complexing with α-MSH lead to activation of tyrosinase allowing melanogenesis to proceed (490, 579, 666). Yet to be explained is coincidence of melanogenesis induction and induction of thioredoxin reductase in black and brown guinea pigs and in murine melanoma cells (664). Epidermal thioredoxin reductase activities also increase linearly with increase in skin phototypes (from type I to VI) (670).

5. Other melanogenesis-related proteins

Additional enzymatic regulators of melanogenesis include peroxidase (EC 1.11.1.7), PMEL 17/HMB45/gp100/SILV protein(s), and catechol-O-methyltransferase (COMT) (EC 2.1.1.6) (29, 387, 530, 531, 597, 598, 765). Peroxidase catalyzes the oxidation of DHI and DHICA (597, 598). The enzyme responsible for O-methylation of DOPA and its dihydroxyindolic intermediates, COMT, is present as soluble and membrane-bound isoforms (765). Its proposed role is inactivation of toxic intermediates of melanogenesis, and thus it may regulate the velocity of the early steps of melanogenesis (765). Indolic melanogens can be conjugated with glucuronic and sulfuric acid to form indolic sulfates and glucuronate complexes (597, 598).

The human gene PMEL 17/HMB45/gp100/SILV maps to chromosome 12q12-q13 and is homologous to the silver locus in mice (387, 388). The gene comprises 11 exons and 10 introns spanning 9.1 kb; processing of the transcribed mRNA generates at least two alternatively spliced isoforms coding for PMEL17 and GP100 proteins (515, 773). PMEL17 is a 68-amino acid protein with a potential signal peptide and a single transmembrane domain near the COOH terminus (515, 773). GP100 is a 661-amino acid protein with an ~100 kDa molecular mass that differs from PMEL17 by the presence of one substitution (P274L), and by the deletion of the heptapetide (588VGILLT594) located before the transmembrane domain. Both glycoproteins are recognized by HMB45 monoclonal antibodies, contain cysteine, and histidine-

---

**Physiol Rev • VOL 84 • OCTOBER 2004 • www.prv.org**
rich regions and are associated with the melanosomal membrane and matrix. They share the ExxPLL motif (proposed as melanosomal targeting signal) and cysteine and histidine-rich regions (reviewed in Refs. 515, 773). PMEL17 catalyzes the polymerization of DHICA to melanin (109). In addition, PMEL17/GP100 may act in melanosomes as scaffold for deposition of melanin, stabilizing melanin intermediates (262). GP100 and PMEL17 transcripts are expressed in many tissues, but expression of the protein is restricted to normal and malignant melanocytes, indicating tight translational regulation (515, 773).

Other possible regulators of melanogenesis that remain to be characterized and cloned include DHI inhibitor factor, which decreases the rate of DHI transformation to melanin, and stablin which prevents autoxidation of DHICA to melanin (515, 561, 573). Among the enzymes indirectly affecting melanogenesis are glutathione reductase and glutathione peroxidase that regulate the levels of reduced and oxidized glutathione (515, 597, 598). Catalase regulates H₂O₂ removal; H₂O₂ is a potent inhibitor of reduced and oxidized glutathione (515, 561, 573). Among the enzymes that directly affect melanogenesis are glutathione reductases and/or inhibit glycoprotein phosphorylation (683, 684, 727). Through these mechanisms melanogenically active melanosomes may affect functions and responses of keratinocytes or macrophages (746).

Because of the sharing of L-DOPA precursor, melanogenesis and catecholaminogenesis may be subject to potential interactions. For example, the presence of dopamine in TH null mice suggests an alternative route to dopamine synthesis not mediated by TH. In this regard, the presence of tyrosinase in pigmented TH null mice has been associated with higher tissue levels of catecholamines compared with albino TH null mice (621). This potential TH-independent source of dopamine is consistent with the observation of age-related decreases in dopamine production in the periphery during the early postnatal period in TH-null pigmented mice (161). Tyrosinase-dependent dopamine production could also occur via additional decarboxylase activities to convert L-dopa to dopamine. Reportedly the incidence of Parkinson’s disease is lower in humans with heavier pigmentation (630). Also, sensitivity to the dopamine agonist apomorphine is greater in mice with reduced, or no tyrosinase activity (e.g., albino mice) (630). Also, sensitivity to the dopamine agonist apomorphine is greater in mice with reduced, or no tyrosinase activity (e.g., albino mice) (630, 799). Tyrosinase has indeed been detected in the brain (826), and the infusion of tyrosinase into the striatum may increase striatal dopamine levels (16).

TYRP-2/DCT is expressed in migrating melanoblasts and in the telencephalon of mouse embryos, where the tyrosinase and TYRP-1 genes are not normally expressed (785). DCT mRNA is also expressed in glioblastoma multiforme (797) and in retinoblastomas (846). It is therefore conceivable that the DCT expressed in these tissues may be responsible for functions other than melanin production, such as detoxification of metabolites derived from association with multiple haplotypes including HLA-A2, HLA-A24, HLA-B44, HLA-A1, HLA-DR4, and HLA-DR15 (651, 718, 760, 766, 869). MRP antigens may also represent immune targets for the melanocyte destruction in vitiligo (255, 869), or for the initiation of alopecia areata (558).

MRPs also have indirect extrapigmentary functions related to their catalytic activity with production of L-DOPA and other intermediates of melanogenesis (736, 739, 743, 746). Thus L-DOPA and products of its oxidation inhibit the immune system (729, 743), whereas inhibition of T-cell response against melanin-producing fungi is dependent on melanogenesis (302, 808). Melanin precursors have genotoxic and mutagenic effects, which may be amplified by the free radicals and reactive oxygen species generated during melanogenesis. This mutagenic environment in melanoma cells may lead to genetic instability and appearance of new, more aggressive cell populations resistant to therapy (743). Melanogenesis and its intermediates can switch cell metabolism from aerobic to anaerobic glycolysis, stimulate pentose phosphate pathway, and/or inhibit glycoprotein phosphorylation (683, 684, 727). Through these mechanisms melanogenically active melanosomes may affect functions and responses of keratinocytes or macrophages (746).

C. Extrapigmentary Functions of Melanogenesis-Related Proteins

Tyrosinase and gp100 are MRPs that represent recent diagnostic markers and therapeutic additions to the management of melanoma (reviewed in Refs. 97, 716, 718). Tyrosinase, TYRP-1, TYRP-2, GP100, and melanosome specific MART 1 are classified as major histocompatibility complex (MHC) class I-restricted tumor antigens (or MHC-I and -II in case of tyrosinase), thus being potentially useful in melanoma diagnosis therapy (reviewed in Refs. 97, 716, 718, 809). Therapeutic applications would involve the generation of specific peptides to activate a T-lymphocyte response against melanoma cells. Such a T-cell immune response could however be highly variable because MRP-derived peptides can be recognized by T cells in association with multiple haplotypes including HLA-A2, HLA-A24, HLA-B44, HLA-A1, HLA-DR4, and HLA-DR15 (651, 718, 760, 766, 869). MRP antigens may also represent immune targets for the melanocyte destruction in vitiligo (255, 869), or for the initiation of alopecia areata (558).

MRPs also have indirect extrapigmentary functions related to their catalytic activity with production of L-DOPA and other intermediates of melanogenesis (736, 739, 743, 746). Thus L-DOPA and products of its oxidation inhibit the immune system (729, 743), whereas inhibition of T-cell response against melanin-producing fungi is dependent on melanogenesis (302, 808). Melanin precursors have genotoxic and mutagenic effects, which may be amplified by the free radicals and reactive oxygen species generated during melanogenesis. This mutagenic environment in melanoma cells may lead to genetic instability and appearance of new, more aggressive cell populations resistant to therapy (743). Melanogenesis and its intermediates can switch cell metabolism from aerobic to anaerobic glycolysis, stimulate pentose phosphate pathway, and/or inhibit glycoprotein phosphorylation (683, 684, 727). Through these mechanisms melanogenically active melanosomes may affect functions and responses of keratinocytes or macrophages (746).

Because of the sharing of L-DOPA precursor, melanogenesis and catecholaminogenesis may be subject to potential interactions. For example, the presence of dopamine in TH null mice suggests an alternative route to dopamine synthesis not mediated by TH. In this regard, the presence of tyrosinase in pigmented TH null mice has been associated with higher tissue levels of catecholamines compared with albino TH null mice (621). This potential TH-independent source of dopamine is consistent with the observation of age-related decreases in dopamine production in the periphery during the early postnatal period in TH-null pigmented mice (161). Tyrosinase-dependent dopamine production could also occur via additional decarboxylase activities to convert L-dopa to dopamine. Reportedly the incidence of Parkinson’s disease is lower in humans with heavier pigmentation (630). Also, sensitivity to the dopamine agonist apomorphine is greater in mice with reduced, or no tyrosinase activity (e.g., albino mice) (630, 799). Tyrosinase has indeed been detected in the brain (826), and the infusion of tyrosinase into the striatum may increase striatal dopamine levels (16).

TYRP-2/DCT is expressed in migrating melanoblasts and in the telencephalon of mouse embryos, where the tyrosinase and TYRP-1 genes are not normally expressed (785). DCT mRNA is also expressed in glioblastoma multiforme (797) and in retinoblastomas (846). It is therefore conceivable that the DCT expressed in these tissues may be responsible for functions other than melanin production, such as detoxification of metabolites derived from
DOPA (785). This would be consistent with a postulated role for TYRP2 in melanocyte survival (262).

III. MECHANISMS OF REGULATION OF MELANOGENESIS

A. Transcriptional Regulation

The gene for tyrosinase contains at least one major and three minor transcription starting sites (515); the promoter region contains TATA and CAAT boxes, several potential microphthalmia-associated transcription factor (MITF) binding sites including M-boxes, E-boxes, and tyrosinase distal element (TDE), five AP-1 and two AP-2 binding sites for the phorbol ester-inducible enhancer-binding protein AP-1 (activator protein-1), glucocorticoid responsive elements (GRE), UV responsive elements (URE), Oct-1 boxes (octomer element binding POU domain transcription factors), thyroid and retinoic acid-like responsive elements (TRE and RER), tyrosinase element-1 (TE-1), high mobility group protein (HMG-1) binding element, SP1 element, and two DNase I hypersensitive sites (HS-sites) embedded within a scaffold/matrix attachment region (S/MAR) (48, 72, 196, 329, 515, 700, 703). Of interest is the reported absence of exact CRE sequence (47–49, 72, 196, 329, 515, 700, 703). Of interest is the reported absence of exact sequence of cAMP responsive element (CRE) in the promoter region (S/MAR) (47, 167, 197, 358, 387, 390, 489, 703, 704). Of interest is the reported absence of exact sequence of cAMP responsive element (CRE) in the promoter region. The human tyrosinase promoter contains the hepatocyte nuclear factor (HNF-1) consensus binding sequence, which is activated by dimerization of the cofactor hepatocyte nuclear factor-1/HNF-1 (DcoH/HNF-1) (663).

The TYRP1 gene contains several potential alternate transcription initiation sites with promoter region structurally different from tyrosinase, e.g., unlike tyrosinase it does not contain TATA or CCAAT boxes (48, 72, 329). The 5'-upstream region of TYRP1 contains several positive and negative regulatory elements including the M- and E-boxes, Oct-1, and two melanocyte specific elements in mouse but not humans (MSEu and MSEi) and lacks the CRE sequence (47–49, 72, 196, 329, 515, 700, 703). The promoter region of TYRP2 contains in addition to M- and E-boxes, CRE-like sequences, AP-2, interleukin-1-responsive elements of the interleukin-6 gene (NF-IL6) and DOPA tautomerase distal enhancer 1 (DDE1) (13, 47, 515, 921). The promoter/enhancer structures of other MRPs such as SILV/PMEL17/GP100 also contain E-box elements. Of interest, the promoter region of mouse and human MC1R has also been shown to contain an E-box element (21).

Most significant is the presence of motifs such as M-boxes, E-boxes, TDE, TPE, in the promoter regions of MRPs, that constitute binding sites (with a core CANNTG motif) for a large family of transcription factors sharing a basic helix-loop-helix structure required for DNA binding and dimerization. The important representative of the basic helix-loop-helix-leucine zipper (b-HLH-ZIP) is MITF that plays a fundamental role in the transcriptional regulation of melanogenesis (see sect. vii). Its binding to promoter regions of MRPs is necessary for the melanogenic activity of the melanocytes and the development of melanocytes lineage (see below). Although other b-HLH-ZIP proteins such as TFE3 or TFE3 have been shown to play a role in regulation of melanogenesis in cell culture (860), there is no genetic evidence that various members of this family including USF, Myc and Max, and various TFE3 family members are involved in the developmental regulation of pigmentation (99). A more complex role in transcriptional regulation (positive and negative) of melanogenesis-related genes is played by the member of the class III POU binding protein Brn-2/N-Oct3 (160, 823). The negative transcriptional regulation of TRP1 is mediated by brachyury-related transcription factor (TBX2), while the opposite action is executed by PAX3 (protein identical to MSF) through binding to MSE (98, 196). The positive involvement of the latter is expressed in the phenotypic pigmentation of Waardenburg syndrome types 1 and 3 in which PAX3 is mutated (816, 817). In murine melanoma cells, downregulation of PAX3 results in melanogenesis, with the shut-off through the probable involvement of Mitf promoter silencing (343). Thus regulation of MRP gene expression is mediated by positive and negative transcriptional regulators of which MITF is essential. It must be noted that regulation of gene expression at the mRNA level represents only the initial step; the final regulation of melanin synthesis appears to be predominantly controlled by posttranslational mechanisms.

B. Intracellular Signal Transduction Pathways

Figure 7 shows the major signal transduction pathways involved in the positive regulation of melanogenesis with CAMP as the critical factor. The fundamental role of CAMP in the regulation of melanogenesis and melanocytes proliferation was initially recognized in mouse melanoma cells (415, 568, 569, 899–901). Subsequent studies confirmed stimulation of melanogenesis by factors raising intracellular concentration of cAMP through receptor-mediated activation of adenylate cyclase, inhibition of phosphodiesterase, or transmembrane delivery of modified cAMP into the cell (92, 515).
The mechanism of cAMP regulation of melanogenesis involves the activation of protein kinase A (PKA), which then phosphorylates enzymes, ion channels, and several regulatory proteins. Involvement of PKA in the posttranslational regulation of melanogenesis was clearly demonstrated by Pawelek and co-workers (373, 568, 569, 899, 900) and was confirmed by others (190, 264, 515, 552). In addition, PH and TH hydroxylation phenylalanine to tyrosine and tyrosine to DOPA, respectively, are controlled by the PKA-dependent phosphorylation of regulatory serine residues (790). Regulation of transcriptional activity by activated PKA involves phosphorylation of cAMP responsive element binding protein (CREB) and CREB binding protein (CBP). Phosphorylated CREB interacts with CBP to activate the (566) expression of MITF throughout the CRE in the promoter region of the gene (648, 701, 889). MITF in turn regulates transcription of genes coding MRPs through interactions with M- and E-boxes present in the promoter regions of tyrosinase, TYRP1, and TYRP2. Because CRE is absent from the promoter of tyrosinase and TYRP1 genes, the transcriptional control of melanogenesis by cAMP is coordinated predominantly by MITF (47, 48, 423, 648, 701, 889). However, transcription of TYRP2 can potentially be activated through direct activation of CRE by CREB (49).

cAMP also modifies other pathways controlling melanocyte differentiation and proliferation, for example, the phosphatidylinositol (PI) 3-kinase pathway with its downstream regulatory element p70S6 kinase (92, 94, 240, 241). Inhibition of this pathway stimulates melanogenesis, and the pathway can be partially inhibited by cAMP (92–94). cAMP may also regulate dendritogenesis and possibly melanogenesis through activation of the Rho family of small GTP-binding proteins (92, 93). Of interest, some authors have proposed that cAMP can also inhibit melanogenesis through PKA-independent p21Ras activation (92). Ras would activate B-raf kinase and consequently mitogen-activated protein (MAP) kinases ERK1 and ERK2. MAP kinases phosphorylate MITF leading to its ubiquitination and degradation, thus removing a major transcriptional regulator of MRP genes expression (92, 168, 340). In addition, activation of ras oncogene inhibits melanogenesis in normal and malignant melanocytes (168, 245, 844).

Another signal transduction pathway important in the regulation of melanogenesis is represented by protein kinase C (PKC) (213, 217, 551, 552, 555). Thus diacylglycerol (endogenous activator of PKC) can stimulate melanin synthesis both in cell culture and in vivo (10, 217), while melanogenesis is blocked by PKC inhibitors or cellular depletion of PKC (48, 551, 552). Accordingly, 12-O-tetradecanoylphorbol 13-acetate (TPA) would have an initial activatory effect on melanin synthesis (activation of PKC) and a long-term inhibitory effect from PKC depletion in cells after the TPA treatment. The major PKC isoform involved in the regulation of melanogenesis is PKC-β (551), which can also activate tyrosinase through phosphorylation of serine residues in its cytoplasmic domain (552). In addition, the association of activated PKC-β with melanosomes through interaction with a membrane receptor for the activated PKC-β (RACK-1) has been reported. It is possible that cross-talk between PKC and PKA pathways could amplify their melanogenic effect through cAMP-dependent stimulation of genes transcription (including PKC) (551). Other PKC isoforms potentially involved in the regulation of melanocyte differentiation and proliferation are α, δ, ε, and ζ (551, 552).

Additional pathways that have been involved in the positive regulation of melanogenesis include those activated by nitric oxide (NO) and cGMP (628) as well as thymidine dimers (165, 166, 212). Thus the melanogenic effect of UV radiation could be connected with local production of NO and activation of guanylate cyclase with subsequent accumulation of cGMP in the melanocytes; in fact, inhibition of NO and cGMP production blocked the melanogenic effect of UV radiation (628). Thymidine dimers and small single-stranded DNA fragments (ssDNA) can also stimulate melanogenesis in cell culture and in vivo. This effect is dependent on the sequence and length of the oligonucleotides, regulated at both transcription and translation of MRPs levels, and involved amplification of the melanogenic effect of α-MSH (165, 166, 212, 552). These pigmentary effects of small oligonucleotides could follow a pathway functionally similar to the SOS response system of bacteria (165).
C. Dual Function of L-Tyrosine and L-DOPA: Reaction Substrates and Bioregulators

1. Overview

L-Tyrosine and L-DOPA have long been known to be substrates of the melanogenic pathway that determines their metabolic fate; however, they also possess a recently elucidated and important role as positive regulators of melanogenesis (reviewed in Ref. 739). Thus, in hamster amelanotic and melanotic melanoma cells, both L-tyrosine and L-DOPA stimulate, induce, or regulate various elements of the melanogenic apparatus by overlapping though distinct mechanisms (720, 721, 732–735). When Bomirski hamster melanoma cells were cultured in media relatively low in tyrosine (10 μM), L-tyrosine supplements produced concomitant increases in melanin synthesis and tyrosinase activity (rate-limiting step in the melanogenic pathway) (735). Nevertheless, in parallel experiments performed with mouse Cloudman S91 melanoma cells, while also increasing melanin pigmentation, had no effect or even decreased tyrosinase activity (735). Thus, depending on the experimental model, L-tyrosine can act as a stimulator or modulator of melanogenic apparatus or, only as substrate increasing melanin content without affecting the pathway enzymes. Further studies in human melanocytes system have shown that L-tyrosine and L-DOPA are necessary for the proper folding of tyrosinase in the ER, protecting it from entering the degradation pathway. L-Tyrosine and L-DOPA enhanced tyrosinase exiting from the ER, its carbohydrate modifications in the Golgi apparatus, and its transport into melanosomes increasing melanin pigmentation (244, 246, 247, 249).

2. L-Tyrosine and L-DOPA as positive regulators of subcellular apparatus of melanogenesis

L-Tyrosine stimulates tyrosinase activity in a dose-dependent manner in three different lines of hamster melanoma, with the slope being determined by the melanogenic potential of the cell line (Fig. 8) (735). Thus, in melanotic lines, tyrosinase activity reaches its peak at optimal media tyrosine concentration (200 or 400 μM), and decreases at pharmacological concentrations (400 or 600 μM). The decrease is not observed in amelanotic cells. Stimulation of tyrosinase activity by L-tyrosine is also seen in human malignant melanocytes (472, 895), normal epidermal melanocytes (603), and C57BL/6 mouse melanocytes with p locus mutation (635). L-DOPA shows a similar dose-dependent effect on tyrosinase with peak of tyrosinase stimulation at 25–50 μM, and decreases in enzyme activity at higher concentrations (100 or 200 μM) (721, 735). In Cloudman S91 melanoma cells, prestabilization of L-DOPA by the addition of phosphate (to produce phospho-L-DOPA) was required to express the dose-dependent stimulatory effect on tyrosinase activity and melanin pigmentation through amplification of the MSH receptor system (475). Thus, in Cloudman melanoma cells, L-DOPA itself does not affect melanogenesis (475), although at very low concentrations it does stimulate cell proliferation (560). In in vivo experiments, phosphorylated L-DOPA also stimulates skin melanin pigmentation (7), acting synergistically with UVB (560). Similarly, topical application of L-tyrosine in Skh:HR2 mice amplified the cutaneous melanogenic response to UVB (870). This is consistent with L-tyrosine acting as an inducer of melanogenesis in amphibian embryonic cells (403, 438). A stimulatory effect of L-tyrosine on differentiation of cultured frog melanophores has also been reported (189).

In hamster amelanotic cells L-tyrosine and L-DOPA induced rapid increases of tyrosinase activity and also in melanosomes and melanin synthesis (Fig. 9); the effect was specific since under the same conditions the enantiomers (R-isomers) or related aromatic amino acids had little or no effect, and also required protein synthesis (735). It was positively excluded that these actions would be related to transformation of L-tyrosine and L-DOPA to catecholamines, or to activation of adrenergic or dopaminergic receptors (293). L-Tyrosine and L-DOPA acted through related but distinct mechanisms (720, 721, 732–734, 748), with L-tyrosine inducing both melanosomes synthesis and tyrosinase translocation from the trans-Golgi reticulum (TGR) to melanosomes, while L-DOPA primarily increased tyrosinase leading to its accumulation in the TGR. Their effects on tyrosinase gene transcription differ, e.g., L-tyrosine has no effect on tyrosinase mRNA expression, while L-DOPA produces an initial increase in tyrosinase mRNA followed by a decrease below control levels (720, 721). The latter effect could be due to tyrosinase-mediated oxidation of L-DOPA generating toxic intermediates of melanogenesis, which would in turn shut-off tyrosinase gene expression as protective mechanism against self-destruction (721).

Phenylthiourea (PTU) is a nontoxic inhibitor of melanogenesis that inhibits stimulation of tyrosinase by L-tyrosine, without affecting L-DOPA stimulation in hamster amelanotic melanoma cells (734). However, L-tyrosine does stimulate premelanosome synthesis predominantly at stage II of development in PTU-treated cells. In the same system, melanogenesis induced by L-DOPA in the absence of L-tyrosine was rate limited by inadequate melanosome synthesis (735, 734). Since the formation of melanosomes precedes the induction of melanogenesis, L-tyrosine may have a crucial role in the induction of the subcellular apparatus of melanogenesis, e.g., enhancing both melanosome synthesis and translocation of tyrosinase from the TGR (Fig. 9) (735, 734). In mouse melanocytes with p mutation, L-tyrosine stimulates melanosome production, maturation, and tyrosinase redistribution (280, 635), while in human normal and malignant melanocytes L-tyrosine enhances tyrosinase exit from the ER, its modifications in Golgi, and its transport to melanosomes,
resulting in increased melanin pigmentation (247). Therefore, L-tyrosine may act as subcellular initiator of melanogenesis, while L-DOPA produced within melanosome would act at a later stage increasing further tyrosinase concentration (730). L-DOPA would then represent a second messenger to tyrosine in the in vivo regulation of tyrosinase synthesis and processing (734). Furthermore, tyrosinase, with its tyrosine hydroxylase (producing L-DOPA) and DOPA oxidase activities, would act as a regulatory protein for the subcellular apparatus of melanogenesis, of which it is itself an integral component (734), participating in the regulation of melanocyte metabolism during active melanogenesis (reviewed in Refs. 736, 739). Acting in concert, L-tyrosine, L-DOPA, and tyrosinase regulate the melanogenic apparatus and the overall physiology of the melanocyte in a stochastic fashion. The latter would depend on changes in the phosphorylation/dephosphorylation pattern (727).

3. L-Tyrosine promelanogenic effect and p locus

Mutations in pink-eyed dilution gene (P) result in a common form of human albinism, OCA2, and in the pink-eyed dilution phenotype in mice (72, 524, 708, 792). These mutations are expressed as decreased pigmentation of hair, skin, and eyes. The p gene product is a transmembrane protein (204, 620) thought to have among various functions (see previous sections) that of melanosomal proton pump (78, 601). Patients with mutations at the p locus have defective processing of tyrosinase and tyrosinase-related proteins with intracellular misrouting, proteolysis, and/or secretion to the extracellular environment (249, 451, 840). These abnormalities result in decreased tyrosinase activity and MRP protein concentration with hypopigmentation. Melanosome number and differentiation levels are decreased, and melanosomal ultrastructure is also abnormal (280, 539). Accordingly, p protein acts directly or indirectly as coordinator of the MRPs routing to melanosomes.

The pigmentary deficit of the OCA2 can be overcome by L-tyrosine, which stimulates melanin synthesis even in amelanotic melanocytes (reviewed in Ref. 539). In fact, mouse melanocytes containing mutations at the p locus show partial correction of the defect by properly targeting tyrosinase and TyrP1 to melanosomes upon increasing the concentration of L-tyrosine (280, 451, 635), similar to its effects in hamster amelanotic cells (see above). In the latter model, tyrosine treatment increased the number of

![Figure 8](http://physrev.physiology.org/)

**Figure 8.** L-Tyrosine and L-DOPA regulate tyrosinase activity in cultured melanoma cells. The cells were cultured in Ham's F-10 medium (low in tyrosine) for 24 h (D and E), 48 h (A–C), or as noted on the x-axis; media concentrations of L-tyrosine and L-DOPA are as presented for A–E. F and G: ○, 200 μM L-tyrosine; ■, 25 μM L-DOPA; ●, control. At indicated time points the cells were harvested and lysed, and tyrosinase activity was measured. [Modified from Slominski et al. (735).]
melanosomes at later stages of maturation as well as activity and concentration of tyrosinase and TyrP1 with their rerouting to melanosomes (280, 451, 635). This up-regulation of melanogenesis appears to be mediated at the posttranscriptional level (635, 720). Studies in cultured melanoblasts and melanocytes from C57BL/10 mice show that L-tyrosine also increases intracellular concentration of c-kit, TyrP1, and TyrP2 protein in both nonmutant (PP) and mutant (pp) cells (280). L-Tyrosine, nevertheless, inhibits proliferation of PP melanocytes while stimulating proliferation of pp melanocytes.

4. L-Tyrosine and L-DOPA regulate MSH receptor expression

L-Tyrosine or phosphorylated isomers of L-DOPA stimulate MSH receptor activity in hamster and mouse melanoma cells (475, 560, 732, 748). In normal human...
epidermal melanocytes, tyrosine levels have been shown to regulate the melanogenic response to \( \alpha \)-MSH (681). In amphibian melanoblasts, \( L \)-tyrosine acts synergistically with MSH in stimulation of melanogenesis (188). Phosphorylated isomers of \( L \)-DOPA increase MSH receptor expression in mouse melanoma cells and stimulate the melanogenic response to \( \beta \)-MSH peptide (475). Similarly, in hamster melanoma cells, \( L \)-tyrosine but not \( L \)-DOPA stimulates cell surface MSH receptor expression, enhances level of tyrosinase stimulation by MSH, and reduces positive cooperativity among cell surface MSH receptors (732, 748). The effect appears to be specific for the MSH receptor, because it does not affect expression of the unrelated insulin receptor (730). Stimulation of MSH receptors does require prolonged exposure to the factors tested (475, 732, 748), and the lack of effect of \( L \)-DOPA is most likely due to its oxidation. In hamster amelanotic melanoma, stimulation of MSH receptor activity is maximal when \( L \)-tyrosine has induced the full mela-nogenic potential of the cells (748). Interestingly, in other melanoma models, stimulation of melanogenesis increases expression of MSH receptors (726). \( L \)-Tyrosine does not change MC1 receptor mRNA concentrations in hamster melanoma (Slominski, unpublished data), while in human melanoma induction of melanogenesis by DMEM increases MC1 mRNA concentration (726).

5. \( L \)-Tyrosine and \( L \)-DOPA as “hormonelike bioregulators”

The overall actions of \( L \)-tyrosine and \( L \)-DOPA in the pigmentary system strongly support an additional role for these melanin precursors as hormonelike bioregulators, and thus melanocytes would regulate \( L \)-tyrosine and \( L \)-DOPA activity affecting both production and metabolic consumption (736). Such roles require support from the identification and characterization of receptors for those amino acids (739), since their dose- and time-dependent actions and stereoselectivity are consistent with receptor-mediated mechanisms. Indeed, cell surface and nuclear binding sites for \( L \)-tyrosine or \( L \)-DOPA have been detected, and the binding was saturable, specific, and reversible (715, 754). Cross-linking experiments also identified cell surface proteins binding specifically \( L \)-tyrosine (5 proteins of 55, 45, 40, 30, and <20 kDa) and \( L \)-DOPA (4 proteins of 55, 30, 25, and <20 kDa) (715, 739, 754). These proteins were neither adrenergic nor dopaminergic receptors or amino acids carriers. Potential candidates include p protein, alternatively spliced products of tyrosinase or tyrosi-nase-related proteins, blurring the classical distinction between specific transporter, enzyme, and receptor. Thus, depending on \( L \)-tyrosine and \( L \)-DOPA concentrations, membrane-bound binding proteins may allow formation of melanosomes and/or delivery of elements for melanogenesis via intracellular or endocytic pathways (739). Be-

cause melanogenesis-related proteins have the cysteine-rich sequences characteristic of peptide hormones, they may regulate melanocyte function through binding to proteins, acting at the translational or transcriptional levels (739). Identification of cytosolic and nuclear binding sites for \( L \)-DOPA but not \( L \)-tyrosine suggests the potential for an additional nuclear receptor for this relatively short-lived molecule, allowing coordination of intracellular functions in an intracrine fashion (739). In lower organisms (uni- or multicellular), there are indications of \( L \)-tyrosine and \( L \)-DOPA receptor expression; in mammalian systems, \( L \)-tyrosine and \( L \)-DOPA may act as as neurotransmitters (reviewed in Refs. 736, 739). Definitive establishment of the concept will require the testing of primary epidermal and follicular melanocytes for expression of putative \( L \)-tyrosine and \( L \)-DOPA receptors.

With regard to the metabolic effect of \( L \)-DOPA, this consists of in vitro inhibition of glycoproteins phosphor-ylation (727); in isolated cells, \( L \)-DOPA stimulates the pentose phosphate pathway (683) and switches the energy metabolism from aerobic to anaerobic glycolysis (682).

D. Summary

Therefore, key elements in the regulation of melano-genesis are represented by tyrosinase and TYRPs. The complexity and precise control of melanogenesis are evident by the presence in the genes of motifs for binding sites of a large family of transcription factors. At the intracellular level, the major regulatory pathway involves the common mediator cAMP, although PKC is also involved. A new turn in the regulatory process has been introduced by cumulative evidence indicating that \( L \)-tyrosine and \( L \)-DOPA, besides serving as substrates for mel-anin, are also bioregulatory agents. Evidence obtained with the improvement of OCA2 by tyrosine strongly sup-ports this concept.

IV. HORMONAL STIMULATORS OF MELANOCYTIC DIFFERENTIATION AND THEIR RECEPTORS

A. G Protein-Coupled Receptors and Ligands

1. Melanocortins, ACTH, and melanocortin receptors

A) OVERVIEW OF MELANOCORTINS PHENOTYPIC EFFECTS. I) Melanogenic effect in vivo. The fundamental role of melanocortins (MSH) and adrenocorticotropins in the regulation of melanogenesis was established during the last century (157, 242, 412, 514, 559, 561, 569), culminating in the definition of their regulatory role with purification and full sequencing of the \( \alpha \)- and \( \beta \)-MSH peptides (412). Structurally, MSH peptides (that include \( \alpha \)-MSH, \( \beta \)-MSH, and \( \gamma \)-MSH peptides) have in common with ACTH the amino
acid sequence -Tyr-x-Met-x-His-Phe-Arg-Trp- containing the tetrapeptide His-Phe-Arg-Trp critical for melanotropic activity (157, 242). There is consensus that the proopiomelanocortin (POMC) peptides with significant melanogenic activity are ACTH, α-MSH, and β-MSH (see below).

Initial experiments in amphibians determined that α- and β-MSH induced darkening of the skin (reviewed in Refs. 242, 412). In mammalian systems, such as rodents, MSH peptides do stimulate both melanogenesis and the switching of the pheo- to the eumelanogenic pathway (127, 157, 209, 225, 242, 515, 813). In several strains of adult mice as well as hamsters, α-MSH specifically stimulates follicular melanogenesis, depending on genotype and hair cycle (89, 90, 127, 209, 225, 242, 418, 433, 515). For example, e/e mice (recessive for the E locus encoding MC1 receptor) are unresponsive to MSH pigmentary activity at the transcriptional, translational, or posttranslational level depending on the phase of hair cycle (89, 90, 157, 209, 242, 515). This is consistent with hair cycle restricted expression of melanogenesis-related genes, protein concentration, and enzymatic activity (737, 741, 745). β-MSH also stimulates tyrosinase activity, as observed in skin of newborn Syrian golden hamsters as well as black and brown mice (588) and has actual melanogenic activity in adult guinea pigs and hairless mice (63, 64). Overall, the promelanogenic effect of MSH peptides has been documented in a number of species (127, 157, 209, 242, 515).

In humans, the systemic administration of α-MSH, β-MSH, or ACTH stimulates skin pigmentation, predominantly in sun-exposed areas (414, 419). Clinical observations have shown that the pathologically increased levels of plasma ACTH in Addison disease, or the excessive secretion of plasma ACTH in Addison disease, or the excessive ACTH induced hyperpigmentation and skin atrophy (reviewed in Refs. 181, 515, 759). Prolonged administration of ACTH, α-MSH, and β-MSH results in pigmentation and skin atrophy (157, 242, 515, 561, 573). Studies in rodent malignant and normal melanocytes have uncovered the role of MSH receptors in the regulation of the melanocyte functions, acting via cAMP-dependent pathways (157, 242, 277, 412, 487, 515, 559, 561, 562, 564, 565, 573, 570, 572, 574, 733). In rodent malignant melanocytes, α-MSH and β-MSH are more potent than ACTH in stimulation of melanogenesis (157, 487, 559). The effect of MSH on cell proliferation is variable and depends on cellular genotype (157, 303, 487, 515, 559, 562, 564, 566, 567, 570, 707); for example, MSH inhibits proliferation in amelanotic cells, indicating that this effect is unrelated to production of toxic intermediates of melanogenesis (487, 559, 733). In addition, MSH stimulates dendrite production through a pathway independent from that regulating melanogenesis, although still CAMP mediated (515, 733). Similar MSH effects, e.g., stimulation of melanogenesis, dendrite formation, and stimulation of cell proliferation are also seen in normal cultured mouse melanocytes (242, 277, 515).

Affinity of ACTH or MSH peptides for MC1 receptor differs according to the species investigated. For example, cloned rodent MC1 receptor has high affinity for α-MSH, but low for ACTH and β-MSH, and even lower for γ-MSH (127, 515). In cultured rodent cell lines, α- or β-MSH are more potent that ACTH in stimulation of melanogenesis (402). The human MC1 receptor affinity is equally high for α-MSH and ACTH, and lower for β-MSH and γ-MSH. The MC2 receptor exhibits absolute specificity for ACTH. Mutations in the MC1 receptor that produce unresponsiveness of epidermal melanocytes to MSH result in the red hair phenotype (515, 851). In cultured human melanocytes, α-MSH, β-MSH, and ACTH at concentrations in the nanomolar range or lower stimulate melanogenesis, cell proliferation, dendrite formation, and CAMP production (2, 303, 304, 798). In some studies ACTH was more potent than MSH (303, 304), while in others both peptides were equipotent (2, 798). γ-MSH, which stimulates CAMP production, had no significant effect on melanogenesis or proliferation in human melanocytes (798), and low melanogenic activity in murine and hamster malignant melanocytes (723), and in frog and lizard melanophores (157, 242, 515). It is possible selected γ-MSH peptides could still modulate pigmentation indirectly, by modifying the cellular response to other melatonins. For example, γ2-MSH potentiates the melanogenic activity of α- or β-MSH, while γ9-MSH (acting as a partial agonist on MSH receptors) largely inhibited the melanogenic activity of α- or β-MSH (723). α-MSH also stimulates the attachment of human melanocytes to laminin and fibronectin and inhibits TNF-α-stimulated intercellular adhesion molecule-1 (ICAM-1) expression in normal and malignant human melanocytes (reviewed in Ref. 756).
B) MOLECULAR CHARACTERIZATION OF MELANOCORTIN RECEPTORS. Cross-linking experiments identified a membrane-bound MSH receptor of ~45 kDa in a number of melanocytic lines (774), and subsequently, a family of melanocortin (MC) receptors (MC1 to MC5) was cloned (119, 120, 200, 201, 391, 497, 498, 634). They belong to the superfamily of seven transmembrane G protein-coupled receptors, share amino acid sequence homology of 40–60%, and have short intracellular carboxy-terminal and short extracellular amino-terminal domains. MC receptors are coupled to adenyl cyclase, with possible additional coupling to phospholipase C in the case of MC3 (200, 634). MC receptors have different pharmacological profiles of activation by MSH and ACTH peptides; MC1R is the most important in the regulation of melanogenic activity (498, 624; for review, see Ref. 660).

I) MC1 receptor or MSH receptor. Human and mouse MC1R consist of 317 and 315 amino acids, respectively, and share 76% homology in amino acid sequence (120, 498). MC1R has the highest affinity for α-MSH and ACTH, as judged by intracellular cAMP accumulation (200, 201, 498) and in vitro binding assay (120). MC1R mRNA is expressed in melanocytes and melanoma cells and in other human skin cells (762).

The mouse extension (E) locus encodes the MSH receptor (MC1R) (624) that determines the relative amount and distribution of brown/black pigment (eumelanin) and yellow pigment (pheomelanin) through its actions on hair follicle melanocytes (708). The dominant allele increases eumelanin synthesis while the recessive yellow allele (e) inhibits eumelanin synthesis by coding for a nonfunctioning MC1 receptor. This results from a frameshift that generates a termination codon immediately after the fourth transmembrane domain, thereby deleting the third intracellular loop essential for the receptor-G protein coupling (624). In contrast, three dominant alleles, the sombre (Eso-3J) and tobago (Eotb) result from missense mutations clustered around the second transmembrane region, which produce hyperactive MC1 receptors (624). The sombre alleles produce a fairly uniform black coat, whereas the tobacco allele produces dorsal darkening. Functional analysis reveals that the Eso-3J receptor is constitutively activated, while the Eotb receptor remains hormone responsive and produces greater activation of adenylyl cyclase (624). Importantly, agouti protein cannot inhibit eumelanin formation induced by the constitutively active sombre receptor (897, 898).

MC1R gene sequence variants were found in over 80% of individuals with red hair and/or fair skin that tans poorly, but in fewer than 20% of individuals with brown or black hair and, in <4% of those who show a good tanning response (851). Human MC1R variants are present in ~50% of white populations (660). The loss-of-function MC1R mutations largely account for the red hair phenotype in humans and are associated with fair skin and decreased ability to tan, with a significant heterozygote effect in individuals without red hair. The Asp84Glu variant of MC1R is associated with melanoma (882), and the loss-of-function MC1R variants may increase the risk for developing melanoma and nonmelanoma skin cancer.

II) MC2 receptor or ACTH receptor. Human MC2R consists of 297 amino acids and is 39% identical to human MC1R (498). MC2R has specific affinity for ACTH, and its mRNA is predominantly expressed in the cortex of the adrenal gland, especially the zona fasciculata, since MC2R is primarily responsible for glucocorticoid production. MC2R mRNA has nevertheless been detected by RT-PCR in human skin biopsy specimens of compound melanocytic nevus, and in cultured normal and malignant melanocytes (725). MC2R was also detected in skin of the C57BL/6 mouse by Northern blotting, being present at concentrations significantly lower (severalfold) than MC1 and in a pattern independent of hair cycle (169). Because some authors found ACTH more potent than α-MSH in stimulation of melanogenesis in human melanocytes (303, 304, 307), a potential role for MC2R in the regulation of melanocytic activity needs clarification.

III) MC3–5 receptors. MC3R responds to α, β, γ-MSH, and ACTH with equal potency and efficacy, unlike the MSH and ACTH receptors (201). MC3R is unique because of its potent activation by γ-MSH peptide (634). Mouse MC3R is expressed in brain, placental, and gut tissues but not in melanocytes or melanoma cells nor in the adrenal gland (201); MC3R is involved in the regulation of energy homeostasis (95, 113), but not pigmentation.

MC4R responds equally to both α-MSH and ACTH. MC4R is expressed primarily in the brain and is undetectable in the adrenal cortex, melanocytes, and placenta. Null mutations of the MC4R are associated with hyperphagia, obesity, and accelerated longitudinal growth in mice (308). This obesity syndrome could explain the characteristic features of the agouti obesity syndrome in lethal yellow mice, which results from ectopic expression of agouti protein, namely, the overexpressed agouti protein induces obesity by antagonizing at the MC4R. In contrast to MC3R(−/−) mice, MC4R knockout mice exhibit increased food intake and obesity (354). Mice lacking both MC3R and MC4R become significantly heavier than MC4R(−/−) (113). These results suggest that MC3R and MC4R are involved in the regulation of energy homeostasis through separate mechanisms and do not participate in mammalian pigmentation.

MC5R is preferentially bound by α-MSH and is widely expressed in peripheral tissues. These include skin, adrenal gland, skeletal muscle, bone marrow, spleen, thymus, gonads, uterus, and brain (391), with high expression levels in exocrine tissues such as Harderian, preputial, lacrimal, and sebaceous glands (116). MC5R-deficient
mice exhibit exocrine gland dysfunction, such as severely defective water repulsion and thermoregulation due to decreased production of sebaceous lipids, indicating that the MC5R is required for the correct function of the exocrine glands. MC5R has no effect on melanin pigmentation (116).

C) CELL BIOLOGY AND BIOCHEMISTRY OF MELANOCORTIN RECEP-
TORS. The phenotypic effects of MSH and ACTH peptides in melanocytes are mediated via interactions with cell surface receptors containing seven transmembrane domains linked to the Gα protein and cAMP-dependent pathways (reviewed in Refs. 128, 157, 515). In addition, activation of PKC by α-MSH may also be involved in stimulation of melanogenesis (85, 554). MSH receptor signal transduction may probably be also coupled to phospholipase C-activated production of inositol trisphosphate (IP₃) and diacylglycerol (DG) with subsequent mobilization of intracellular calcium (85). Studies in different melanoma models have generated conflicting results, e.g., in human melanomas α-MSH stimulates IP₃ production (796), while in hamster melanoma the MSH signal transduction and subsequent phenotypic effect are linked to cAMP without any evidence of IP₃ production (733). Pharmacological studies with cloned MC receptors have shown that signal transduction (including MC1) is coupled exclusively to activation of adenyl cyclase (127, 515). In one case, modest activation of IP₃ production was noted, and related to stimulation of MC3 type receptor only. There is no evidence that MC1 and MC2 receptors are coupled to pathways other than cAMP second messenger generating systems (127, 515).

That phenotypic effect of MSH is mediated through interaction with a specific cell surface receptor was first established in frog melanophores, when α-MSH was found to induce cAMP production and darkening of the frog skin (412). Studies in the mammalian system murine S91 melanoma cells were the first to show that MSH interacts with specific cell surface receptors that activate adenyl cyclase activity that increases intracellular cAMP (569). This resulted in increases in tyrosinase activity and melanin production, stimulation of dendrite formation, and inhibition or stimulation of cell proliferation (415, 559, 563, 570–572, 571). These findings established that in mammalian melanocytes the phenotypic effects of ligand activation of MSH receptors are mediated by cAMP through activation of PKA and phosphorylation/dephosphorylation reactions (373, 551, 559, 562).

After binding the ligand, the MSH receptor is internalized and targeted to either endosomal compartments, the Golgi region, or melanosomes (107, 415, 487, 559, 561, 563, 856). Binding of MSH to the MSH receptor and the subsequent activation of adenyl cyclase were found to be dependent on the presence of Ca²⁺ in the receptor milieu; calcium binding protein (CBP) may partially activate the receptor even in the absence of the ligand (170). Intracellular MSH binding sites with different subcellular localization have also been detected; it has been proposed that these internal MSH receptors would participate in the regulation of cellular phenotype without circulating through the plasma membrane (107, 561). In fact, in the intramelanosomal environment MSH receptor activated signaling cascade may stimulate tyrosinase activity through mechanisms involving phosphorylation/dephosphorylation cascades (373, 551, 553, 559). Delivery of α-MSH to melanosomes could also change the physicochemical interaction of tyrosinase with 6-BH₄ to stimulate tyrosinase activity (490, 579, 666). Thus delivery of MSH-MSH receptor complex to the melanosome may be an integral regulatory step of melanogenesis (415, 487, 561), whereas its delivery into the endosomal/Golgi region may affect the posttranslational regulation of the melanogenic apparatus. It must be noted that MSH stimulates the processing of tyrosinase and tyrosinase-related proteins and the formation of melanosomes (262, 263, 515). Regulation by MSH of transcription and translation of tyrosi-

nase and MRPs could be mediated indirectly through MITF or directly through activation of PKA- or PKC-dependent pathways. Nevertheless, there is a consensus that MSH stimulates production and activity of MRPs at the transcriptional, translational, and posttranslational levels. Furthermore, MSH stimulates delivery of tyrosine to melanosomes (592). Other functions of MSH receptors including immunoregulation and its coupling to different signal transduction system in nonmelanocytic cells such as stimulation of the Janus kinase 2 (JAK2) and signal transducers and activators of transcription (STAT1) pathways, suppression of nuclear transcription factor NFκB, inhibition of NO, and neopterin production and prosta-
glandin synthesis (442, 762) are outside the scope of this review.

D) REGULATION OF MSH RECEPTORS EXPRESSION. Expression and activity of MSH receptors in mammalian pigment cells are also regulated by intrinsic and extrinsic factors of which the most important is UV radiation (UVR) (63, 103, 105, 561, 747, 762). Thus Pawelek et al. (561) have proposed that UV-induced melanogenesis was mediated via upregulation of the MSH receptor system. Indeed, UVR does upregulate expression of MSH receptors, amplifying the melanogenic effect of exogenous MSH in a dose-dependent manner in vivo and in cell culture systems (63, 104, 561). In murine melanoma, UVR action appeared to involve arrest of the cell cycle at the G₂ phase, when cultured melanocytes express maximal MSH receptor activity and responsiveness to MSH (476, 561). The G₂ phase coupling of increased MSH receptor expression was associated with increased cellular responsiveness to the ligand (149, 476, 855, 901). Nevertheless, G₂ restricted expression and activity of MSH receptors appears to be specific for rodent melanocytes, since it has not been observed in a human model. In both mouse and...
human melanocytes, UVR similarly stimulates expression of MSH receptors (103).

Factors known to raise intracellular cAMP levels such as MSH itself, ACTH, dibutyryl cAMP, cholera toxin, and phosphodiesterase inhibitors also stimulate MSH receptor expression and activity (105, 149, 559, 561, 762). In addition, positive cooperativity of MSH receptors has been documented in mouse and hamster melanoma cells (475, 476, 732). In normal and malignant melanocytes, interleukin (IL)-1, IL-1β, endothelin-1, adult T-cell leukemia-derived factor/thioredoxin (ADF/TRX), interferon γ-treated H9251, H9253, H11011, IFN-α, IFN-β, IFN-γ, dibutyryl cAMP, and the hormones α-MSH, β-MSH, and ACTH can stimulate expression of the MC-1 gene and of functional cell surface MSH receptors (reviewed in Refs. 442, 762). IL-1 can also stimulate MC-1 receptor expression in normal and malignant human keratinocytes (50). The melanin precursors L-tyrosine and phosphorylated isomers of L-DOPA also stimulate expression of MSH receptors and melanogenic responsiveness to MSH peptides (475, 560, 732, 748). A similar effect was described for thymidine dimers and small single-stranded DNA fragments (ssDNA) that are produced intracellularly after UV-induced damage (165, 166, 212). Retinoic acid, while stimulating MSH receptor expression, inhibits MSH-induced melanogenesis (108, 540, 541). In addition, retinoic acid and vitamin E inhibit MSH-sensitive adenylate cyclase activity in mouse melanoma cells (644). Tumor necrosis factor (TNF)-α inhibits MC1 expression in melanocytes (192). Thus, while MSH receptors are important regulators of melanocyte activity, they are also subject to positive and negative regulation by multiple factors.

The function of the MC1 receptor, being the subject of multiple regulatory inputs while also controlling melanogenesis at different levels, suggests that it represents a molecular switchboard (“molecular chip”) for the various melanogenic signals. An example of such integration would be the melanogenic response to UVB, which is not a collection of random events but, instead, a highly coordinated sequence involving MSH receptors expression and activity, and local production of its ligands (MSH and ACTH peptides) that act as cofactors in the stimulation of cutaneous melanogenesis (103, 561, 747).

### E) PARA-, AUTO-, AND INTRACRINE MODES OF REGULATION OF MELANOCYTIC ACTIVITY

Since the first demonstrations of POMC gene and protein expression in skin of both rodents (742) and humans (678), several laboratories have documented that skin cells can produce different POMC peptides (reviewed in Ref. 762). The relative skin concentration of POMC mRNA is, however, severalfold lower than that detected at the central level (724). The size of POMC message detected in the skin was, depending on the source, similar, larger, or shorter than the 1.1–1.2 kb usually detected in pituitary or hypothalamus (762). A short POMC mRNA of ~0.9 kb contained the coding exon 3 but lacked the sequence encoding the signal peptide (762). Nevertheless, this cutaneous POMC mRNA was translated into the 30- to 33-kDa POMC precursor protein. Depending on tissue or cell source, the precursor is further processed to final products that included β-lipotropin (LPH), β-endorphin, β-MSH, ACTH1–39, ACTH1–17, ACTH1–13, ACTH1–10, acetyl-ACTH1–10, α-MSH, diacetyl-α-MSH, and γ-MSH peptides (714, 731, 758, 821, 866, 896). Because skin cells also express the convertases PC1 and PC2 and 7B2 protein (necessary to generate enzymatically active form of PC2), POMC processing may be similar to that described at the central level, including compartmentalized processing, e.g., specific for corticotrophs and melanotrophs as in the pituitary (762). In fact, we have already detected differential, cell type-associated and hair cycle phase restricted expression of PC1 and PC2 convertases in the skin of C57BL/6 mouse (470). The final POMC peptides can potentially be produced in all cutaneous compartments (epidermis, dermis, and adnexa) by epithelial and melanocytic cells and cells of mesenchymal origin such as immune cells, fibroblasts, and endothelial cells and also by release from sensory nerve endings (reviewed in Ref. 762). Local POMC gene expression and production of POMC peptides can be modulated with UVR, cytokines, growth factors, and cAMP and varies according to phase of the hair cycle (762).

Thus locally produced melancortins and adrenocorticotropic hormone could regulate melanogenesis though para-, auto-, or intracrine mechanisms (762). Specifically affected cutaneous histocompartment, and prevalent signal (UV radiation, cytokines, or phase of hair cycle) would define the cell populations releasing POMC-derived peptides to change the activity of neighboring melanocytes (paracrine mechanism). The same signals (UV, IL-1, or cAMP) could even directly upregulate both POMC and MC1 receptor expression (reviewed in Refs. 442, 759, 762), implicating concerted action (“fine-tuning”) of POMC expression and MC1 receptor activity. Such interactions should ensure specificity and selectivity in the final result. For example, bidirectional communication through MSH or ACTH signals between melanocytes and keratinocytes within the epidermis or anagen hair follicle would regulate production and transfer of melanin pigment to keratinocytes and thus skin or hair pigmentation. While autocrine regulation of MSH receptor activity may be operative in melanocytes in vitro, it is the intracrine mechanism that has a predominant role in vivo. Melanocytes do produce and process POMC and express intracellular MSH receptors (reviewed in Ref. 762), and a POMC processing system has been identified in human melanosomes (579). These findings underscore the specific targeting of POMC or intermediate products of its processing by internal (intracellular) MSH receptors to the target organelles. Similarly, β-endorphin and µ-opiate antigens have been colocalized in melanosomes (348). Accordingly, expression of shorter POMC transcripts encoding products lack-
ing the signal peptide would interfere with the export of POMC peptides from the cell to ensure restriction of its effect to the same cell or its immediate vicinity. Thus the cutaneous POMC system may counteract local stresses through highly restricted regional circuits that self-regulate their level of expression independent of the central nervous system (762). The system could operate at different organizational levels (cellular, tissue, and organ) via combinations of intra-, para-, and perhaps autocrine mechanisms of action (reviewed in Ref. 762). Of clinical interest, the local peculiarities of the POMC system can also explain the increased skin pigmentation of patients with Addison’s disease, particularly in the sun-exposed areas. Thus the extremely high plasma ACTH levels in conjunction to UV-induced damage would overcome the dermal-epidermal barrier to reach melanocytes overexpressing MC1 receptors (758). In this context we have proposed that ACTH after binding to the MC1R could be internalized and further processed to α-MSH that would stimulate on site melanogenesis (758).

2. β-Endorphin and opioid receptors

A) AN OVERVIEW. The category of opioids is divided into those containing the message domain Try-Gly-Gly-Phe, comprising enkephalins, endorphins, and dynorphins; and those with the Tyr-Pro-Phe/Trp sequence, comprising the endorphins-1 and -2. Receptors for these ligands represent an heterogeneous set and include the μ (μ), δ, and κ-opioid receptors (206, 557). β-Endorphin is produced by a cleavage from the β-LPH fragment by prohormone convertase 2 (41, 137, 691) and binds with high affinity to the opioid receptors μ and δ; and with low affinity to κ receptors (214). The genes for these receptors are similarly organized, with coding regions extending over three exons to encode extracellular, transmembrane, and cytoplasmic domains of the G protein-coupled receptors that belong to the same superfamily (884). β-Endorphin, like the opioids enkephalins and dynorphins, mediates its biological actions by activation of receptors coupled with one of multiple G proteins to regulate adenylyl cyclase, PI 3-kinase, MAP kinase pathways, and Ca2+ and K+ channels (129). Even in the absence of ligand, opioid receptors can exhibit intrinsic activity that can also be reversed by opioid antagonists.

B) ROLE OF β-ENDOPHRIN IN SKIN BIOLOGY AND PIGMENTATION. β-Endorphin has been implicated in the pathogenesis of several dermatoses, for example, elevated β-endorphin plasma levels have been reported in psoriasis (215) and in atopic dermatitis (216). These similarities have been related to β-endorphin action as a differentiation factor for keratinocytes through upregulation of cytokeratin 16 expression (55). β-Endorphin plasma levels are also higher in patients with the depigmentation disorder vitiligo, whereas in the skin itself, they are higher in lesional versus uninvolved areas (499). To date, only the μ- and δ-opioid receptors have been localized to the skin where their expression has been detected in normal epidermal keratinocytes (53, 929), in chronic and acute wounds (54), and in epidermal melanocytes (348).

A role for β-endorphin in pigmentation has been suggested by the increased plasma β-endorphin and β-LPH levels that may occur post UVA exposure (420) with attendant skin pigmentation. β-Endorphin has been identified in normal and malignant human melanocytes in vitro (714) and in normal human skin (348, 763). β-LPH, the immediate precursor of β-endorphin and β-MSH, can stimulate melanogenesis in sheep (434), and elevated serum levels of β-LPH may be associated with generalized hyperpigmentation in humans (12). Studies performed with rodent malignant melanocytes have nevertheless shown a lack of melanogenic activity for β-endorphin and its different modified forms (173, 446).

The β-endorphin/μ-opiate receptor system is prominently expressed in human epidermal melanocytes in situ and in vitro, and the peptide and its receptor are closely associated with melanin-producing melanosomes. This suggests that the β-endorphin/μ-opiate receptor system is functionally active via its ability to upregulate melanocyte dendriticity, proliferation, and pigmentation (348). Because both β-endorphin ligand and μ-opiate receptors are detected in epidermal melanocytes and keratinocytes, autocrine and paracrine mechanisms of action appear highly likely in the regulation of melanocyte physiology. In fact, the finding of a positive correlation between β-endorphin expression and melanocyte differentiation status (i.e., pigmentation and dendriticity) suggests that β-endorphin expressed by epidermal melanocytes may indeed be involved in the modulation of melanocyte differentiation through autocrine control. Expression of the μ-opiate receptor also correlates positively with melanocyte differentiation in vitro, supporting that μ-opiate receptor expression may be upregulated by its ligand β-endorphin, similar to the binding of α-MSH to MC1R (104, 747). Both opioid agonists and the antagonist naltrexone appear to downregulate the same receptor in keratinocytes (53).

Cultured normal epidermal melanocytes treated with β-endorphin show increased melanogenesis and proliferation, providing direct evidence that the β-endorphin/μ-opiate receptor system is functionally active in skin melanocytes (348). Importantly, these changes were of a similar magnitude to those reported for the known melanotropins α-MSH and ACTH (304, 306, 307). β-Endorphin also exerts potent dendritogenic effects in epidermal melanocytes, where it not only increases production of melanized pigment granules, but also facilitates their active transfer to recipient keratinocytes.

It is well documented that α-MSH and ACTH stimulate melanogenesis acting via the MC1 R through the adenylyl cyclase/cAMP second messenger system (92).
Paradoxically, β-endorphin exerts similar biological actions via inhibition of the same signaling pathway. Thus opioid peptides, unlike α-MSH and ACTH, decrease the formation of cAMP (537). Nevertheless, other intracellular pathways, such as the PKC-β-dependent pathways, are increasingly being implicated in the regulation of melanogenesis (555). Experimentally, the topical application of bisindolylmaleimide, a selective PKC inhibitor, reduces skin pigmentation in guinea pig skin in vivo. Thus it is likely that β-endorphin/μ-opiate receptor (R) interactions would signal via the PKC β-isoform to cause direct activation of tyrosinase with stimulation of melanogenesis. Alternately, the β-endorphin/μ-opiate R signaling system could operate at the level of gene transcription increasing tyrosinase expression with consequent upregulation of melanogenesis. Of note, patients with rheumatoid arthritis exhibit localized high levels of melanogenesis. Of note, patients with rheumatoid arthritis exhibit localized high levels of β-endorphin in synovial fluid of affected joints (143), raising the possibility that local increases in β-endorphin might be involved in the highly restricted associated hyperpigmentation (207). Thus β-endorphin can act as a regulator of human skin pigmentation; however, its pigmentary response appears to be mediated via an MC1R-independent mechanism.

3. Endothelins and their receptors

A) Overview. Endothelin (ET) was originally described as an endothelium-derived peptide with potent vasoconstrictor activity (915), although it is also detected in a broad range of tissues (641, 710) that include skin (315). ET comprises the isopeptides ET-1, ET-2, and ET-3, the molecular forms emerging from the cleavage of three large peptide-specific prohormones (preproendothelin) by prohormone convertases, in a similar manner to that in melanocortin production (239, 317, 404). The ET receptors, ET_A and ET_B, are members of the heptahelical G protein-coupled receptor family (22, 653). The genes for the two receptors are similarly organized and have amino acid homology of 55–64% depending on the tissue tested. ET_A has very high affinity for ET-1 and ET-2 (pM range), but lesser affinity for ET-3 (nM range); in contrast, the ET_B receptor has similarly high affinity for all three ETs (22, 653). There appears to be considerable tissue specificity in the expression of ET receptors; in the skin, both ET-1 and ET-3 binding sites have been determined (corresponding to ET_A and ET_B) on micro and large blood vessels, sweat glands, epidermis, and hair follicles (367).

Endothelins affect multiple intracellular signaling pathways that may differ according to cell type and result in short-term (e.g., secretion) or longer term (e.g., proliferation) biological actions (711). Thus, upon binding to the G protein-coupled ET receptor, ET activates phospholipase C with production of IP_3 and DG, Ca^{2+} influx, and activation of phospholipase C. ET also activates phosphatidylinositol-specific phospholipase D in a step regulated by PKC and intracellular Ca^{2+} concentration ([Ca^{2+}]_i) (511) or is directly coupled to plasma membrane Ca^{2+} channels. The mitogenic effects of ET-1 are likely the result of its phosphorylation of tyrosine and threonine residues, activation of MAP kinase, upregulation of platelet-derived growth factor (PDGF) gene expression, and enhancement of c-fos, c-jun, and c-myc gene expression (710).

B) Endothelins and melanocyte development. Mice deficient in ET-1 or ET_A exhibit nearly identical defects in cephalic and cardiac neural crest cells subsets (124, 383), while mice deficient in ET-3 (lethal spotting; point mutation in the is gene) and ET_B (piebald-lethal; deletion of the s^' gene) show coat color deficits (in addition to aganglionic megacolon) with absence of melanocytes (34, 288). Inactivation of the gene for endothelin converting enzyme-1 (needed for proteolytic activation of ET-1) also results in lack of skin melanocyte development, despite the presence of ET-1 in nonmelanocyte relevant sites in the embryo. A human homolog for these gene inactivation models is represented by patients with sporadic and familial Hirschprung disease, who often present with hypopigmentation of the skin and hair (600).

The involvement of the endothelin system, in the process of melanocyte development, appears to occur at a very early stage, with the critical time being E10.5 in mice implying its participation in melanoblast expansion/proliferation. Because melanocyte progenitors are also lost at a similar stage in SL or W mutant embryos (stem cell factor and c-kit, respectively), both systems are probably crucial for the development and survival of melanocyte progenitors. Pigmentation in s/s' mice (ET_B null) is restricted to a narrow region of the craniofacial and caudal skin, suggesting that melanocyte proliferation is suppressed in the absence of a functional ET_B receptor (922). However, melanoblast proliferation can occur in the epidermis independently of ET-3 itself, possibly related to the binding of other endothelins to the ET_B receptor. Thus ET-3 is functionally required only for melanoblasts to begin their dorsolateral path migration.

ET-3 stimulates the differentiation of neural crest progenitors into fully mature pigmented melanocytes, melanoblast proliferation, and acts synergistically with stem cell factor (SCF; Steel factor) (612). Nevertheless, compensatory interactions of ET-3 for SCF in the survival and proliferation of those cells are not seen in vivo (534). Exposure to ETs of mouse neural crest cells expressing the early melanoblast marker dopachrome tautomerase (Dct) result in a proliferative and pigmentary response, with ET-1 and ET-3 being more potent proliferating agents than ET-2, and the response is blocked by an ET_B antagonist (536). ET receptor gene expression in tissues that include the skin appears to increase during the later stages of embryonic development to reach maximal expression immediately after birth (5).
C) ENDOTHELINS AS REGULATORS OF ADULT MELANOCYTES. Endothelin has been identified as a potent stimulator of proliferation and differentiation of human melanocytes (910). ET is in fact secreted by keratinocytes and stimulated by UVB radiation to evoke a melanocyte response characterized by proliferation and melanogenesis (315, 910). Addition of ET-1 to cultured human epidermal melanocytes results in increased tyrosinase activity and TRP-1 mRNA expression, whereas expression of the same genes in human skin is increased after UVB irradiation (313). The effect of ETs on tyrosinase activity is probably mediated via activation of PKC, elevation of cAMP, and activation of PKA (313). ETs have also been implicated in development of melanocyte dendriticity (258). The ET-converting enzyme-1, which is involved in the processing and UVB-inducible secretion of ET-1 by keratinocytes, is also expressed in melanocytes (239). ETs can also cooperate and synergize with other growth factors to alter melanocyte phenotype. For example, melanocyte cultures treated briefly with ET-1 upregulate mRNA for MC1R, and also MC1R binding activity for a-MSH (192, 806). Conversely, ET-induced melanocyte differentiation may be enhanced by a-MSH, although this finding is not universal (279).

D) ENDOTHELINS AND PATHOLOGY OF SKIN PIGMENTATION. ET-1 protein expression is higher in lentigo senilis lesional skin, compared with perilesional skin; moreover, lesional skin shows increased expression of transcripts for ET-1, ETB, and tyrosinase, as well as the ET-inducible cytokine TNF-a. Thus this type of hyperpigmentation may be associated with overactivity of the ET cascade. As regards ET-1, both binding and growth response are lower in metastatic melanoma cells than in primary melanoma cells (158). A consistent finding has been that despite significant ET receptor expression in melanoma cells, the cells exhibit reduced growth response to ET-1 compared with normal melanocytes.

4. Histamine and its receptors

A) OVERVIEW. Histamine (β-imidazolylethylamine) is generated by enzymatic decarboxylation of histidine by L-histidine decarboxylase and is stored within cell granules. In some systems, the decarboxylation step may be alternatively performed by an aromatic amino acid decarboxylase, dopa-decarboxylase (227). Intracellular histamine may participate in cellular proliferation, while histamine released into the intercellular space is catabolized to form imidazole-carboxyaldehyde, 1-methyl-histamine, or 1-methyl-imidazole-acetic acid (227). Histamine metabolism proceeds very rapidly in skin (805). Following the cloning of histamine receptors H1 and H2 (202, 914), their pharmacological functions have been better defined (37). The H1 receptor is ~56 kDa and H2 ~59 kDa (274). One additional receptor exhibits “autoreceptor” activity (H3A-C) of 70 kDa (118, 437), and a fourth histamine receptor of 85 kDa, H4, closely related to H3, has recently been identified (430, 507, 521). As H4 appears to be expressed on mast cells, it may also be present in skin (931).

All four known histamine receptors are G protein-coupled receptors. H1 histamine receptor induces functional responses by activating phospholipase C via a Gq11 followed by an increase in inositol phosphate, mobilization of [Ca2+]i, and activation of PKC (417). H2 can also activate other signaling pathways such as guanylyl cyclase with subsequent stimulation of NO synthase activity (927), and it can also induce the release of arachidonic acid and its metabolites prostacyclin and thromboxane A2 (501). Histamine H2 receptors couple via Ga protein to simulate adenyl cyclase activity (273). There is also evidence of H2 coupling to other pathways including [Ca2+]i, although these effects appear to be cell type specific. In contrast, signaling via H4 receptors is more speculative (123). Signal transduction via the H2 receptor appears to be similar to that of H3, i.e., coupling to a G protein to inhibit adenyl cyclase (931) with subsequent mobilization of Ca2+.

B) CUTANEOUS HISTAMINE FUNCTION. Histamine is found at high levels in mast cells in skin, lung, intestinal mucosa, basophils in the blood, the so-called histaminocytes in the gastric mucosa, and the central nervous system. In the skin, dermal mast cells store large amounts of histamine within granules, and it mediates itching upon release. The itch sensation is abolished by epidermis removal; itching increases when integrity of the epidermis versus dermis is compromised (640). Antihistamine agents are effective treatment for pruritis associated with inflammation (1). Histamine generation has also been demonstrated in human skin keratinocytes (450), which can release up to 50% of the release from dermal mast cells (122). Histamine roles may include regulation of cell proliferation/differentiation, neurotransmission, and immunomodulation (525, 587). Histamine has been demonstrated in several skin compartments including mast cells, blood vessels, eccrine gland, hair follicles, and epidermis (341, 450).

Primary cultures of epidermal keratinocytes contain and release significant amounts of histamine, and UVB irradiation increases further its levels and also stimulates its release (450). Epidermal keratinocytes also express H1 and H2 receptors (183, 226), and there may even be H3 receptors in skin, as suggested by flare responses to intradermal injections of selective H3 agonists (349). A role for histamine in epidermal proliferation is indicated by the inhibition of reactional epidermal hyperplasia after histamine receptor antagonists have been applied to barrier-disrupted epidermis (27).

C) HISTAMINE ACTION ON MELANOCYTES. Mast cells release histamine if irradiated in the presence of photolabile red/yellow pheomelanin and pheomelanoprotein (605), but not when irradiated alone or in the presence of the pho-
tostable brown/black eumelanin. Antimalarials (e.g., chloroquine) may also alter cutaneous pigmentation by antagonizing histamine responses (372). The level of constitutive melanization of the skin does appear to affect histamine action, since direct intradermal injection of histamine phosphate induces greater wheal sizes in black versus white skin (854).

A link between histamine biology and melanogenesis may be represented by the inhibition of tyrosinase activity and melanogenesis in melanoma cells exposed to histamine H$_2$ receptor agonists (473). Moreover, histamine H$_1$ receptor antagonists (mepyramine) and H$_2$ receptor antagonists (cimetidine, ranitidine) appear to increase tyrosinase activity, while H$_2$ receptor agonists stimulated cell proliferation. H$_2$ receptor antagonists stimulate melanin accumulation in some melanoma lines, but this is likely to be associated with inhibition of proliferation (845).

Stimulation of the H$_2$ receptor increases cAMP production and tyrosinase activity in melanoma cell lines (887), although increases in tyrosinase activity, albeit minimally, are also seen with histamine H$_2$ receptor antagonists (e.g., cimetidine) in normal human epidermal melanocytes (408). Histamine had no effect on white or black foreskin melanocyte cultures in concentrations up to 1 $\mu$M (325). The histamine H$_2$ receptor agonist analog S-[2-(N,N-dialkylamino)ethyl]isothiourea was able to depigment melanoma cells, with or without inhibition of tyrosinase, suggestive of downregulation of the message from pigmentation genes (174). However, melanocytes cultured directly with 5 $\mu$M histamine undergo phenotypic changes that do include increased dendricity and tyrosinase protein expression (837), whereas histamine in doses as low as 0.1 $\mu$M rapidly increase tyrosinase activity and TRP-1 protein expression. These melanogenic and morphogenic effects of histamine elicited at 0.1–10 $\mu$M in normal human epidermal melanocytes can be inhibited by H$_2$ receptor antagonists (e.g., famotidine), but not by antagonists of either H$_1$ or H$_2$ receptors (923). The central involvement of signaling through the H$_2$ receptor was evidenced by the similar stimulation of melanocyte phenotype by an H$_2$ agonist (dimaprit) and by histamine itself. In the latter case, melanogenesis stimulation was likely due to accumulation of cAMP and subsequent PKA activation, as these effects could be blocked by the PKA-specific inhibitor H-89. Some of these discrepancies may be due to the varying doses of agonists and antagonists used. Furthermore, melanocyte culture conditions, such as the inclusion of growth factors (e.g., basic fibroblast growth factor), are likely to be important given the associated activation of PKA (923).

The duration of histamine exposure/treatment appears also to be important, since only patients with urticaria pigmentosa develop hyperpigmentation and not those with recurrent episodes of urticaria itself. Indeed, pigmentation may require cooperation between histamine and other factors such as SCF (131). H$_2$ receptor antagonists inhibit constitutive pigmentation and also facultative pigmentation induced by UVB irradiation (923). In this regard, it is interesting to note that UVR stimulates the release of histamine from keratinocytes (450), although the inhibition of UVR-induced pigmentation is incomplete. Recently, it has been reported that histamine can increase the eumelanin-to-phaeomelanin ratio in cultured normal epidermal melanocytes (405). Thus histamine may be an important mediator of UV-induced hyperpigmentation in human melanocytes.

D) Histamine in Pigmentary Disorders. The increased skin pigmentation associated with urticaria pigmentosa and systemic mastocytosis appears to result from increased local concentrations of histamine. Melanin-containing cells and mast cells may exhibit very close associations in lesions of nodular mastocytosis (532). Indeed, these lesions may even contain mast cells with phagocytosed melanin granules.

Serum histamine levels have been associated with melanoma development (494), but treatment with both histamine receptor agonists/antagonists has been associated with the induction of antimalanoma responses (767). Because mast cells often concentrate around melanoma, this could have perhaps prognostic significance (355, 617). Histamine itself can act as a growth factor and chemoattractant for melanoma cells via stimulation of H$_1$ receptors followed by mobilization of Ca$^{2+}$ (827). Human melanoma cells also exhibit higher histamine levels than normal melanocytes (616) and express histidine decarboxylase, the enzyme that catalyzes the formation of histamine from L-histidine (237). In general, histamine signaling via H$_1$ may decrease melanoma cell proliferation, while enhancement of cell growth may result from signaling via H$_2$ (265, 616). Other data suggest that the impact of local histamine action may depend on number, availability, and ratio of H$_1$ and H$_2$ receptors (172). In vivo studies involving the xenografting of human melanoma cells onto SCID mice have shown that H$_2$ receptor antagonists can significantly improve the survival of the engrafted mice (804). Furthermore, melanoma metastases in the liver can be induced to regress if histamine is coadministered with IFN-$\gamma$ (6).

5. Eicosanoids and their receptors

A) Overview. The arachidonic acid-derived eicosanoids consist of a family of lipid-derived second messengers that include the prostaglandins, leukotrienes, and thromboxanes. Prostaglandins and leukotrienes signal through G protein-coupled seven-transmembrane receptors that differ in their G protein specificity. Multiple prostaglandin receptors have been cloned, and coexpression of prostaglandin receptors on the same cell leads to
opposing effects (375). Prostaglandin receptors are defined as DP (for PGD), EP1, EP2, EP3 (6 isoforms), and EP4 (for PGE), FP (for PGF), and IP (for PGI) and the thromboxane A receptor TP subtypes (26). Most of these receptors signal via increasing cAMP, but EP3 reduces cAMP levels. EP1 and FP signal via PLC. Thus it is not necessary for coexpressed prostaglandin receptors to signal via the same second messenger systems. Thromboxane A2 signals via TP receptors (2 isoforms) and also increases phospholipase C concentrations. The profiles of leukotrienes LTB4 versus the sulfidopeptide or cysteiny]_leukotrienes (LTC4, LTD4 or LTE4) is mirrored by their having different receptors whereby LTB4 binds two BLT receptors, and the cysteiny]_leukotrienes bind CysLT1 (formerly known as the LTD4 receptor) and CysLT2 receptors (136). Coupling via their G protein-coupled receptors (either Galphaq, Galphai, or Galphao) dictates whether the responses are pro- or anti-inflammatory (772).

B) EICOSANOIDS AND MELANOCYTES. It has long been clinically observed that inflammatory dermatoses are associated with striking changes in melanocyte function (514). Eicosanoids were the first mediators investigated for their effects on melanocyte function, since their levels are increased in skin after sunburn (60), atopic dermatitis-associated acute inflammation (643), contact dermatitis (636), psoriasis (864), and urticaria pigmentosa (835).

Cultured Cloudman S91 mouse melanoma cells respond to PGE1 and PGE2 by increasing tyrosinase activity and by decreasing proliferation; PGA1 and PGD2 inhibit cellular proliferation and tyrosinase activity, while PGF2alpha had no effect. PGE1alpha, but not PGE2alpha or PGD2alpha, increases cellular cAMP levels after 30 min of treatment (4). Eicosanoid effects on normal melanocyte function include increased pigmentation (LTB4, LTC4, PGE2, PGF2alpha), growth (LTC4), differentiation (LTC4), and motility (LTC4) (519). LTB4 has been shown to stimulate melanogenesis directly in human melanocyte cell culture (492), while LTC4 induces a marked decrease in pigment production in cultured cells (834), although both LTC4 and its metabolite LTD4 stimulate melanocyte proliferation via PKA activation (491, 492). LTC4 is also an important regulator of melanocyte differentiation not only increasing life span of melanocytes in culture, but also facilitating nevoid-appearance colony formation via reduction/loss of contact inhibition (477). Normal human epidermal melanocytes cultured for 2 days with either PGD2alpha, LTBrho, LTC4, LTD4, LTE4, thromboxane B2, or 12-HETE become swollen and more dendritic, with increase in the expression of tyrosinase and TRP-1 protein; in contrast, PGE1, PGF2alpha, and 6-ketoPGF1alpha did not show any significant stimulatory effect. It has therefore been suggested that arachidonate-derived chemical mediators, especially LTC4, can induce postinflammatory hyperpigmentation of the skin (836). Phospholipase A2, which catalyzes the release of free fatty acids from membrane phospholipids, has also been shown to significantly upregulate expression and activity of tyrosinase in cultured melanocytes, suggesting that it may act as a mediator of UV-induced or postinflammatory pigmentation (447).

While melanocyte behavior is influenced by inflammatory mediators, the cells in turn contribute to the process by producing and releasing IL-8 and monocyte chemotactic and activating factor in response to the proinflammatory cytokines IL-1 and TNF-alpha (928). Moreover, IL-1 together with LTD4 and 12-HETE are also secreted by melanocytes (801), albeit at lower levels than in cultured keratinocytes (386). Of note, LTC4 is a potent enhancer of melanocyte chemokinesis (491), and human melanoma cells may express LTA4 hydrolase, catalyzing the conversion of LTA4 to LTBrho. Similarly, considerable activity of LTC4 synthase, which catalyzes the conversion of LTA4 to LTBrho, may be detected in the microsomal fraction of melanoma cells (528).

C) EICOSANOIDS AND PIGMENTARY DISORDERS. Topical treatment of vitiligo lesions with PGE2 may be associated with marginal repigmentation with hyperpigmented borders (556). Hyperpigmentation of the eyelid and of eyelashes may be a complication of topical ocular hypotensive therapy with latanoprost, a PGE2 analog (269, 867). Pigmentation returns to normal upon cessation of therapy. Latanoprost is also associated with increased pigmentation of the iris in both primates and humans (599), although it does not appear to induce proliferation of iridial melanocytes. Latanoprost directly affects melanogenesis itself via activation of tyrosinase.

6. Catecholamines and their receptors

A) OVERVIEW. The catecholamines (dopamine, norepinephrine, and epinephrine) are small polar biogenic amines that are synthesized primarily by cells of neuroectodermal origin from tyrosine via its conversion to L-DOPA catalyzed by tyrosine hydroxylase (TH) with its essential cofactor 6-tetrahydrobiopterin (BH4). L-Dopa is converted to dopamine via the enzyme aromatic amino acid decarboxylase (AADC) and then to norepinephrine (via dopamine beta-hydroxylase) or epinephrine (via phenylethanolamine N-methyltransferase, PNMT) in the catecholamine storage vesicle. Catecholamines are also produced in multiple peripheral sites (44, 146), including the skin (665, 677). Classically, the catecholamines act as neurotransmitters, but they have been shown to be involved in the regulation of nearly every organ system (44, 484, 784, 789, 890), including skin function (378). The catecholamines act through G protein-coupled seven-transmembrane receptors subclassified into several alpha- or beta-subtypes. Each adrenergic receptor subtype binds a different subfamily of G-proteins, which interact in turn with a range of effector molecules.
B) CATECHOLAMINE ACTION ON MELANOCYTES. Catecholamines were first shown to play a role in pigmentation in nonmammalian tissues, especially amphibian chromatophores where both α- and β-adrenergic receptors are expressed. While norepinephrine and epinephrine lighten the skin of *Rana pipiens* (906), they have the opposite effect on *Xenopus* skin (91). The human epidermis has the full capacity to synthesize catecholamines (675); bioterpertin-dependent TH and PNMT, the key enzymes for the biosynthesis of epinephrine, have been detected in cell-free extracts of human skin epidermis, dermis, and cultured human keratinocytes. However, these enzyme activities were not detected in cultured human melanocytes and fibroblasts. The presence of TH, PNMT, monoamine oxidase (MAO-A), and catechol-O-methyltransferase (COMT) in the epidermis was confirmed immunohistochemically (411). The biosynthesis of epinephrine in the epidermis results in the expression of increased numbers of β2-adrenoceptors in undifferentiated keratinocytes (786), which may control keratinocyte differentiation via increased intracellular cAMP and Ca$^{2+}$ (665). In contrast, norepinephrine induces α2-adrenoceptors in melanocytes (662). Thus keratinocytes secrete catecholamines, which may be critically important for α1-adrenoceptor expression and signaling in melanocytes, underlining their symbiotic relation. Activation of α1-adrenoceptor in melanocytes results in the activation of various effector enzymes, e.g., PLC, PLA$_2$, and increases in intracellular Ca$^{2+}$ (219). Specifically, activation of PLC results in the cleavage of membrane phospholipids to yield second messengers IP$_3$ and DG with subsequent activation of PKC. PKC can then phosphorylate a variety of cellular substrates, not least of which are the serine residues on tyrosinase (552), with moderate increases in its activity. Studies performed on cultured melanoma cells have indeed shown that epinephrine or norepinephrine as well as other adrenergic agonists can stimulate moderately tyrosinase activity and melanin production (293).

C) CATECHOLAMINE IN PIGMENTARY DISORDERS. Production of the essential cofactor for catecholamines, 6-BH$_4$, is enhanced in lesional and nonlesional skin of vitiligo, leading to the accumulation of the oxidized 6-BH$_4$. This metabolite is toxic to melanocytes in culture (665). High levels of 6-BH$_4$ also lead to upregulation of TH levels (505), perhaps explaining the higher levels of catecholamines in patients with vitiligo in both their skin and plasma (665). Expression of β2-adrenoceptors in epidermal melanocytes obtained from vitiligo skin may be higher than in healthy controls. Epidermal cells from vitiligo patients also express higher levels of COMT activity (411). COMT is involved in the metabolism of epinephrine, norepinephrine, and dopamine and also prevents the formation of toxic o-quinones during melanin synthesis in melanocytes (765). Indeed, methylation of the melanin precursor molecule DHI by COMT prevents its further incorporation into melanin. Melanocyte “autodestruction” by intermediates of melanin metabolism has been implicated in the etiology of vitiligo (411, 740).

B. SCF and Its Receptor

1. Overview

SCF, also known as mast cell growth factor (MGCF), c-kit ligand (KL), or Steel Factor (SL), is a peptide growth factor/cytokine encoded by a gene with a multi-exon structure (208). Differential splicing produces mRNAs that either include or lack exon 6, resulting in the production of two transmembrane forms of SCF; one 248 amino acids long (SCF$_{248}$), the other 220 (SCF$_{220}$). Rapid proteolytic cleavage (by increased [Ca$^{2+}$]), activation of PKC, and some metalloproteases) of SCF$_{248}$ produces a soluble SCF form that dimerizes in solution. Importantly, differential effects of soluble and transmembrane forms of SCF are also seen in the dispersal and survival of melanocyte precursors (see below) (879). Normal skin keratinocytes constitutively produce SCF (435). SCF synergizes with myriad growth factors such as IL-3, IL-6, IL-7, IL-9, Epo, granulocyte-macrophage (GM)-colony stimulating factor (CSF), and G-CSF (429). Steel mice, with deletions in the SCF gene, also exhibit defective formation of germ cells leading to sterility (233), and defective microenvironment for the development of melanocytes, hence their steel-colored coat (see below) (611).

SCF signals via the c-kit receptor (51, 195, 917) were expressed on various cell types including melanocytes (80). The c-kit receptor consists of five extracellular Ig domains, one transmembrane domain, one inhibitory domain at the cytoplasm/membrane junction, and one cytoplasmic kinase domain (848). c-kit signaling is initiated when SCF binds to its extracellular Ig domains thereby inducing multiple interconnected signaling pathways that follow the rapid formation of c-kit dimers and internalization of the SCF-c-kit receptor complex. SCF binding not only activates receptor kinase activity, but also turns c-kit into a phosphorylation substrate via creation of tyrosine phosphorylated receptor docking sites on c-kit. Subsequent binding of multiple intracellular signaling proteins, mediating protein tyrosine phosphatases SHP-1 and SHP-2, and SH2- and PTB-containing molecules (377), as well as the phosphoinositide 3-kinase (PI3K) and phospholipase C-γ can regulate c-kit activity. Initial expansion of the melanoblast pool requires signaling from c-kit, MITF, and the ET$_B$ receptor (EDNRB) (291). Signaling by c-kit also favors melanocyte proliferation (697). Thus c-kit can influence gene expression during the development of melanocytes in a gene-selective way.
2. SCF/c-kit in melanocytes

Mutations in the receptor tyrosine kinase c-kit [mapped to the white spotting (W) locus in mice] or its cognate ligand SCF [mapped to the steel (sl) locus in mice] (380, 496, 510) exert deleterious effects on three migratory cell lineages: primordial germ cells, hematopoietic stem cells, and melanocytes, resulting in reduced fertility, anemia, and loss of pigmentation, respectively. Mice with homozygous c-kit mutations have an almost white coat, while c-kit mutations in humans are associated with piebaldism (778, 802). Melanoblasts express c-kit from the time they leave the neural crest; it continues to be expressed on some, but not all, melanocytes in postnatal animals, while expression of its ligand SCF is more selective (380, 496, 510).

Studies on the role of c-kit/SCF signaling on melanoblast/melanocyte regulation have been based on phenotypic finding after c-kit/SCF signal disruption (by mutations or antibody treatment) (76, 879, 880, 922); and on the effects of SCF treatment on c-kit expression, melanoblast proliferation, differentiation, and apoptosis (322, 340). The c-kit/SCF interaction is critical for melanocyte survival (785) as shown by the induction of apoptosis in murine melanocytes after injection of a c-kit-blocking antibody (ACK2) (322). When ACK2 is injected just before migration of melanoblasts from the epidermis into developing hair follicles, the entire coat remains white (510, 922); with later injections patches of white hair develop and melanocytes are detected only in those hair follicles that were developed to at least stage 4 of morphogenesis at the time of ACK2 treatment (922). In adult mice hair follicle cycling, administration of c-kit neutralizing antibodies to depilated mice disrupts melanocyte activation during anagen (71, 510). Thus c-kit is also required for melanocyte activation during the murine hair cycle (71, 578). Notably, melanoblasts/cytes that enter the follicular pigimentary unit retain c-kit expression while differentiating into melanin-producing melanocytes, whereas melanocytes that remain in the outer root sheath lose c-kit expression at the end of hair follicle development (578).

Epithelial-derived SCF may be the physiological regulator in the c-kit-expressing melanoblasts and melanocyte of mammalian skin by modulating migration and melanocyte cytoskeleton (71, 218, 685, 687, 880), differentiation (395, 444), melanogenesis (131, 444), and cell survival/apoptosis (322). At least two isoforms of SCF are present in skin (membrane-bound and soluble) (380); melanoblasts are detectable in mice deficient in membrane-bound SCF, but the cells do not disperse into the developing skin resulting in only white coat (76, 879). Correct migration and differentiation of melanoblasts appears to require the localization of membrane-bound SCF to the basolateral cell compartment within the hair follicle epithelium (880). Moreover, hair shafts fail to pigment if SCF levels are reduced in the epidermis (50), or if there is increased competition for SCF from ectopic c-kit expression in the somites (156), even if the development and distribution of melanoblasts was normal before hair follicle morphogenesis. In contrast, overexpression of the membrane-bound SCF isoform, under the K14-promotor (380), and SCF release from beads implanted into organ-cultured skin results in follicular and epidermal hypermelanosis (340). Overexpression of both the soluble and membrane-bound isoforms, under the K14-promotor, produces mastocytosis (380).

The targeting of c-kit-positive melanoblasts to the epidermis and hair follicle appears to require chemoattractant stimuli that cosignal with c-kit/SCF. These stimuli include growth factors such as endothelin (314, 354) or specific adhesion molecules such as β3-integrin (36, 685). Further chemoattractant signals may be expressed by the hair follicle papilla, which may be an important local source of SCF production.

3. SCF/c-kit in pigmentedary disorders

Mutations in the c-kit receptor have been identified within a continuous range of human piebaldism phenotypes (184, 211, 781). Interestingly, a common side effect of recombinant SCF therapy has been focal hyperpigmentation at the site of subcutaneous injection (131, 231). There is evidence that melanocytes in the perilesional skin of vitiligo patients may exhibit reduced c-kit expression (518). It must also be noted that both alopecia areata and vitiligo contain a pool of functional melanocytes in local hair follicles that is responsive to SCF stimulation (832).

The expression of c-kit in melanoma decreases progressively during the local growth and invasion phases (300, 406). Moreover, tumor growth and metastasis are inhibited in nude mice after forced c-kit expression; SCF induces apoptosis of c-kit-positive human melanoma cells both in vitro and in vivo (301). Nevertheless, the loss of c-kit expression in melanoma cells is more consistent and appears to correlate with the loss expression of the transcription factor AP-2. AP-2 is involved in gene expression in neural crest and epidermal cell lineages throughout development and adult cell differentiation (312). The c-kit promoter contains three binding sites for AP-2 (913). Interestingly, induction of AP-2 expression in human melanoma cells led to c-kit expression and inhibition of tumor growth and metastasis (300). Furthermore, c-kit is an imatinib mesylate-sensitive tyrosine kinase, and thus a potential candidate for the use of this drug in c-kit-positive melanomas (177).
C. Nuclear Receptors and Their Ligands

1. Estrogens and their receptors

a) Overview. Estrogens, C_{18} steroids, are produced from C_{19} androgens by the microsomal enzyme P-450 aromatase (P450arom). Estrogens are produced from testosterone or androstenedione in the ovary, testis, and adrenal gland as well as in peripheral tissues such as adipose tissue. Estrogens are essential components of female and male reproduction, with well-characterized functions in the uterus, ovaries, mammary gland, and hypothalamic-pituitary axis. The multiple estrogen actions are mediated mainly by two estrogen receptors: ERα and ERβ (228, 229). ERα consists of 595 amino acids with a molecular mass of 66.2 kDa, and ERβ consists of 485 amino acid residues with a molecular mass of 54.2 kDa. ERβ shares 97 and 60% identity with the DNA- and ligand-binding domains of ERα, respectively. Both receptors have high binding affinity for 17β-estradiol (E2), followed by estriol and estrone.

ERα and ERβ belong to a superfamily of ligand-activated transcription factors. In the absence of ligand (hormone), the receptor is sequestered in a multiprotein inhibitory complex within the nuclei of target cells. The binding of hormone induces conformational changes and promotes homodimerization of ER, which is able to bind to specific DNA response elements (estrogen-response elements). Each receptor exhibits differential tissue expression patterns during human fetal development (75). ERα and ERβ mRNAs are expressed at low levels in the skin. Loss of both receptors leads to a unique ovarian phenotype, indicating that both receptors are required for the maintenance of germ and somatic cells in the postnatal ovary.

Some effects of estrogens are mediated through a mechanism independent of ER transcriptional activity (252, 282, 376). Notably, ERα binds in a ligand-dependent manner to the p85α regulatory subunit of phosphatidylinositol-3-OH kinase [PI(3)K] (709). Thus this nonnuclear estrogen-signaling pathway requires the direct interaction of ERα with PI(3)K.

b) Estrogens and melanocytes. Estrogens have significant effects on many aspects of skin physiology and pathophysiology (695, 824), including skin aging, pigmentation, hair growth, sebum production, and skin cancer. The ERα and ERβ are expressed in male and female nonbalding scalp skin, and their expression profiles show lack of any obvious differences in the skin between both sexes but, distinct regional localization (825). ERβ is preferentially expressed in human epidermis, blood vessels, and dermal fibroblasts. In the hair follicle, ERβ expression is localized to nuclei of outer root sheath, epithelial matrix, and dermal papilla cells. ERα is not clearly detected in the epidermis or hair follicles. Both ERβ and ERα are expressed in the sebaceous gland.

Subjects with elevated serum estrogen concentrations tend to develop increased skin pigmentation, suggesting that estradiol may be involved in the pathogenesis of melasma (chloasma). The effects of estrogens on melanogenesis are uncertain (824). The incidence rates of melanoma rise steeply in women until about age 50, but there is no confirmatory evidence of linkage to estrogens (175).

Human melanocytes derived from normal foreskin express the functional estrogen receptor (331). Estradiol treatment of those melanocytes stimulated proliferation and reduced the melanin content by day 10, and reduced the tyrosinase activity by day 4 (331). In contrast, incubation of similar melanocytes with estradiol for only 24 h causes dose-dependent increase in tyrosinase activity (606), and treatment with estradiol for 2 days increases immunoreactive TRP-1 but not tyrosinase activity in cultured normal human melanocytes derived from adult forearm skin. Pituitary hormones, such as ACTH, follicle-stimulating hormone, and luteinizing hormone, increased both tyrosinase activity and immunoreactive TRP-1 (448). An estradiol-mediated increase in melanogenesis gene transcripts has been reported (361); namely, treatment of cultured melanocytes with estradiol increased the levels of tyrosinase transcripts by 1.5- to 2.5-fold, TRP-1 transcripts by 1.5-fold, and TRP-2 transcripts by 20-fold. These results suggest that the effect of estradiol on the tyrosinase activity may be influenced by multiple factors, such as culture conditions, sex, and age. In fact, estrogen has shown inconsistent effects on proliferation and tyrosinase activity of cultured human foreskin melanocytes (311).

2. Androgens and their receptors

a) androgen function and signaling. Androgens are a group of C_{19} steroids secreted by the adrenal glands and also the gonads. Androgens signal via the androgen receptor (AR), a member of the nuclear receptor superfamily of transcription factors that maps to band q11–12 on the X chromosome and encodes a 110-kDa phosphoprotein of 919 amino acids (111). Testosterone and 5α-dihydrotestosterone (DHT) are ligands for the AR, and in the skin testosterone is converted to DHT by types I and II 5α-reductases. The AR bound to either ligand is translocated from the cytosol to the nucleus where it initiates gene transcription events by binding androgen response elements (ARE) on multiple genes (79). At least two regions of the AR are involved in transcriptional activity, i.e., AF-1 and AF-2 (332). AR activity is regulated via recruiting of activator and repressor proteins [e.g., steroid receptor coactivator-1 (SRC-1)]; although AR binding alone may directly activate...
the MAPK signaling pathway (580), MAPK appears to be required for both ligand-dependent and ligand-independent activation of the AR (847). An alternative signaling pathway may involve reactive oxygen species and action on AP-1 and NF-κB DNA binding (622).

b) Androgens and melanocyte biology. The skin is a major target of androgens and expresses androgen receptors in cells of the epidermis, dermis, sebaceous glands, and hair follicle (11). Moreover, skin has the capacity to metabolize androgens into DHT (861). Early work by Hamilton (253) uncovered a poor tanning response to UVR in white eunuchs, whereas treatment with testosterone increased melanization. Melanogenesis in localized areas of the skin can be stimulated by androgens in males (883) and in similar sites in females during their breeding season (382). In the black-pelted rat, castration decreased in vitro incorporation of [14C]tyrosine into melanin, while testosterone pretreatment for 4 days reversed the effect (893). Testosterone also blocks imidazole induction of tyrosinase activity, most likely at a pretranslational level (366).

Prepubertal Syrian hamsters chronically treated with DHT exhibit increased pigmentation on dorsal costovertebral spots and scrotal skin, but not elsewhere on the skin, and estradiol had the opposite effect (147). There is regional specialization in the responsiveness of melanocytes to sex steroids, as seen in follicular and perisoeobaceous gland, human genital, and areolar skin (771). This skin becomes particularly pigmented after puberty and during pregnancy. Melanocytes cultured from genital skin express the AR protein in a nuclear distribution (807). Melanocytes may also metabolize testosterone to produce DHT and express type I 5α-reductase mRNA (117, 807). A synthetic androgen (methyltrienolone) stimulates tyrosinase activity, and cAMP levels in cultured melanocytes are reduced by testosterone, DHT, and methyltrienolone.

C) Androgens and pigmentation disorders. Women with melanoma are reported to have a better prognosis compared with men (604, 699). In mice, blocking of androgen signaling enhanced immune responses to melanoma vaccine, and improved by 10% the rate of survival (296). Oral contraceptives (containing progestins or estrogens) (822) are contraindicated if there is a personal or family history of malignant melanoma. Chloasma/melasma is one of the most commonly reported OC-related dermatoses, and this is exacerbated by sun exposure. Androgen treatment in women may also accompany a decrease in age-related skin hyperpigmentation (777). In male hypogonadism, genital skin fails to exhibit the normal puberty-associated increase in pigmentation (309), whereas male pseudohermaphroditism with complete feminization is associated with intense cutaneous pigmentation (270). Castrated mallards injected with testosterone show lower eumelanin-to-pheomelanin ratio in the flank feathers, compared with noninjected castrates. The high pheomelanin levels in the breast feathers of castrated birds were significantly reduced after testosterone administration, while eumelanin content increased (238). There is some evidence that generalized vitiligo may be improved by oral administration of a preparation containing testosterone and estrogen (502).

3. Vitamin D and its receptors

A) Overview. Vitamin D3 is formed in the skin by UVB light (wavelengths 290–315 nm) (877). Rapid photolysis (i.e., bond cleavage) converts 7-dehydrocholesterol to previtamin D3, a thermodynamically unstable sterol that subsequently isomerizes, via double bond rearrangements, to vitamin D3. Circulating vitamin D3 must be converted to its active form 1,25-dihydroxycholecalciferol. Thus 25-OHase in the liver converts vitamin D3 into 25-hydroxycholecalciferol, and in the kidneys it undergoes further hydroxylation to either 1,25-dihydroxycholecalciferol (via 1-OHase) or 24,25-dihydroxycholecalciferol D (via 24-OHase). Both 1-OHase and 24-OHase are expressed in cultured keratinocytes (409) and in skin (680).

The nuclear receptor for vitamin D (VDR) is expressed on several target tissues that include the skin (284). VDR is a transcription factor and member of the steroid nuclear receptor superfamily, and in human epidermis binds its enhancer element as heterodimers with retinoid X receptor. Vitamin D is also involved in cytoplastic signaling events, i.e., nongenomic signaling pathways, stimulating Ca2+ transfer across the intestine within 1–2 min (833). Interactions between nongenomic and genomic routes occur via either direct phosphorylation of the nuclear VDR or via the upregulation of genes with VDREs, which themselves encode signaling molecules, e.g., phospholipase C-γ. Vitamin D signaling has important implications for cell growth, differentiation, and apoptosis of skin cells, particularly keratinocytes, which may indirectly regulate melanocyte behavior in skin. Vitamin D-associated antiproliferative effects are centered on the G1/S checkpoint of the cell cycle, where at pharmacological levels it inhibits/arrests the cell cycle. Control of human keratinocyte growth by vitamin D may also involve transforming growth factor (TGF)-β2. Also, calcipotriol, a 1–25-dihydroxyvitamin D3 [1,25(OH)2D3] analog, increases expression of p21 (which contains a VDRE) in normal skin (596). Vitamin D may reduce keratinocyte proliferation via downregulation of the epidermal growth factor receptor (466). Vitamin D3 also plays a role in keratinocyte differentiation possibly via an increase in intracellular Ca2+ (56).

B) Vitamin D and melanocyte biology. Melanocytes in situ express the VDR (481, 791), with possible tyrosinase-activating and melanogenic effects. Although some authors have reported increased tyrosinase activity after vitamin D3 treatment (606, 839), others reported no effect...
(3, 455). Topical application of 100 μg cholecalciferol to ear epidermis in mice for a week increased DOPA-positive melanocytes, and this effect synergized with UVB (3). However, cholecalciferol added to human melanocyte cultures did not affect melanocyte proliferation, tyrosinase activity, or melanogenesis. Instead, a 25(OH)D$_3$ and 1,25(OH)$_2$D$_3$ may have suppressed tyrosinase activity in these cultures. In murine melanocyte precursors 1,25(OH)$_2$D$_3$ can induce differentiation, including induction of tyrosinase and DOPA activity, established from mouse neural crest cells (871).

C) VITAMIN D AND PIGMENTARY DISORDERS. Proliferation of human melanoma cells (expressing the VDR) is inhibited by 1,25(OH)$_2$D$_3$ (125, 171), and B16 melanoma cells are induced to differentiate, with an increase in both tyrosinase activity and melanogenesis after treatment with vitamin D$_3$ (527). However, not all melanoma cells express the VDR, or do so at very low levels, and so may not be as responsive to the antiproliferative effects of 1,25(OH)$_2$D$_3$. The presence of the VDR may also enable 1,25(OH)$_2$D$_3$ to induce apoptosis in melanoma cells (138). Vitamin D$_3$ may inhibit migration of melanoma cells on extracellular matrix and in some melanoma cell lines downregulates, transcriptionally, the α$_6$-subunit of the integrin laminin receptor (256). Melanoma patients may present with lower levels of 1,25(OH)$_2$D$_3$ in their sera (130). Polymorphisms at the VDR have been suggested to influence susceptibility to malignant melanoma (309). Furthermore, certain VDR genotypes may be associated with red hair in melanoma patients, similar to the case at the MC1R. Hyperpigmentation may occur after topical calcipotriol use in patients with psoriasis (370, 788). Moreover, there is some evidence that topical calcipotriol may be effective in the treatment of vitiligo (912). In another study calcipotriol was effective even in patients that previously responded poorly to topical corticosteroids and PUVA (14). One possible explanation of the repigmentation noted after calcipotriol therapy may be stabilization of aberrant Ca$^{2+}$ homeostasis in vitiligo skin (keratinocytes and melanocytes) (668, 669) by increasing expression of VDR in treated skin (610).

D. Other Positive Regulators of Melanogenesis: Bone Morphogenic Proteins

1. Bone morphogenic proteins and their receptors

Originally discovered as an osteoinductive extract derived from bone matrix, the bone morphogenic proteins (BMPs) consist of a family of dimeric proteins (BMP-2 to BMP-15) that belong to the TGF-β superfamily (905). In species as diverse as worms, flies, frogs, and humans, BMPs play multiple pivotal roles including development, especially in the specification of positional information in the embryo. These secreted signaling molecules also regulate several aspects of cutaneous development and function via their participation in cell proliferation, differentiation, and death (70). In addition to their involvement in epidermal homeostasis, hair follicle growth/cycling, and melanogenesis, evidence is accumulating to implicate these molecules in cutaneous pathologies such as in carcinogenesis, hyperproliferative disorders (e.g., psoriasis), wound healing, and innervation. Biologically active BMPs are released extracellularly as homo/heterodimers after cleavage of precursors proteins. Transduction of BMP signaling ensues after the formation of a high-affinity heterotetrameric complex that incorporates the binding of BMP to BMP-specific type I and II receptors and in some cases to other members of the TGF-β receptor superfamily. Two independent signaling pathways appear to be activated by BMPs including a canonical pathway involving the phosphorylation of cytosolic Smad family proteins, resulting in their translocation to the nucleus where they can alter gene transcription. Alternatively, BMPs can signal via a noncanonical or BMP-MAP kinase pathway. BMP binding to its receptors can be antagonized by noggin and follistatin among others with higher affinity to BMP than the latter has with the BMP receptor complex.

2. Bone morphogenic proteins and melanogenesis

BMPs and their associated downstream transcription factors also influence neural crest-derived cell populations, including melanocytes, in several species. For example, BMP-2 specifically targets tyrosinase gene expression in primary quail neural crest cultures resulting in increased melanin synthesis (58), although BMP-2 does not regulate melanocyte differentiation per se. Furthermore, BMP-4 may stimulate proliferation of normal human melanocytes in culture, likely via the proliferation-associated receptor BMPR-IA (909). BMPR-IA and BMPR-IB proteins are also expressed in retinal pigment epithelium of rat eyes (520). Unlike the BMP-2 effect in quail melanocytes, BMP-4 treatment of human cutaneous melanocytes reduces the expression of mRNA and protein for tyrosinase and the tyrosinase activator PKC-β. Production of BMP-4 is greater in melanocytes than keratinocytes, suggesting that this BMP may be an autocrine factor for melanocytes. In contrast to its effect in human melanocytes, purified BMP-4 reduces the number of melanocytes in cultures of avian neural crest cells (337, 857). Since in these cultures Wnt signaling appears to select melanocytes at the expense of neuronal and glial lineages, Wnt and BMP signaling may have antagonistic functions in cell fate determination in the trunk neural crest.

Recently, pigmentation defects in the hair follicle were reported to occur in Noggin transgenic mice (698). Overexpression of Noggin, an antagonist of BMP-2 and BMP-4, in agouti mice resulted in a wide range of pheno-
types including accelerated hair follicle development, up-regulation of keratinocyte proliferation, and downregulation of apoptosis in the hair bulb. In addition, these mice exhibited increased eumelanogenesis in hair bulb melanocytes that replaced the normal agouti pheomelanogenesis that occurs in wild-type mice. Thus the switch between eumelanogenesis and pheomelanogenesis may be in part regulated by the BMP signaling pathway. There has been a single report showing that BMP is expressed in ocular melanoma tissue (42).

E. Summary

Therefore, among the myriad factors regulating melanogenesis, the melanocortin/MC1R complex stands out as being the most important. The demonstration of receptor upregulation by UV light is particularly interesting, indicating a novel site for physicochemical interactions with the environment. Other important positive regulators of melanin pigmentation include endothelins, histamine, eicosanoids, and SCF acting via interaction with cell surface receptors. Sex steroids and vitamin D can also modify cutaneous pigmentation. Thus the substantial overlapping in positive regulation of melanogenesis does exist. In this context detailed characterization of animal genetic background becomes indispensable for the evaluation of mechanisms in pigmentary control in gene knockout experimental models.

V. HORMONAL INHIBITORS OF MELANOGENESIS AND RECEPTORS

A. G Protein-Coupled Receptors and Their Ligands

1. Serotonin and its receptors

A) OVERVIEW. Serotonin is the product of a multistep metabolic pathway involving hydroxylation of L-tryptophan, followed by enzymatic decarboxylation (352, 486). Mammalian skin can both synthesize and metabolize serotonin by either arylalkylamine N-acetyltransferase (AANAT) (205, 749, 750, 752, 757) or arylalamine N-acetyltransferase type 1 (NAT-1) (751) to produce N-acetylserotonin (NAS), and possibly melatonin (717, 752). Serotonin by itself can act as neurotransmitter, regulator of vascular tone, immunomodulator, and growth factor; in the skin it exerts proedema, vasodilatory, proinflammatory, and/or pruritogenic actions (96, 352, 694, 759). Serotonin actions are mediated via interaction with membrane-bound receptors categorized into seven families (5HT1–7) with at least 21 subtypes (811). Skin cells express mRNA encoding serotonin receptors 5HT-1A, -1B, -2A, -2B, -2C, and 7, and serotonin shows variable effects on cell proliferation (753).

B) EFFECTS OF SEROTONIN AND ITS METABOLITES ON MELANOCYTES. Serotonin may be involved in the regulation of apoptosis and proliferation of melanocytes through receptors expressed by normal and malignant melanocytes (753). Thus serotonin uptake inhibitors appear to inhibit melanization in human melanoma cells (472). In human SKMEL-188 melanoma cells serotonin inhibits in a dose-dependent fashion DMEM-induced melanin production and tyrosinase activity (Fig. 10). The serotonin metabolites NAS and 5-methoxytryptamine (5-MT) are nevertheless devoid of effect on induced melanogenesis in rodent melanoma cells and histocultured anagen skin; however, they can stimulate or inhibit cell proliferation, but only at extremely high concentrations of ligands (close to millimolar) (719, 755).

2. Melatonin and its receptors

A) MELATONIN PRODUCTION. Melatonin is transformed from serotonin through a two-step pathway involving serotonin acetylation by AANAT to NAS, and methylation by hydroxyindole-O-methyltransferase (HIOMT) to produce melatonin (793, 926). Melatonin is produced predomi-
B) BIOLOGICAL FUNCTION OF MELATONIN AND ITS RECEPTORS.

Systemically, the main biological roles of melatonin are regulation/modulation of circadian rhythm, seasonal reproduction, and retinal function (926). Depending on production site and target organ, melatonin can act as a hormone, neurotransmitter, cytokine, or biological modifier. Melatonin effects are mediated through interactions with high-affinity membrane-bound or nuclear melatonin receptors. In addition, it has antioxidative properties and free radical-scavenging activity (102, 347). In mammals two distinct seven-transmembrane domain G protein-coupled receptors have been cloned and named MT1 (Mel1a) and MT2 (Mel1b) (613, 615). The two receptor subtypes that show 60% homology at the amino acid level can inhibit adenylyl cyclase via pertussis toxin-sensitive G× proteins. In addition, MT1 receptors can control calcium mobilization through pertussis toxin-insensitive G911 proteins, and MT2 receptors may be coupled to cGMP inhibition. Both receptors are widely expressed (614). Expression of melatonin receptor genes has been detected in both human skin and cultured skin cells (753), whereas specific melatonin binding sites have been found in melanomas and rodent skin (reviewed in Ref. 759).

C) MELATONIN EFFECTS ON THE PIGMENTARY SYSTEM.

Melatonin was first isolated from pineal gland, and its biological activity was defined by its lightening effect on frog skin where it induces melanosome aggregation around the nucleus of melanophores (242). The lightening response of melatonin on skin of lower vertebrates depends on species and source tested (139, 176, 242, 874). Melatonin in a dose-dependent manner reverses the darkening response to α-MSH. In furry animals of subarctic or northern latitudes, circulating or local melatonin levels may participate in the seasonal changes in pelage color (874). Subcutaneous melatonin implants inhibit pigmentation of regrowing hairs (after depilation) in the short-tailed weasel, during molting in white-footed deer mouse and Syrian hamsters (874), and may attenuate melanosis in dogs (874). An effect of melatonin on skin pigmentation in humans is uncertain (471, 516).

In cultured hair follicles from Siberian hamsters, melatonin inhibits basal, MSH, or cAMP-stimulated melanogenesis through post-tyrosinase mechanisms (431, 432, 875). High concentrations of melatonin also inhibited tyrosinase activity in histocultured skin from C57BL/6 mouse with hair follicles at anagen stage, although NAS or its metabolite 5-MT was without effect (719). Similar results were observed in Bomirski hamster amelanotic melanoma cells and Cloudman mouse melanoma cells (755). These actions represent antagonistic activity of melatonin against inducers of melanogenesis (L-tyrosine or MSH), since noninduced or already melanized cells did not react to melatonin (755). The requirement for high concentrations of melatonin to elicit its antimelanogenic effect suggests that melatonin is not acting through melatonin receptor, e.g., this is either a metabolic effect or it interacts with a receptor for unrelated ligand. Similar inhibitory effect of melatonin on MSH stimulated melanogenesis was found in B16 melanoma, but at much lower concentrations (850). Specific melatonin binding sites have been found in mouse, hamster, and human melanoma lines (705, 755); functional melatonin receptors were found in normal and malignant uveal melanocytes (298, 299, 625). Melatonin receptor gene expression was reported in human normal and malignant epidermal melanocytes (753). Melatonin signal transduction in hamster melanomas appears to be coupled to phosphoinositide hydrolysis (163), while in human and rat retinal pigment cells melatonin receptors appear to be negatively coupled to adenylyl cyclase (506).

3. Dopamine and its receptors

Dopamine is an endogenously produced catecholamine whose actions are mediated through specific cell surface receptors coupled to G proteins. They are grouped into two main superfamilies (D1-like and D2-like) based on biochemical, pharmacological, and molecular characteristics (15). Strong evidence suggests that the melanocortin and dopamine systems are functionally linked (425). Dopaminergic compounds exert inhibitory effects on the pituitary content and secretion of α-MSH and β-endorphin, while dopamine receptor agonists and antagonists may also affect the level of POMC mRNA expression in the pituitary (35, 114). There are also data suggesting competitive interaction between α-MSH and the receptor agonists on the D1 receptor (421).

A) Dopamine and Melanogenesis.

The specific dopamine receptor D2 agonist (LY 171555) has been reported to inhibit hair follicular melanogenesis in pubertal (eumelanin phase) C3H-HeAvy mice (88); the decrease in tyrosinase activity was reversed by treatment with the D2 receptor antagonists sulpiride. However, no inhibition of hair follicular melanogenesis was observed in adult (pheomelanin phase) mice. Thus different control mechanisms may be operative during periods of eumelanin and pheomelanin synthesis.

Tyrosinase oxidizes dopamine to produce melanin via dopamine quinone (485), although dopamine quinone itself can in turn inactivate tyrosine hydroxylase (908). Dopamine excess generates reactive oxygen species and is associated with toxic effects on catecholaminergic cell lines (396). Viability of the cells is reduced if tyrosinase activity is selectively inhibited by phenylthiourea or 5-hydroxyindole (25, 271). Idiopathic Parkinson’s disease is associated with massive cell death in the dopamine-derived neuromelanin-pigmented tyrosinase-positive substantia nigra (281, 826). Indeed, there is a direct correla-
tion between cell loss and percentage of neuromelanin-pigmented neurons remaining in this region with greater relative sparing of nonpigmented than of neuromelanin-pigmented neurons.

The D1B receptor has been implicated in modulating phagocytosis by retinal pigment epithelium while the D4 receptor is thought to be involved in the inhibition of melatonin synthesis in photoreceptors (508). Moreover, movement of photoreceptor cells and migration of melanin granules in retinal pigment epithelial cells as well as synthesis of melatonin in photoreceptors are mediated by D2 receptors (679). Dopamine treatment results in dispersion of black and red pigments within chromatophores in the crab *Gecarcinus lateralis*, which could be blocked by the dopamine antagonist haloperidol (459).

### B) Dopamine and melanocyte disorders

In vitiliginous skin sections, both epinephrine and dopamine can enhance melanogenesis in dendritic but not in nondendritic melanocytes, suggesting variable responsibility in melanocytes of different differentiation states (327). D1 receptor mRNA has been demonstrated in mouse melanoma cells, but not in human metastatic melanoma cells (66). Similarly, D2 receptor mRNA was not detected in melanoma cells, and all metastases were receptor negative by immunohistochemistry (67). Thus antitumor effects against melanoma cells are probably mediated by toxic products of dopamine oxidation (888). Because of their cytotoxicity, dopamine and their metabolites may play a role in pathogenesis of vitiligo (135, 495).

#### 4. Acetylcholine and its receptors

One of the important neurohormonal components of the skin is the epidermal cholinergic system (82, 220–222). Its neurotransmitter, acetylcholine (ACh), is synthesized from acetyl coenzyme A in keratinocytes by the enzyme choline acetyltransferase. After secretion, ACh interacts with muscarinic and nicotinic cholinergic receptors expressed predominantly in the basal or suprabasal epidermal layers, to regulate keratinocyte proliferation, migration, and differentiation. ACh availability is also determined by its local degradation through the action of acetylcholinesterase (AChE), present at its highest levels in the basal keratinocyte layer, to decrease gradually along the vertical axis, with the lowest concentrations below the stratum corneum. In addition to local synthesis, cutaneous ACh is also derived from skin cholinergic nerve endings release.

ACh is produced from choline (in the diet) and acetyl CoA via choline acetyltransferase, and is thereafter metabolized to choline and acetate by AChE. Human epidermal keratinocytes express cholinergic enzymes and can synthesize, secrete, and degrade ACh (221–223). Expression of choline acetyltransferase has also been detected in skin appendages (338). There is some evidence that ACh metabolism may be altered in some dermatoses, e.g., atopic dermatitis (234) and melanoma, where expression of ACh receptors has been linked to invasiveness (646).

ACh interacts with two subclasses of cholinergic receptors, muscarinic and nicotinic. Direct actions occur at nicotinic receptors, while indirect action occurs via second messengers at G protein-coupled muscarinic receptors. Human epidermal keratinocytes express both nicotinic and muscarinic cholinergic receptors on their cell surfaces which bind ACh and initiate cellular responses that include maintenance of cell viability, proliferation, adhesion, migration, and differentiation (220–223). Calcium is the mediator of ACh effects in keratinocytes, which in turn regulate expression and function of cholinergic enzyme and cholinergic receptor in these cells. The epidermis expresses several nicotinic cholinergic receptors (nAChR) that can change in number and subunit composition dependent on their differentiation status. They are ion channel-coupled neurotransmitter receptors that upon ACh binding maintain keratinocyte viability and aid cell differentiation. In contrast, muscarinic G protein-coupled receptors respond more slowly, with M1, M3, and M5 receptors stimulating phosphoinositide metabolism and M2 and M4 receptors inhibiting adenylyl cyclase. Muscarinic receptor pathways can regulate keratinocyte proliferation and migration.

A) Acetylcholine and melanogenesis. As in other neural crest-derived cells, melanocytes express cholinesterase activity and muscarinic receptors during their migratory phase, in the embryo. Thus it is altogether likely that these cells are responsive to ACh, as has already been shown for melanoma cells (646; see below). ACh appears to inhibit melanogenesis and also has an inhibitory effect on dopa oxidase activity of marginal melanocytes in vitiligo (326). Similar inhibition of melanin synthesis was demonstrated in human melanoma cells (83). In a study designed to assess the effects of prostaglandins on human iridal pigmentation, ACh (used as another test substance in this study) was found not to affect pigmentation (43). Still, all five mAChR subtype mRNAs have been detected in normal human melanocytes, and expression of the receptors themselves was noted in human skin specimens by immunohistochemistry (82). Similarly, mAChR subtypes (m2 and m3) have been detected in the retinal pigment epithelium of chick (178, 186, 545) and humans, where they are coupled to phosphoinositide hydrolysis and Ca$$^{2+}$$ mobilization. Melanocytes in culture express ~9,000 high-affinity receptors per cell, and micromolar concentrations of muscarine or carbacbol can transiently increase intracellular Ca$$^{2+}$$ (82). However, the literature is inconsistent here, whereby some reports suggest that muscarinic ACh receptors are expressed in human melanomas but are not present in normal skin melano-
cytes. Notably, nevocytes were positive for muscarinic receptors (399, 646).

B. Acetylcholine and Melanocyte Disorders. An autocrine muscarinic cholinergic system has been reported in human melanoma (646); thus muscarinic acetylcholine receptors were detected in primary and metastatic human melanomas, as was choline acetyltransferase and cholinesterase activity in melanoma cell lines (646). Moreover, the expression of muscarinic receptors appeared to be associated with melanoma cell contractability. Since the same investigators did not detect ACh receptors in normal melanocytes, they concluded that their reexpression in melanoma cells, after transient expression during embryogenesis, may be involved in melanoma invasive growth. The expression of muscarinic receptors in primary malignant melanomas appears to be heterogeneous and correlates with melanoma cell infiltrative and metastatic capacity (399). Tumor cells located centrally were found to express little or low levels of ACh receptor while melanoma cells intensely ACh positive were located around this negative center as clusters of atypical melanocytes. Interestingly, melanoma cells infiltrating the surrounding normal tissue were also reported to express muscarinic receptors (399). One study has reported a lower level of acetylcholinesterase activity in vitiligo skin compared with normal skin (326). Moreover, perilesional regions of depigmenting vitiligo epidermis containing dendritic melanocytes were negative for acetylcholinesterase, becoming positive upon repigmentation. The author concluded that lower acetylcholinesterase activity in melanocytes may result in increased inhibition of melanocyte ACh aggravating depigmentation in vitiligo.

B. Melanocortins Antagonists

1. Agouti protein

Agouti coloration is typically seen in the wild-type color of mice as a banded pigmentation pattern of the pelage, in which each hair is black with a subapical band of yellow. The agouti locus (a) on mouse chromosome 2 regulates the cyclical production of black and yellow pigment granules, thereby generating the agouti coat color of the mouse (708, 897). Agouti protein acts within the microenvironment of the hair follicle during hair growth, switching eumelanin synthesis into pheomelanin synthesis.

The mouse agouti gene encodes a 131-amino acid polypeptide with a signal peptide; the mature protein has 10 cysteine residues near the carboxy terminus (87). Agouti gene transcripts of 0.8 kb are expressed in the testis and skin but not in melanocytes (87). Alternative isoforms of agouti mRNA contain different noncoding first exons located 100 kb apart, and their expression is controlled by regulatory elements that are either ventral specific or hair cycle specific (865). The agouti protein is produced in dermal papilla cells (482). Recessive agouti mutations result in all-black hairs, while the dominant alleles cause an all-yellow phenotype in mice. Structural alterations in the agouti gene cause detectable changes in the expression of gene transcripts; for example, the 0.8-kb mRNA is not detected in the skin of C57Black mice carrying the a mutation (87).

In humans, the agouti gene has been mapped to chromosome 20q11.2 and encodes a protein of 132 amino acids with 85% homology to the mouse agouti protein (390, 892). The human agouti gene is expressed in adipose tissue, testis, ovary, and heart and at lower levels in liver, kidney, and foreskin (892). Expression in transgenic mice of the human agouti protein, also named agouti signaling protein (ASP), produced a yellow coat (892), although human hair does not show the agouti pattern. Expression of ASP in cell culture blocks the α-MSH-stimulated accumulation of cAMP in mouse melanoma cells (892). Notably, agouti protein is produced in a hair stage-specific manner and functions as antagonist for the MC1R (430). MC1R is encoded by the extension (e) locus on mouse chromosome 8 (624). Dominant extension locus mutations are associated with the all-black phenotype of recessive agouti mutations, while recessive extension locus mutations cause the all-yellow phenotype as in dominant agouti mutations.

A dominant agouti mutation, lethal yellow (A<sup>y</sup>), has received particular interest, because in addition to an all-yellow phenotype, lethal yellow heterozygotes display profound obesity, diabetes, and increased tumor susceptibility. The lethal yellow heterozygotes overexpress a larger agouti transcript in all tissues examined (87, 483). This aberrant expression is due to chromosomal rearrangement that results in the production of a chimeric gene and mRNA of ~1.1 kb. The lethal yellow mutation is caused by a 120-kb deletion in the agouti gene (153), where the first exon is replaced by a novel sequence on the lethal yellow mRNA, but the 3′-portion of the mutant RNA retains the intact protein-coding region of the agouti gene. The DNA source for the 5′-novel sequence of lethal yellow RNA is the 5′-noncoding exon of a previously uncharacterized gene, termed Raly (480) or Merc (153). Raly/Merc may represent an RNA-binding protein; it is expressed in preimplantation embryo, throughout development, and in adult tissues, but Raly is not expressed in the lethal yellow allele. Thus the dominant pleiotropic effects associated with A<sup>y</sup> mutation may result from ectopic overexpression of the wild-type agouti gene product under control by the Raly promoter, and the recessive embryonic lethality may be the results of the lack of Raly gene expression in the early embryo.

Murine agouti protein causes both time- and concentration-dependent suppression of melangenesis in B16 F1 murine melanoma cells, while the same protein has
minimal or no effect on α-MSH stimulation of melanogenesis (305). Similar to the murine protein, human agouti protein decreased melanogenesis in cultured human epidermal melanocytes, and markedly inhibited pigmentation and the production of eumelanosomes in black eumelanogenic murine melanocytes (652). In the latter, melanosomes became pheomelanosome-like in structure, and eumelanin production was significantly decreased. Agouti protein also induced time- and dose-dependent decreases in melanogenic genes expression, including those encoding tyrosinase, tyrosinase-related protein 1, and TRP2/DCT. Agouti protein coordinate regulates lipid metabolism in adipocytes. Dietary composition influences the pigmentary phenotype in viable yellow agouti mice (873). Maternal supplementation of a/a dams food with extra folic acid, vitamin B₁₂, choline, and betaine did switch fur color in Aʸ/y a offsprings from yellow (agouti) towards brown (pseudoagouti) phenotype. It was concluded that in mammalian systems transposable elements can serve as targets for early nutritional effects on epigenetic gene regulation of which Aʸ is an example (873).

1) AGOUTI-RELATED PROTEIN (AGRP) was identified from a search of the EST database using the sequence of agouti as a template (706). Ubiquitous overexpression of human AGRP cDNA in transgenic mice caused obesity without altering pigmentation (533). The human AGRP gene exhibits polymorphisms both in its promoter and coding regions, which could affect the expression levels of AGRP and expression of phenotype (23, 469, 863). Like agouti protein, AGRP contains a putative signal sequence and a cysteine-rich carboxy terminus. AGRP functions as a paracrine-signaling molecule that regulates body weight in the hypothalamus by antagonizing signaling through MC3R and MC4R. This orexigenic function of AGRP is responsible for the obesity seen in lethal yellow (Aʸ) mice, in which agouti protein is aberrantly overexpressed in many tissues, including the brain, and mimics the function of AGRP. Conversely, AGRP does not bind MC1R in vitro, as determined by its failure to induce cAMP accumulation in the cells overexpressing MC1R (533), and by direct binding assay (916). However, AGRP does appear to inhibit the binding of agouti protein to MC1R (533). The latter observations suggest that AGRP and agouti protein may share a binding site on MC1R. However, in transgenic mice, AGRP has no noticeable effect on pigmentation (533).

2. Agouti modifiers

A) ATTRACTIN OR MAHOGANY. The mahogany (mg) locus was identified as the source for a recessive suppressor of agouti protein; namely, functional mahogany protein is required for the action of agouti protein that modifies coat color by antagonizing the MC1R. Mahogany is a 1,428-amino acid, single-transmembrane domain protein that functions as an accessory receptor for agouti protein and is expressed in many tissues, including pigment cells and the hypothalamus (236). The extracellular domain of the mahogany protein is the ortholog of human attractin, a circulating molecule produced by activated T cells, suggesting a molecular basis for cross-talk between melanocortin receptor signaling and immune function (236). These two proteins are generated by alternative splicing of mRNAs. Attractin (Atrn) is a low-affinity receptor for agouti protein, but not AGRP (260). Attractin affects the balance between agonist and antagonist at receptors on melanocytes and mediates interactions between activated T cells and macrophages.

Attractin is also involved in the control of metabolic rate and feeding behavior independent of its suppression of agouti (148). Mice homozygous for the Atrn(mg-3J) allele have reduced body weight due to increased energy expenditure.

B) MAHOGANOID OR MAHOGUNIN. The mutant mahoganoid (md), also known as Mahogunin (Mgrn1), darkens the coat color and decreases the obesity of A(y) mice that aberrantly overexpress agouti protein. Pigmentary phenotype and genetic interactions of mahoganoid are similar to those of Atrn. The mahoganoid trait prevents hair follicle melanocytes from responding to agouti protein. Mahoganoid encodes a 494-amino acid protein containing a C3HC4 RING domain that may function as an E3 ubiquitin ligase (260, 582). The human homolog is 81% identical to mice in the primary structure, and its gene maps to16p13.3. Like Atrn mutations that cause spongiform neurodegeneration, a null mutation for mahoganoid causes age-dependent neuropathology (261). The mahoganoid protein may represent a component of a conserved pathway for regulated protein turnover, which is essential for neuronal viability.

3. Melanin concentrating hormone

A) OVERVIEW. In amphibians and fishes, a dual hormonal control of color change is regulated by two antagonistic pituitary melanophorotropic hormones, MSH and melanin-concentrating hormone (MCH). MCH is a 17-amino acid cyclic peptide that was originally isolated from chum salmon pituitaries (350). Salmon MCH induces melanosome aggregation within melanophores of teleost fish (whitening of the color). MCH is present in the neurons of lateral basal hypothalamus of fishes, and MCH-immunoreactive axons project into the brain and pituitary (504). In addition, salmon MCH has a potent inhibitory action on CRF-induced α-MSH and ACTH secretion in vitro by teleost pituitary glands (30).

Human MCH, a 19-amino acid cyclic peptide, is identical to rat MCH (503, 595, 858), but differs from salmon MCH by an amino-terminal extension of two amino acids...
and four additional substitutions. MCH is an orexigenic neuropeptide showing opposing and antagonistic actions to α-MSH on feeding behavior and energy homeostasis through a mechanism other than interference with the MC3 or MC4 receptor (441). The MCH receptor of 353 amino acids was identified as the orphan G protein-coupled receptor SLC-1 that is sequentially homologous to the somatostatin receptor (110, 649). The receptor SLC-1 is stimulated by MCH to mobilize intracellular Ca²⁺ and reduce forskolin-elevated cAMP levels (110). Subsequently, a second form of MCH receptor, MCHR2, was identified (18, 272, 493, 645), and the SLC-1 is referred to as MCHR1. MCHR2 consists of 340 amino acids and shares ~38% identity with MCHR1. MCHR1 and MCHR2 are widely expressed in various regions of the brain.

B) MCH SIGNALING SYSTEM AND MELANOCYTES. In lower vertebrates, MCH induces melanosome aggregation within melanophores (whitening of the color). In mammals, MCH expression was detected in cultured human endothelial cells but not in human keratinocytes, melanocytes, and fibroblasts (285). MCHR1, but not MCHR2, expression was detected in human melanocytes and melanoma cells (285, 286, 650). Stimulation of cultured human melanocytes with MCH reduced the α-MSH-induced increase in cAMP production (285). Furthermore, the melanogenic actions of α-MSH were inhibited by MCH. MCHR1 has also been identified as a novel autoantigen in patients affected with vitiligo (353). Thus the MCH/MCHR1 system is functional in human skin and may regulate skin pigmentation through modifications of melanocortin signaling.

C. Cytokines, Growth Factors, and Receptors

1. IL-1, IL-6, and IFN-α and -γ and their receptors

Pigmentary changes are common features of postinflammatory and immunomodulatory events (513) and involve cytokines and growth factors. IL-1 is one of the most potent proinflammatory mediators and exists in two 17-kDa forms, IL-1α and IL-1β, synthesized as 31-kDa precursors in a range of cell types including epidermal keratinocytes and melanocytes (20, 764). IL-1 binds two specific receptors: a biologically active 80-kDa form called IL-1RI and an inert 60-kDa decoy protein, called IL-1RII. When IL-1α and IL-1β bind to IL-1RI, the IL-1 accessory protein joins to form the active complex that signals via NFκB, JNK/AP-1, and p38 MAP kinase pathways (422). Similarly, IL-6 (formerly known as BSF-2 and IFN-β) is a pleiotropic cytokine that participates in immunomodulation, hematopoiesis, inflammation, and oncogenesis; it is produced by many cell types, including keratinocytes and fibroblasts, and stimulates proliferation in keratinocytes, being essential for wound healing (424). The receptor for IL-6, IL-6R, shares subunits with other members of the cytokine superfamily of receptors. The IL6-R consists of two molecules, IL-6Rα and gp130; it activates JAK tyrosinase kinases to induce the SHP-2/GAB-mediated ERK MAP kinase pathway and the STAT3-mediated pathway (276). Lastly, the interferons consist of a large family of antiviral peptides including IFN-α (12 subtypes), IFN-κ (keratinocyte specific), IFN-τ, and IFN-ω. These are classified as type I interferons with common three-dimensional structure and class of cell surface receptors. Type II interferon is represented by the acid labile IFN-γ, with its associated distinct cell surface receptors. IFN-γ is a 45-kDa homoglycoprotein with pleiotropic and primarily immunologic functions that is produced under pathological conditions, mostly by lymphocyte subpopulations. Biological function of IFN-γ is mediated by a receptor complex that signals via JAK1 and JAK2 members of the Janus family of protein tyrosine kinases (818).

A) IL-1, IL-6, and IFN and Melanogenesis. Melanocytes express and react to a myriad of cytokines and growth factors and thus can be viewed as an immunocompetent skin cell type with the potential to modulate its responses under different conditions. In fact, melanocytes have a dual function as participants and targets in the inflammatory response (440). Melanocyte phenotype is modulated in vitro by IL-1α, IL-1β, IL-6, TNF-α, and TNF-β, all of which markedly reduce the expression of melanocyte-specific antigen gp100, while enhancing the expression of VLA-2, ICAM-1, and HLA class I antigens, and inducing the expression of HLA-DR (379). IFN-γ also induces the expression of MHC II antigens in melanocytes, although not on all melanoma cell lines; some of these constitutively express the class II antigens. Nevertheless, IFN-γ appears to be unique in its ability to induce MHC II expression in melanocytes and melanoma (28, 292).

Melanocytes express and produce both IL-1 and IL-6 in culture (764, 801). IL-1α and to a lesser extent IL-6 elicit a dose-dependent decrease in tyrosinase activity in normal human epidermal and uveal melanocytes in vitro (297, 379, 800). IL-1β also inhibits tyrosinase activity (801). Both interleukins inhibited melanocyte proliferation, but in a noncytotoxic manner, as evidenced by the resumption of melanocyte proliferation after cessation of treatment. However, IL-1α has also been reported to stimulate melanogenesis in organ-cultured guinea pig skin (449).

Similar variability of IL-1 effects on melanocytic cells has been reported on α-MSH binding in melanoma cells (59). When stimulatory for α-MSH binding, IL-1 treatment correlated with α-MSH-associated increase in both tyrosinase activity and melanin formation (192).

UVB radiation exposure stimulates the synthesis of both IL-1 and ET-1 in keratinocytes. However, while ET-1 stimulates melanogenesis and melanocyte proliferation (313), IL-1α is reported to do the opposite (106, 315, 678,
Both IL-1 and ET-1 upregulate MC-1R activity and message, while TNF-α has the opposite effect. With regard to IL-6 inhibition of melanogenesis, this appears to be mediated by downregulation of the paired homeodomain factor Pax3 (343). Thus a sharp decrease in mRNA and gene promoter activity precedes the IL-6 associated reduction in melanogenesis. The Mitf promoter contains a cis-acting element that binds Pax3 and that mediates the IL6R/IL6. Pax3 expression declines after IL-6 treatment in B16/F10.9 melanoma cells.

Both IFN-α and IFN-β mRNA are expressed in normal cultured cutaneous melanocytes, but IFN-β mRNA, unlike IFN-α, is rarely expressed in melanoma cells (659). Expression of the proteins may be inducible, by polyinosinic polycytidylic acid (PPA), in the case of IFN-β in melanocytes and some melanoma cell lines. Notably, PPA also induced IFN-β mRNA and protein in some melanoma cells and inhibited the proliferation of melanoma cells, an effect blocked by anti-IFN-β antibody in cell lines that produced IFN-β. Skin hyperpigmentation has indeed been described during antiviral therapy with IFN-α (891), occurring on the skin and tongue in dark-skinned individuals. Increased melanogenic activity was also confirmed at the affected sites.

Intercellular adhesion molecule-1 (ICAM-1), an important regulator of immune cell-target interactions, is normally expressed at very low levels by normal cultured human melanocytes. Those levels can be significantly increased, in a physiologically relevant dose-dependent manner by IFN-γ, TNF-α, or IL-1α (919). Indeed, mice overexpressing IFN-γ (under the influence of involucrin promoter) exhibit striking reduction in IFN-γ receptor expression but increased in ICAM-1 and MHC class II molecules expression on the surface of the transgenic keratinocytes. Transgenic mice exhibit hypopigmentation of the hair, due to a reduction in DOPA-positive melanocytes, as well as reddened skin, hair loss, and flaky skin lesions. It is of note that IFN-γ can upregulate the expression of some melanomas antigens in melanoma cells, e.g., gp75, and that monoclonal antibody to gp75 can lead to tumor rejection in syngeneic mice (808). The overall inhibitory effect of INF-γ is documented by the observation that transgenic mice overexpressing INF-γ in epidermal keratinocytes develop hair hypopigmentation (100).

b) IL-1, IL-6, IFN, AND MELANOCYTE DISORDERS. IL-1α obtained from stimulated human monocytes inhibits the proliferation of some human melanoma cells in culture and may even exhibit cytotoxic effects (535). Moreover, growth inhibition is reported to become irreversible with time, and cells are eventually lost from the cultures. However, IL-1α antiproliferative effects in cultures of melanoma cells are variable, and sensitivity to growth inhibition by this cytokine may not correlate directly with the origin or biological behavior of the tumor lines (393).

IFN-α and IFN-γ that do not stimulate melanin synthesis when used alone exert differentiation influences on murine melanoma cells in the presence and absence of α-MSH (synergism) (345). In fact, the increase in pigment levels is significantly higher than in cells cultured with α-MSH only. Tyrosinase levels were unaffected, and thus stimulation of melanogenic activity is likely to occur via the activation of preexisting tyrosinase. The number of α-MSH receptors on IFN-treated cells also increased significantly, a mechanism that could participate in postinflammatory skin pigmentation (345).

In lentigo senilis-associated hyperpigmentation, ET-1 is increased in lesional, compared with perilesional, epidermis. The expression of TNF-α is also upregulated in lesional epidermis, whereas IL-1α appears to be downregulated (342). IgG anti-melanocyte antibodies have been reported to stimulate IL-1β and IFN-γ production in mononuclear cells in vitiligo, a phenomenon possibly linked to melanocyte destruction by monocytes (925). IL-6 production was also increased in vitiligo mononuclear cells, and ICAM-1 expression was enhanced on vitiligo melanocytes, perhaps increasing leukocyte-melanocyte attachment.

2. TNF-α, TNF-β (lymphotoxin-α), and TGF-β1 and their receptors

TNF-α (formerly cachectin), its closely related cytokine TNF-β (now called lymphotoxin-α, LT-α), and TGF-β are involved in multiple cellular and inflammatory immune reactions through activation of corresponding receptors (144, 416, 814). TNFs and TGF-βs, along with a myriad of other cytokines (371), are modulated in the skin by diverse stimuli, most importantly UVR. As indicated elsewhere in this review, melanocytes are stimulated by some cytokines and growth factors (e.g., basic fibroblast growth factor, ET-1, hepatocyte growth factor, SCF) and inhibited by these and other cytokines.

TNF-α and LT-α are encoded by genes that reside within the HLA class III region on chromosome 6 in humans. They bind to two receptors of the TNF receptor family, TNF-R1 and TNF-R2, and transduce signaling intracellularly via these receptors when expressed on the cell surface. TNF effects are blocked when these receptors are expressed as soluble “decoys” in body fluids. Both TNF-α and LT-α are trimeric proteins that exert their effects after receptor trimerization at the cell surface. While both TNF-α and LT-α can bind to both receptors with high affinity, soluble TNF-α may bind preferentially to TNF-R1. TNF-R1 is considered the most active and upon binding of TNF-α activates NFkB and AP-1 transcription to induce genes for proinflammatory and immunomodulatory molecules (814).

A) TNF-α, TGF-β1, AND MELANOGENESIS. TNF-α is present in both the epidermis and dermis of normal skin (359).
TNF-α elicits a dose-dependent decrease in the activity of tyrosinase and inhibits melanocyte proliferation (800). While TNF-α also appears to be cytostatic, it is not cytotoxic, since melanocytes remain viable despite continuous treatments with the cytokine, with recovery of cell proliferation upon cessation of TNF-α treatment. TNF-α-associated inhibition of melanogenesis has also been reported in B16 melanoma (461), where TNF-α at nanomolar concentrations inhibits both tyrosine hydroxylase and dopa oxidase activities of tyrosinase, without affecting levels of tyrosinase-related protein 2/dopachrome tautomerase (TRP2/DCT).

TNF-α treatment of B16 mouse melanoma cells can also alter the expression of other melanosomal proteins and has been shown to reduce melanoma expression of gp87 (mouse ortholog of gp100 encoded by the silver locus) (462). It is of note that while gp87 protein expression was almost undetectable after TNF-α treatment, α-MSH blocked this TNF-α-associated reduction in protein expression without affecting gp87 mRNA levels. These results suggest the involvement of regulatory translational and/or posttranslational events. In B16 melanoma cells and melan-a melanocytes, TGF-β1 also inhibits melanogenesis by decreasing tyrosinase and TRP-1 levels, although, unlike TNF-α, α-MSH and TGF-β1 only slightly diminish MC1 receptor gene expression and have no effect on the intracellular levels of cAMP, or even the α-MSH-dependent rise in cAMP levels. Indeed, there is no evidence that TGF-β1 or TNF-α block the response to α-MSH. Thus these effectors are likely to operate via α-MSH-independent routes, and the overall balance may dictate phenotypic outcome (463). Contribution to the overall hypopigmentary effect of both TNF-α and TGF-β1 may involve in the expression of gp87, although, unlike TNF-α, TGF-β1 does not affect the expression of this melanosomal protein (462). Both TGF-β and TNF-α exhibit variable antiproliferative effects on melanoma cell lines that correlate positively with their stimulation of collagenase secretion. Notably, a TNF-α-associated increase in NFκB levels is seen in the apoptosis-sensitive melanocyte lines; the TNF-α-induced sensitivity to apoptosis correlated with low basal pigment levels, and resistant cells were more heavily pigmented (696).

B) TNF-α, LT-α, and TGF-β in Melanocyte Disorders. A major limitation in the clinical use of TNF has been severe dose-limiting toxicity when administered systemically. However, when TNF-α is administered at low doses with melphalan, it reportedly exhibits significant antitumor activity (639). There is also some evidence that TNF-α can downregulate the vascular epidermal growth factor receptor and fetal liver kinase-1 (Flk-1) on endothelium in a human melanoma xenograft model (479). This may explain the apparently selective targeting of tumor vasculature, and the sparing of injury to surrounding normal tissues. However, tumor sensitivity to TNF-α appears to be variable, and the release of endothelial-monocyte-activating polypeptide II (EMAPII) may render the tumor-associated vasculature more sensitive to TNF-α. Indeed, if EMAPII is constitutively overexpressed in TNF-α-resistant human melanoma cells, increased tumor TNF-α sensitivity can be observed in vivo (907).

Pretreatment of some melanoma lines with inhibitors of NFκB activation can markedly increase apoptosis in lines expressing death receptors for TNF-α-related apoptosis-inducing ligand (TRAIL). Thus activation of NFκB by TRAIL may play an important role in resistance of melanoma cells to TRAIL-induced apoptosis. Treatment of both normal melanocytes and melanoma cells in vitro with TNF-α has been reported to upregulate the expression of ICAM-1 (362, 862). The high concentrations of ICAM-1 in sera of patients with metastatic melanoma have been shown to correlate with raised serum concentrations of TNF-R1 and TNF-R2 (362, 862).

In addition to TNF-α, human melanoma cell lines also express LT, where it appears to be constitutively expressed and characterized by the presence of a spliced and full-unspliced LT mRNA (478). Mice deficient in LT-α exhibit enhanced growth of syngeneic B16F10 melanoma cells compared with wild-type littermates, and metastases to lung were enhanced in the LT-α−/− mice. The principal immune deficiency associated with lack of LT-α appeared to be an impairment in the recruitment of NK cells to lung and liver, despite their normal total numbers (320). Overall, genetic variation in either TNF-α or LT-α production is nevertheless unlikely to play a major role in the clinical course of melanoma (294).

D. Other Negative Regulators of Melanogenesis

Vitamin E (α-tocopherol) can act as a potent inhibitor of melanogenesis (310). This effect is connected with inhibition of tyrosinase activity via posttranslational mechanism (193) and inhibition of active oxygen species-induced DNA damage (310). Ceramide-2, which belongs to a novel class of lipid second messengers, also inhibits...
that triiodothyronine (T3) but not thyroxine (T4) inhibited melanogenesis in human melanocytes through stimulation of extracellular signal-regulated protein kinase (ERK) and Akt/protein kinase B (360). Zinc α2-glycoprotein is produced locally by keratinocytes, and it inhibits melanogenesis in normal and malignant melanocytes (251).

A potential role for thyroid hormones in melanin pigmentation was analyzed in vitro using the B16 melanoma model (365, 768, 769). These studies demonstrated that triiodothyronine (T3) but not thyroxine (T4) inhibited both basal tyrosinase activity and melanin synthesis acting at the transcriptional level. Furthermore, T3 inhibited imidazole-stimulated tyrosinase gene expression and activity in B16 melanoma cells. However, further studies are necessary to define pigmentary effects of thyroid hormones, since Graves’ disease can be associated with generalized urticaria, alopecia areata, vitiligo, and generalized hyperpigmentation (759). Nevertheless, local autocrine mechanisms of action can be envisioned, since molecular elements of pituitary-thyroid axis were detected in the mammalian skin (761).

E. Summary

Therefore, suppression or inhibition of melanogenesis is difficult to demonstrate as a primary effect and requires most often proof of antagonism with stimulating agents. It is nevertheless the predominant influence of the agouti protein that makes it stand as a significant player in the regulation of rodent hair pigmentation. In fact, the agouti mutations powerfully underline the importance of its melanocortin receptor target. However, such a prominent role of agouti protein cannot be assigned to human pigmentation.

VI. MISCELLANEOUS REGULATION OF MELANOGENESIS BY NUCLEAR RECEPTORS AND THEIR LIGANDS

A. Glucocorticoids and Their Receptors

1. Glucocorticoid function and signaling in skin

The genomic glucocorticoid receptor (GR), the type II corticosteroid receptor, is a member of the nuclear receptor superfamily. However, glucocorticoids can also act through specific receptors at the membrane to exert effects within seconds to a few minutes, i.e., nongenomic effects (69). Skin cells, at least malignant melanocytes, may be able to synthesize corticosterone from progesterone or deoxycorticosterone to yield 11-deoxycorticosterone, corticosterone, and 18-hydroxydeoxycorticosterone (728). Cultured human epidermal keratinocytes, fibroblasts, and whole skin biopsies contain cytosolic proteins that bind corticoids with high affinity (526, 589). Down-regulation of GR receptor expression in these cells has been noted after dexamethasone treatment (526). GR distribution in skin is heterogeneous, with the strongest expression in basal and isolated suprabasal keratinocytes and Langerhans cells. Only weak expression was detected in the differentiated layers of the epidermis.

2. Glucocorticoids and melanocyte biology

Both inhibition and stimulation of melanin synthesis were reported after glucocorticoid treatment. Thus glucocorticoid inhibition of melanogenesis via action on tyrosinase was noted in black guinea pig skin (24) and in the C57BL/6 mouse, where dexamethasone treatment induced catagen development and termination of anagen-associated melanogenesis (169). The latter effect was connected with a decrease of tyrosinase and DCT activities, attenuation of tyrosinase gene expression and protein production, as well as inhibition of MC1 receptor and POMC genes expression (169). It has been suggested that dexamethasone inhibited melanogenesis indirectly, for example, through attenuation of MSH receptor signal system (762).

Glucocorticoids may also be involved in melanocyte development and differentiation. Thus hydrocortisone inhibits the proliferation of mouse epidermal melanoblasts inducing instead the proliferating cells to differentiate into melanocytes. These hydrocortisone effects were seen only when pigment cells were cultured in the presence of keratinocytes, and not in medium conditioned with keratinocytes or their extracts (278). The synthetic glucocorticoid triamcinolone acetonide has been reported to inhibit growth in the GR-expressing mouse melanoma cell lines B16/F10 and B16/C3 (623). Interestingly, inhibition of B16 cell growth by glucocorticoids may occur only in vivo (in established tumors and transplants) and not in vitro (134). As regards effects on pigmentation, dexamethasone treatment of B16 melanoma cells results in a dose-dependent increase in melanin content (319), a phenotypic effect that correlates with increased expression of tyrosinase mRNA. Moreover, dexamethasone was noted to antagonize the 12-O-tetradecanoylphorbol 13-acetate (TPA)-associated decrease in tyrosinase mRNA level, suggesting that glucocorticoid regulation of tyrosinase activity is exerted at a transcriptional level. All steroids, dexamethasone, hydrocortisone acetate, and prednisolone, produce significant inhibition of B16 melanoma growth as assessed by mean tumor diameter and weight (but not by effect on pulmonary metastases).

The GR is expressed in the majority of human melanoma tumors, with higher expression levels in metastasis to lymph nodes and soft tissue compared with primary tumor. The expression of GR also increased in parallel with tumor invasion and thickness levels. Notably, pa-
tients with GR-negative melanomas tend to have a longer survival than those with GR-positive tumors. As already mentioned, glucocorticoid treatment inhibits the growth of GR-expressing human melanoma cells in culture (150), and triamcinolone increases melanogenesis in the human melanoma cell line NEL, by increasing tyrosinase activity and DOPA incorporation into melanin. Triamcinolone-treated NEL cells showed no changes in cAMP levels, whereas actinomycin prevented the increase in tyrosinase activity. Glucocorticoids also enhance the killing effect of photodynamic therapy combined with a hematoporphyrin derivative in B16 melanoma cells engrafted in a transplantable mouse tumor model (133).

B. Retinoids and Their Receptors

1. Retinoid function and signaling

Retinoids represent a group of natural and synthetic analogs of vitamin A or all-trans-retinol, which can bind and activate nuclear retinoid receptors. All-trans-retinoic acid is biologically the most active retinoid (346), with the skin being one of its production sites. The cellular retinoic acid binding proteins (CRABPs) can regulate retinoic acid action by preventing binding to nuclear retinoid receptors. When applied to human skin, all-trans-retinoic acid can be metabolized to the less-active 4-hydroxyretinoic acid (152). All-trans-retinoic acid binds and activates members of the retinoic acid receptor family (RAR-α, -β, -γ), while 9-cis-retinoic acid activates mainly the retinoid X receptor family (RXR-α, -β, -γ), but also RARs (453). These receptors usually pair-up and form RAR/RXR heterodimers that bind specific DNA sequences, the retinoid responsive elements (RARE or RXRE). Human epidermis contains up to five times more RXR protein (90% RXR-α) than RAR (179).

2. Retinoids and melanocyte biology

Retinoic acid can induce, in a developmentally restricted manner, differentiation of neural crest-derived cells (17, 154). In general, retinoic acid appears to influence, in a concentration-dependent manner, cell lineage fate decisions in neural crest-derived cells to favor catecholaminergic over melanocytic cells (17, 154), which suggest antipigmentary action. However, retinoic acid (at 100 nM) can terminally differentiate melanocyte progenitors (propigmentary effect) (154). This suggests that retinoic acid appears to be more potent as inducer of melanocyte maturation than development; it can thus promote basal levels of melanogenesis (i.e., differentiation) in melanoma cells (436). In humans with different basal pigment levels, retinoic acid can induce tyrosinase activity in white skin, but not in black skin (812).

Retinoic acid can inhibit melanoma and melanocyte proliferation (185, 436), although with considerable variability in the response across melanoma cell lines (159, 289). Both all-trans-retinoic acid and 9-cis-retinoic acid induce growth arrest and differentiation of S91 melanoma cells (776). Induction of differentiation is preceded by increased expression and activity of PKC-α (637). Melanoma clones overexpressing PKC-α exhibit reduced doubling times, diminished anchorage-independent growth, and increased melanin production, similar to the phenotypic changes induced by retinoic acid treatment in control cells (235). A role for PKC-α in the retinoic acid-induced melanoma differentiation is supported by the observation that retinoic acid action is antagonized by the PKC inhibitor TPA. The latter is commonly used in melanocyte culture systems to stimulate melanocyte growth and differentiation (162). Retinoic acid also increases AP-1 activity in some melanomas. The mechanism for the retinoic acid-induced cell cycle arrest of melanomas is not known (509). Differences in retinoid metabolism between melanocytes and melanoma include increases in the former in endogenous retinol and in [3H]retinoic acid production from [3H]retinal (631). Retinoic acid stimulates α-MSH receptor expression in S91 melanoma cells (108) and upregulates pigmentation in B16 melanoma cells by increasing α-MSH receptor expression (637).

Some reports have presented results discrepant with above, e.g., that retinoic acid inhibited the melanogenetic response to α-MSH or L-tyrosine (540, 541) or that it blocked imidazole-induced tyrosinase expression in B16 melanoma cells (770). Retinoic acid may have also inhibited UVB-induced melanogenesis in S91 melanoma cells and normal neonatal melanocytes through inhibition of tyrosinase and TYRP1 synthesis (627). Studies examining the efficacy of topical tretinoin on photoaging show limited reduction in epidermal melanin on actinic lentigines and mottled hyperpigmentation (52, 232, 882). Topical tretinoin also lightens postinflammatory hyperpigmentation (52, 232, 882). Topical tretinoin also lightens postinflammatory hyperpigmentation and may even partially lighten normal skin in black individuals (86). While retinoic acid does not appear to significantly alter melanogenesis of cultured normal human melanocytes, it can alter cell shape, suggesting that retinoic acid may act on cytoskeleton proteins (397, 543). More recent contradictory data on retinoic acid effects on melanocytes (924) leave unclear its precise contribution to bleaching treatments (364).

C. Summary

Therefore, the effect of glucocorticoids and retinoids is more selective on differentiation than pigmentary activity. Further insight into the chemistry of these factors and their receptors may prove fruitful in the management of pigmented disorders including melanoma.
VII. FUNCTIONAL REGULATION OF FOLLICULAR (HAIR) AND EPIDERMAL MELANIN UNITS

A. The Epidermal Melanin Unit

1. Development of cutaneous pigmentary units

Cutaneous melanocytes originate in the neural crest, where the emergence of a committed melanocyte lineage cells appears to be determined mainly by MITF, fibroblast growth factor 2, and ET-3 amongst others (155). Melanocyte precursors, melanoblasts, migrate from the dorsal portion of the closing neural tube (609) and move dorsolaterally to eventually populate, nonrandomly, the basal layer of the epidermis and the hair follicle. It appears that human melanocytes enter the dermis and are already present in the epidermis earlier than 7 wk estimated gestational age, at 2 wk before hair morphogenesis (283). Recently, it has been shown that keratinocyte-derived hepatocyte growth factor may be involved in this dermal localization of melanocytes by downregulation of E-cadherin in melanoblasts (381).

Melanocyte precursors experience changing microenvironments during their migration from the neural crest, through the dermis to the epidermis, and to their final location within the growing hair follicle (see below). There are at least 150 loci that affect coat color (Mouse Genome Database). Primary among these are mutations in the receptor tyrosine kinase e-Kit [mapped to the white spotting (W) locus in mice] and its cognate ligand, SCF. Another signaling pair that appears to be essential for the development of neural crest-derived melanocytes is ET-3 with its receptor B (Ednrb) (155, 394). ET-3 itself is highly mitogenic for undifferentiated neural crest cells and results in the preferential expansion of melanocytes (34).

The temporal and spatial regulation of adhesive properties of melanoblasts and melanocytes are also likely to affect migration from the neural crest to the skin. Movement of these cells, guided by their migration substrate, involves both integrins (577) and extracellular matrix molecules (266). The expression of cadherins also changes along the path of migrating melanoblasts/melanocytes. E-cadherin expression is restricted to the epidermis while P-cadherin expression is observed in the hair bulb matrix (275). Thus the migratory pathway taken by melanocytes en route to the skin compartments during development is likely to involve multiple signaling events, both permissive and nonpermissive.

2. Melanocyte-keratinocyte interactions

Melanocytes reside, as scattered dendritic cells, in the basal layer of the human epidermis. Considerable interindividual and intraindividual variations in melanocyte population densities exist, with more than twice as many melanocytes located in head and forearm skin compared with elsewhere on the body, regardless of racial origin (182). Thus the main contributor to racial differences in skin pigmentation is cellular activity rather than absolute melanocyte numbers (803). The issue of the intrinsic proliferative potential of epidermal melanocytes has not yet been convincingly settled. An increase in melanogenically active melanocytes is indeed seen after UV irradiation (632), but it is not clear if these additional cells are truly derived from division of already functioning melanocytes. In contrast, melanocytes in the hair follicle divide during the hair cycle. Melanocyte loss (mostly probably via apoptosis) occurs in both sun-exposed and covered skin with an ~10% reduction per decade after 30 yr of age until 80 yr, followed by more dramatic cell loss thereafter (512). This age-related reduction is more marked in number of epidermal than hair follicle melanocytes, but the effect on overall loss of pigmentation is subtler.

Cutaneous melanocytes, like other neural-crest derived cells, exist in the context of supporting cells. In the skin, this “supporting” role is provided by the keratinocyte with which melanocytes forms the epidermal-melanin unit. These structural and functional cellular units exhibit complex, life-long, cellular interactions originally laid down during embryonic life. Each single, well-differentiated, melanocyte interacts with a remarkably consistent complement of ~36 viable keratinocytes at various stages of progression to the upper cornified layer of the epidermis (180). The “blueprint” for epidermal-melanin unit function appears to be finely drawn, with a mosaic of discrete unit areas that are remarkably consistent between races, but variable at the regional level, e.g., the darker skin in the folded areas of axillae and perineum. When differentiated, melanocytes assume the highly dendritic phenotype that facilitates closer contact with keratinocytes. While the keratinocyte partners are all linked via desmosomal intercellular junctions, melanocytes remain as singly scattered cells with the degree of contact with keratinocytes being determined by the level of ramiﬁcation/aborization of their dendrites. Of note, the regulatory role exercised by keratinocytes is restored in melanoma cells if expression of E-cadherin is induced permitting their adhesion to keratinocytes (295). The obvious interaction between melanocytes and keratinocytes is the transfer of melanin granules; nevertheless, melanocyte growth, dendricity, spreading, cell-cell contacts, and melanization can all be regulated by keratinocyte-secreted factors (819). Keratinocytes in coculture with melanocytes can also suppress melanogenic proteins such as the TyrP1, an important consideration for grafting in patients with depigmenting disorders (583).
3. Melanin transfer to keratinocytes

Transfer of melanin to keratinocytes in the epidermis or cortical and medullary keratinocytes of the growing hair shaft is presumed to involve the same mechanism(s). At least four theories have been proposed to be involved for this “whole organelle donation” to another cell, a unique biological process: 1) the “cytophagic” theory, where the keratinocyte, as active partner, phagocytoses the tips of dendrites that contain stage IV mature melanosomes (203); 2) the “discharge” theory, where mature melanosomes are released into the intercellular space to be internalized by adjacent keratinocytes; 3) the “fusion” theory, where mature melanosomes pass from melanocyte to keratinocyte via fusion of their respective plasma membranes (529); and 4) the “cytotocrine” theory, whereby melanocytes would inject melanin into recipient keratinocytes (465). Once transferred into epidermal keratinocytes, melanin forms pigment caps over the keratinocyte nuclei. Epidermal melanocytes rarely collect mature melanosomes intracytoplasmically; instead, it translocates them to keratinocytes. This is in contrast to bulbar follicular melanocytes, which are commonly heavily laden with fully mature stage IV melanosomes.

Studies using time-lapse digital video imaging and electron microscopy have shown filopodia from melanocyte dendrites as the conduits for melanosome transfer to keratinocytes (686). When melanocytes were cocultured with keratinocytes, a highly dendritic phenotype was induced characterized by extensive contacts between melanocytes and keratinocytes through filopodia, many of which contained melanosomes. Melanocyte dendricity is also likely to be important in melanin transfer and the dendrites of melanotic bulbar melanocytes in some mouse mutants, e.g., dilute (d) or pink-eye dilute (p) are abnormally short. Notably, myosin V (encoded by the dilute gene) has also been proposed as the molecular motor involved in dendrite outgrowth in mammalian melanocytes (398, 853, 881); mutations at that locus are associated with dilution of hair color (257). Moreover, phagocytosis of melanosomes by keratinocytes is mediated via the activation of the protease-activated receptor 2 on keratinocytes, and inhibitors of PAR2 retard melanosome transfer (690).

B. Regulation of Hair Cycle-Coupled Follicular Melanogenesis

1. Development of hair follicle

By 7 wk estimated gestation age, melanocytes are already present in the human epidermis and remain there until hair morphogenesis begins, ~2 wk later (283). With the onset of hair follicle morphogenesis, some melanoblasts leave the epidermis and distribute randomly as dopa-positive and dopa-negative cells in the forming hair follicle and occasionally in the sebaceous glands (321). Melanogenic melanocytes can be detected in all stages of human hair morphogenesis from the hair germ stage onwards, usually confined to the peripheral regions of the hair follicle (259). Once the hair fiber has formed, melanocytes are noted in large numbers near the basal lamina around the apex of the follicular papilla. While melanocyte mitosis is observed in the human epidermis at 14 wk estimated gestation age, mitosis of pigment cells is rarely observed in the hair follicles themselves. Melanocytes undergoing apoptosis are occasionally seen in the follicular tract (259).

During embryonic life murine follicular melanocytes do undergo apoptosis after injection of a Kit blocking antibody (ACK2) (320). Postnatally c-kit is also required for melanocyte activation during the hair growth cycle, although the melanocyte stem cell compartment appears to exhibit SCF/c-kit independence (71). Melanoblasts express c-kit as a prerequisite for migration into the SCF-supplying hair follicle epithelium. While differentiated c-kit-positive melanocytes target the bulb, c-kit-negative melanoblasts invade the outer root sheath and bulge in fully developed hair follicles (578).

2. Adult hair follicle

Melanocytes in the fully developed anagen follicle can be assigned to four distinct anatomic compartments on the basis of staining patterns with DOPA, Masson silver, toluidine blue, and thionine. In the mature hair follicle, dopa-positive melanotic melanocytes are readily detectable in outer root sheath of the infundibulum and around the upper dermal papilla. Dopa-negative amelanotic melanocytes are detectable in the mid to lower outer root sheath. The fourth sector demarcates the amelanotic dopa-negative melanocytes distributed in the periphery of the bulb and most proximal matrix. Immature melanocytes have been clearly demonstrated in the adult hair follicle (287, 828). Immunostaining with NKI-beteb, a monoclonal antibody that detects a (pre)melanosome glycoprotein (859), detects all dopa-positive cells but also highlights some dopa-negative melanocytes of the mid outer root sheath (287). While the dopa-oxidase activity of tyrosinase is not detectable in amelanotic hair follicle melanocytes, the protein itself may be detected in some of these cells (546). Similarly, while Kit and Bcl-2 reactive melanocytes are present in this hair follicle compartment (231), these amelanotic melanocytes do not express the melanogenic enzymes TRP-1 and TRP-2 (287).

The hair bulb, however, is the only site of pigment production for the hair shaft and contains both highly melanogenic melanocytes and a minor subpopulation of poorly differentiated, NKI-beteb+, pigment cells (828, 829). It has been speculated that amelanotic hair bulb
melanocytes may represent a pool of “transient” melanocytes that migrate from precursor melanocytes stores in the upper outer root sheath (783, 828, 829). The restriction of melanogenically active melanocytes to the upper hair matrix of the anagen hair follicle, just below the pre cortical kerat inocyte population, correlates with the observation that melanin is transferred during anagen to the hair shaft cortex, less so to the medulla, and, very rarely, the hair cuticle. Melanogenically active melanocytes in the hair bulb form functional units with neighboring immature precortical keratinocytes that receive their melanized secretory granules and ultimately form the pigmented hair shaft. Bulbar melanocytes also interact closely with the dermal papilla as evidenced by their direct contact during the anagen with the thin and permeable basal lamina separating from the mesenchymal dermal papilla.

3. Follicular melanin unit

While follicular melanocytes are derived from epidermal melanocytes during hair follicle morphogenesis, these pigment cell subpopulations diverge in many important ways as they distribute to their respective distinct compartments. The “follicular-melanin unit” resides in the “immune privileged” proximal hair bulb (57, 121, 886) and consists of one melanocyte for every five keratinocytes in the hair bulb as a whole; the ratio is 1:1 in the basal epithelial layer next to the dermal papilla (831). Hair bulb melanogenic melanocytes differ from epidermal melanocytes in being larger, with longer and more extensive dendrites, containing more developed Golgi and rough endoplasmic reticulum, and producing two- to fourfold larger melanosomes (39). While melanin degrades almost completely in the differentiating layers of the epidermis, eumelanin granules transferred into hair cortical keratinocytes remain minimally digested (39). Thus eumelanic white individuals may have dark black hair but very fair skin and blue eyes.

Activity of the hair bulb melanocyte is under cyclical control and melanogenesis is tightly coupled to the hair growth cycle (738), in contrast to epidermal melanogenesis, which appears to be continuous (517). Hair grows cyclically through a finite period of hair shaft formation (anagen; ~3–5 yr in human scalp), a brief regression phase resulting in the apoptosis-driven resorption of up to 70% of the hair follicle (catagen; ~3 wk in human scalp), and a relatively quiescent period (telogen; ~3 mo in human scalp) (112, 363). Even before catagen-associated structural changes, towards the end of anagen VI, the earliest signs of imminent hair follicle regression become apparent, e.g., retraction of melanocyte dendrites and attenuation of melanogenesis (744, 745). Keratinocyte proliferation, however, continues for some time, and most proximal telogen hair shaft remains unpigmented. The melanogenically active melanocytes of the anagen phase are no longer detectable during catagen. The hair bulb melanocyte system has long been viewed as self-perpetuating whereby melanocytes involved in the pigmentation of one hair generation are also involved in the pigmentation of the next (794). However, melanocytes would need to survive/avoid the extensive apoptosis-driven regression of the hair bulb (426, 878). It now appears that “redifferentiating” melanocytes in early anagen are more likely to correspond to newly recruited immature melanocytes derived from a melanocyte reservoir (230) located in the upper, “permanent,” outer root sheath. This view is supported by the observation that immature melanocytes are located very close to the secondary epithelial germ of the telogen club (708) where they are commonly small, have high nuclear to cytoplasmic ratios, and inactive cytoplasm with very few organelles. In the C57BL/6 mouse model, many highly melanotic hair bulb melanocytes do not survive catagen (830).

The relatively quiescent telogen hair germ contains precursors for all the cell types that will make the fully developed anagen VI hair follicle. Melanin synthesis is not detected by histologic or histochemical examination in telogen hair follicles, but very low tyrosine hydroxylase activity of tyrosinase can be detected; this disappears on days 1 and 2 after anagen induction (741). Undifferentiated melanocytes/melanoblasts of the telogen germ are stimulated at the start of anagen and respond by increasing their cell volume. This anagen-associated signal precedes the melanogenic stimulus delivered during anagen III and is followed by active melanogenesis and subsequent transfer of mature melanosomes into precortical keratinocytes. Melanocytes in the S phase of the cell cycle occur as early as anagen II, and significant proliferation is clearly apparent by anagen III (795). Mitosis is also observed in melanogenically active cells, indicating that melanocyte differentiation does not preclude mitotic activity. Ultrastructural changes in bulbar melanocytes that accompany anagen III to full anagen progression include 1) increased dendricity, 2) development of Golgi and rough endoplasmic reticulum, 3) increased size/number of melanosomes, and 4) transfer of mature melanosomes to precortical keratinocytes.

VIII. UNIFIED CONCEPT FOR THE TRANSCRIPTIONAL REGULATION OF MELANOGENESIS: A KEY ROLE FOR MICROPHTALMIA-ASSOCIATED TRANSCRIPTION FACTOR

MITF plays a fundamental role in the regulation of mammalian pigmentation. This is evidenced by the genetically determined pigmentary disorders resulting from semidominant mutation at the Mitf (Mi) locus in mice.
The main phenotypic effects include loss of pigmentation, reduced eye size, early onset of deafness, lack of mast cells, and failure of secondary bone resorption. Dominant mutations at its human homolog MITF [Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS)] are characterized by patchy depigmentation of hairs and skin, hearing loss, and heterochromia iridis in WS2A, while TS is characterized by generalized albinism, profound deafness, and hypoplasia of eyebrows. Thus clinical, genetic, and experimental observations clearly demonstrate that Mitf/MITF is essential for the development and function of melanocytes, retinal pigment epithelium (RPE), mast cells, and osteoclasts.

The MITF gene contains at least 13 exons, and at least 5 multiple alternative promoters and transcription initiation sites (701) (Fig. 11). There are at least five MITF isoforms (A, B, C, D, H, and M) that are products of alternative initiation of transcription driven by different promoters and process of alternative splicing (810). There are also three additional isoforms MITF-C, MITF-E, and MITF-MC, but the location of their first exon is unknown. All isoforms share the carboxy terminus (encoded by 8 downstream exons) containing a serine-rich region, bHLH-LZ structure, and transcriptional activation domain differing in the amino terminus. The amino terminus in the MITF-M isoform is encoded by the melanocyte-spe-

---

**FIG. 11.** MITF-M protein in the regulation of melanocyte activity. **A:** MITF gene structure. **B:** Regulation of MITF-M. **C:** MITF-M associated transcriptional activity in the Wnt signaling pathway. [Modified from Saito et al. (648).]
pecific exon 1 (exon 1M), and its expression is exclusive to the melanocyte lineage, because of its unique melanocyte-restricted promoter enhancer.

Selective requirement of Mitf-M for melanocyte development was verified by the molecular analysis of black-eyed white, Mitf<sup>mi</sup>-bw mice (911), characterized by white coat color, deafness, and normally pigmented RPE without ocular abnormalities. The molecular lesion in Mitf<sup>mi</sup>-bw mice is the insertion of an L1 retrotransposable element in the downstream intron (see Fig. 11), leading to complete repression of transcription from the M promoter.

The promoter region of MITF-M contains CREB, SOX10, PAX3, and LEF-1 binding sites that stimulate gene transcription by interacting with the corresponding regulatory factors and β-catenin (647, 648, 701, 810, 918) (Fig. 11). The predominant pathways driving the activity of this promoter are those activated by Wnt and MSH. Most recently, MITF-M distal enhancer (MDE) was identified 14.5 kb upstream from exon 1M that would act as an upstream cis-acting element required for efficient transcription of M promoter (Fig. 11). It contains two functional SOX10 binding sites, and its role in regulation of pigmentation is underlied by the phenotype of the homozygous red-eyed white Mitf<sup>mi</sup>-rw mutant showing red eyes and white coat with some pigmented spots around the head and the tail.

WS is genetically heterogeneous and exhibits sensorineural hearing loss and abnormal pigmentation that are caused by melanocyte deficiency in the cochlea and skin. It is noteworthy that other subtypes of WS are associated with mutations in the genes coding for PAX3 and SOX10, both of which are involved in the transcriptional regulation of the MITF gene (701). PAX3, containing a paired homeodomain, is responsible for WS1 and WS3 (31, 290, 815–817). SOX10, containing a high-mobility group box as a DNA-binding motif, is responsible for Waardenburg-Hirschsprung syndrome, also known as WS4 (268, 584), which is characterized by aganglionic megacolon in addition to auditory-pigmentary abnormalities. Thus MITF, PAX3, and SOX10 constitute a regulatory network controlling melanocyte development.

MITF-M function is also regulated at the posttranslational level through phosphorylation at the serine residues and by interaction of MITF-M with CBP/p300 transcription coactivator complex, and with ubiquitin conjugating enzyme hUBC9 (Fig. 11). Phosphorylation of Ser-73 by MAP kinases activated by the Steel/c-Kit signaling pathway upregulates MITF-M functions, being further stimulated by interaction with CBP/p300 (Fig. 11). c-kit also phosphorylates MITF-M at Ser-409 through serine/threonine kinases (Rsk), resulting in short-lived activation followed by proteolytic destruction. Phosphorylation at position Ser-73 by MAP kinases also allows binding of hUBC9 and targeting for degradation. Glycogen synthase kinase 3β (GSK-3β) also phosphorylates MITF-M at Ser-298 (Fig. 11) (648). The latter is complicated in the way that GSK-3β inhibits Wnt signaling (β-catenin) (889), and also is inhibited by the c-Kit signaling pathway through PI3P/AKT cascade (889). Thus regulation of MITF-M as well as of other MITF isoforms is complex and involves transcriptional and posttranslational mechanism activated by different signaling systems (Fig. 11), as well as degradation pathways necessary to provide tight homeostatic control of MITF-M in the melanocytes.

MITF-M is a target for Wnt (a cysteine rich glycoprotein important for neural crest cells development) through activation of its Frizzled receptor, inhibition of GSK-3β, and stimulation of β-catenin accumulation (Fig. 11). β-catenin not only participates in stimulation of MITF-M promoter activity but also in stimulation of MRP gene transcription. MITF-M in cooperation with LEF-1 also stimulates its own transcription and that of tyrosinase-related genes (Fig. 11). Since the M promoter region does not contain M or E boxes, MITF-M acts as a cofactor for LEF-1.

MITF thus plays a fundamental role providing positive regulation of transcription of tyrosinase, TyrP1 and TyrP2 genes through interaction with M and E boxes, a prerequisite for production of melanin pigment. Furthermore, the promoter region of the MCI-R contains E-box sequences and binds MITF-M, thus stimulating the expression of both MRPs and MSH receptor (21). The latter suggests that MITF-M not only regulates production of melanogenic proteins at mRNA level, but also may regulate indirectly posttranscriptional and posttranslational steps of melanogenesis through MCI-R. The hypothesis that MITF-M serves as a master regulator of the melanogenic apparatus is supported by the demonstration of actual melanogenesis after overexpression of this transcriptional factor in fibroblast. Finally, factors that stimulate melanogenesis induce MITF-M, while those inhibiting melanin synthesis inhibit MITF-M, with MITF-M being expressed in all normal melanocytes and the vast majority of melanoma cells. MITF-M can also produce sustained growth and survival of melanocytes through the upregulation of the major antiapoptotic agent bcl2 (474). Therefore, MITF-M may act as a self-regulating switchboard for diverse pathways originating at the cell membrane or intracellular environment and regulating the activity of the melanogenic apparatus (Fig. 12).

**IX. MELANOCENESIS AS MOLECULAR SENSOR AND TRANSDUCER OF ENVIRONMENTAL SIGNALS AND REGULATOR OF LOCAL HOMEOSTASIS**

The type and concentration of cutaneous melanin pigment determines its critical functions in camouflage,
mimicry, social communication, and protection against the harmful effects of solar radiation. Epidemiological data show that highly pigmented skin in humans is associated with a severalfold decrease in the risk of skin cancer. The human skin pigmentation response to UV is biphasic with immediate skin darkening, predominantly seen with UVA, and delayed longer lasting response (tanning), predominantly induced by UVB (181, 213, 561). The immediate darkening effect is rapid (within minutes), and transient (fades within hours). This response implies that the elements of melanogenic apparatus must act as unique molecular receptors of solar light energy, for rapid transduction into visible phenotypic effect (skin darkening) (747). The various physical properties of melanin (paramagnetic, oxidoreductive, ion exchange, optical, photoreactive, and electric) as well as the physicochemical nature of melanogenesis indicate that the light-induced changes must affect epidermal homeostasis through changes in the internal environment of cells bearing melanosomes, and through flux of ions or other bioactive molecules across gap junctions of the epidermis (Fig. 13). Light wavelength per se also affects melanogenesis. Thus UVA induces dark pigmentation predominantly in basal keratinocytes, and UVB induces melanin distribution throughout the epidermis, although the most energetic and mutagenic UVC has little or no pigmentary effect.

Melanosomes are metabolically active organelles that can, and do, affect the state and function of the host melanocyte or keratinocyte (746). This is related to their oxygen consumption that modifies the energy-yielding metabolism, alterations of the intracellular NAD/NADH and NADP/NADPH ratio or stimulation of the pentose phosphate shunt, the buffering of calcium and other ions, the reversible binding of bioregulatory compounds, internalization of toxic factors, and production of biologically active intermediates of melanogenesis (reviewed in Refs.

---

**FIG. 12.** MITF-M as molecular switchboard for melanogenic signals.

**FIG. 13.** Melanogenically active melanocyte as the sensor and computing cell regulating cutaneous homeostasis. [Modified from Slominski et al. (746).]
736, 739, 746). Thus melanosomes represent cell regulatory packages sent to neighboring keratinocytes to coordinate the response to signals that have activated melanocytes. Intermediates of melanogenesis, also released by melanocytes, may even affect the local immune system (743, 746). One intermediate, L-DOPA, serves in fact as a precursor to catecholamines (161). Thus after signals of varying natures are relayed to the melanogenic apparatus, they may trigger cascades of responses modifying local homeostasis. Systemic effects may also become evident as in the attenuation of the vitamin D$_3$ photosynthetic response after tanning, or in its strong dependence on racial pigmentation (468).

It must be emphasized that in addition to environmental physical signals, melanocytes are exposed to multiple chemical and biological signals generated within its vicinity, distally, or by nerve endings. Thus melanogenic responses can also be elicited by local stress within the epidermis. These melanogenesis-associated stress responses are likely addressed at counteracting environmental insults, and/or optimizing homeostatic adaptation mechanisms. Thus this system of multidirectional communications within the skin provides a new level for the local regulation of skin function in which melanogenic activity serves as a unique molecular sensor and transducer of noxious signals and as regulator of local homeostasis.

**X. COMMENTS AND FUTURE DIRECTIONS**

When considering the multiple functions of the melanogenic apparatus, it is understandable that myriad hormones and molecular factors would be involved in the regulation and “fine-tuning” of melanogenesis. Thus the complex regulatory control of the biosynthetic machinery involved in melanogenesis includes receptor-mediated pathways activated by hormones, neurotransmitters, cytokines, growth factors, and eicosanoids as well as receptor-independent mechanisms activated or modified by nutrients, micromolecules, microelements, pH, cations and anions concentrations, and the oxidoreductive potential in the physicochemical milieu. Soluble factors can reach their target (melanocyte) from circulation, from release by nerve endings, or from local production to act as positive or negative melanogenesis regulators.

The most important positive regulator is the MC1R, with its ligands melanocortins and ACTH. Other locally produced factors are represented by the endothelins, important stimulators of melanogenesis in melanocytes, and with a positive role in the embryonic development of pigmentation. A crucial role in embryonic development of the melanin pigmentation as well as in the formation of hair follicle pigmentary unit is the SCF with its c-kit receptor. Less significant, although still potent positive regulators of cutaneous melanogenesis are components of the skin immune system such as histamine and eicosanoids; these are produced locally or delivered from systemic circulation. Miscellaneous participants in melanogenesis are β-endorphin, estrogens, androgens, vitamin D$_3$, and catecholamines. The nutritional factors L-phenylalanine, L-tyrosine, and L-DOPA are crucial for melanin synthesis with the last two amino acids acting as both substrates and positive (hormonelike) regulators in the conversion of L-tyrosine into the pigment melanin. Because the latter functions have only been documented in cultured cells, the general concept will require extensive in vivo testing.

The most important negative regulator of melanogenesis, which determines the type of melanin synthesized, is the locally produced ASP. ASP switches eu- to pheomelanogenesis and also inhibits the pathway by acting as antagonist to melanocortins (competitively and noncompetitively) through its binding to the same or separate sites on the MC1R. ASP is a significant player in the regulation of rodent hair pigmentation; however, such a prominent role as agouti protein cannot be assigned to human pigmentation. Negative regulation is also provided by the cytokines IL-1, IL-6, INF-γ, and TNF-α, produced by the skin immune system, and by growth factor TGF-β. Melatonin is a potent lightening factor in the skin of lower vertebrates that can inhibit hair pigmentation in furry animals, although its function on human pigmentation is still unclear. There are indications that dopamine, ACh, and possibly serotonin can inhibit melanin pigmentation. Among factors with mixed functions, i.e., both positive and negative regulators of melanogenesis, are glucocorticoids and retinoids. Interestingly, a dual effect for ET-1 on melanin synthesis in cell culture has also been described whereby it stimulates melanogenesis at low (physiological) concentrations and inhibits the process at high (pharmacological) concentrations (515).

The most important biochemical pathways regulating melanogenesis are activated by cAMP, although PKC also plays a regulatory role. These pathways act at transcriptional, translational, and posttranslational levels. Among the transcriptional regulators, the most important is MITF that acts as the central switchboard for the routing of the various signals involved in the expression of melanogenesis-related genes, thus defining at any given time the prevailing melanogenic algorithm.

It is worth emphasizing that melanogenesis is regulated directly (through receptor-mediated or metabolic action on melanocytes) or indirectly through stimulation of other cellular targets, which in turn release biologic regulators or simply change the chemical environment of melanocytes. Furthermore, instant receptiveness selectivity to pro- or antimelanogenic signals of melanocytes could also be modulated by modification of receptor expression or signal transduction or transcriptional activity;
it can also be tuned-up by bioregulatory factors that alone would have no activity on melanogenesis. Indeed, sometime conflicting results reported in the literature may have been determined by the environmental context of the particular bioregulator action. These complex interactions are characteristically expressed in the function of the hair pigmentary unit where melanogenesis is coupled to the anagen phase of hair cycle. It is currently assumed that anagen coupled melanogenesis is primarily driven by the local circuitry regulating hair growth interacting at multiple points with follicular melanogenesis.

In summary, the multidirectional nature and heterogeneous character of the melanogenesis-modifying agents clearly define a highly complex regulatory system. It is also clear that the controlling factors are not arranged in simple linear sequences. Instead, as presented in this review, melanogenesis regulators and their modifiers interact in a model best described as a multidimensional network, with extensive overlapping and diversity of factors acting in a nonrandom fashion determined by the biochemical-physical context. Precise definition of hierarchical positions in this model will help clarify existing gaps and discrepancies on the current information on mammalian melanin pigmentation.

We thank Dr. V. Hearing for providing Figures 4 and 5 and valuable comments; Dr. B. Zbytek for Figure 10; Drs. B. Gilchrest, M. Holick, J. Pawelek, P. Pionka, T. Sarna, and K. Shaller for valuable comments; T. Higgins for preparation of Figures 3K, 7–9, 11, and 12; and C. Crawford for excellent secretarial work.

This work was supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant AI-47079–01 and grants from the Center of Excellence in Genomics and Bioinformatics and Center of Excellence in Connective Tissue Diseases (to A. Slominski).

Address for reprint requests and other correspondence: A. Slominski, Dept. of Pathology, Suite 599, Univ. of Tennessee Health Science Center, 930 Madison Ave., Memphis, TN 38163 (E-Mail: aslominski@utmem.edu).

REFERENCES


Downloaded from http://physrev.physiology.org/ by 10.220.33.3 on October 27, 2017


HORMONAL REGULATION OF MELANOGENESIS


HORMONAL REGULATION OF MELANOGENESIS 1213


316. Inazu M and Mishima Y. Detection of eumelanogenic and pheomelanogenic melanosome in the same normal human mela


ing VJ, Lozano JA, and Garcia-Borrón JC. A new enzymatic function in the melanogenic pathway. The 5,6-dihydroxyindole-2-


337. Johnson O and Wang L. Choline acetyltransferase-like immu

nofluorescence in epidermis of human skin. Neurobiology 1: 201–

206, 1993.


346. Karbownik M, Lewinski A, and Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidant processes: com


347. Kauser S, Schallreuter KU, Thody AJ, Guummer C, and Tobin DJ. Regulation of human epidermal melancocyte biology by beta-


348. Kavanagh GM, Sabroe RA, Greaves MW, and Archer CB. The intradermal effects of the H3 receptor agonist R alpha methylhis-


352. Kemp EH, Waterman EA, Hawes BE, O’Neill K, Gottumukkala RV, Gawkroder DJ, Weetman AP, and Watson PF. The mela-
nin-concentrating hormone receptor 1, a novel target of autoanti-


355. Khong HT and Rosenberg SA. Pre-existing immunity to tyrosi

nase-related protein (TRP)-2, a new TRP-2 isofrom, and the NY-


HORMONAL REGULATION OF MELANOGENESIS


389. Lai CT and Yu PH. Dopamine- and l-beta-3,4-dihydroxyphenylala- nine-6-dihydrochloride (L-DOPA) induced cytotoxicity towards catecholaminergic neuraloblastoma SH-SY5Y cells. Effects of oxidative...


HORMONAL REGULATION OF MELANOGENESIS 1217


HORMONAL REGULATION OF MELANOGENESIS


569. Peters EM, Tobin DJ, Botchkareva N, Maurer M, and Paus R. 2 and the regulatory peptide 7B2 are present in melanosomes of opiomelanocortin-related peptides, prohormone convertases 1 and 20: 23


597. Reid K, Nishikawa S, Bartlett PF, and Murphy M. Steel factor directs melanocyte development in vitro through selective regula-
HORMONAL REGULATION OF MELANOGENESIS


601. W. 27, 2017


745. Slominski A and Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the HORMONAL REGULATION OF MELANOGENESIS 1223

HORMONAL REGULATION OF MELANOGENESIS

1225


783. Staricco RG. Amelanotic melanocytes in the outer sheath of the human hair follicle and their role in the regpimentation of regener-


791. Takechi Y, Hara I, Naftzger C, Xu Y, and Houghton AN. A melanosomal membrane protein is a cell surface target for mela-

792. Tassabehji M, Read AP, Newton VE, Patton M, Gruss P, Har-


808. Taiwar HS, Griffiths CE, Fisher GJ, Russman A, Krach K, Benrazavi S, and Voorhees JJ. Differential regulation of tyrosi-


842. Toyofuku K, Wada I, Valencia JC, Kushimoto T, Ferrans VJ, and Hearing VJ. Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Typr1 can affect the processing of both mutant and wild-type proteins. FASEB J 15: 2149–2161, 2001.


857. Varley JE and Maxwell GD. BP-2 and BMP-4, but not BMP-6, increase the number of adrenergic cells which develop in quail trunk neural crest cultures. Exp Neurol 140: 84–94, 1996.


